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SUMMARY 
Epstein-Barr virus is a gamma herpesvirus that is present in human adult’s B-
lymphocytes infecting 90% of the global population. EBV causes many types of 
lymphoma and carcinoma. The virus life cycle can be divided in two stages, latency 
and lytic cycle. Viral gene BZLF1 codes for the viral transcription and replication 
factor Zta (also known as BZLF1, ZEBRA, EB1, and Z) which is part of the signalling 
required to switch from latency to the lytic cycle. Zta is part of the bZIP family of 
proteins, it forms homodimers and can bind to specific sequences termed Zta 
Response Elements (ZREs). It binds to the EBV lytic origin of replication as well as 
to specific targeted promoters in the viral genome and regulates its expression. 
Recent research found and mapped interactions between the key viral transcription 
factor Zta and the B-cell genome, this showed interactions of Zta proximal (closer 
than 2Kb) and distal (farther than 2 Kb) to the transcription start site of several genes. 
In this work, I asked the questions: Can enhancer properties be found in the 
sequences where Zta binds to? Is Zta distally regulating expression by looping of 
DNA? This was approached first by identifying potential sequences that could be 
conferring enhancing activity, then inserting them into vectors and transfecting them 
into two different cell lines. In this way, through luciferase reporter assays, any 
enhancing capabilities of the sequences were tested when placed in a proximal and 
distal manner to promoters known to be regulated by Zta, as well as mutated 
promoters not regulated by Zta. This resulted in finding discreet enhancer activity in 
the sequences analysed, with some being specific to the cell type that was used in 
the experiment. To answer the second question, Chromosome conformation capture 
(3C) was used to test the possibility of a spatial rearrangement bringing together 
distal Zta binding regions and promotor regions of selected genes (looping). However, 
I did not find evidence of looping between Zta binding sites and the neighbouring 
promoters analysed, in the cell context employed. 
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Chapter 1. Introduction 
1.1 Herpesvirales 
Herpesviruses have a long historical presence in humanity; early records of 
diseases kept by ancient practitioners of medicine in Classical Greece described 
particular cutaneous lesions typical of infections now known to be caused by 
herpes simplex viruses (HSV) as well as varicella-zoster virus (VZV). The family 
name of the viruses “Herpes” comes from the Greek description of the lesions 
appearing to crawl over the skin. Studies on herpesvirus have evolved with the 
times, and their transmission as well as their occurrence have been followed by 
scientists through centuries; in the 19th century, experiments showed that HSV 
and VZV could be transmitted from fluid recovered from HSV and VZV lesions, 
and in the first half of the 20th century research showed great advancements in 
the understanding of the latency and reactivation of herpesvirus and how the 
infection persists for life (Arvin and Abendroth 2007). 
In the early 50’s the human cytomegalovirus (HCMV) as well as VZV were the 
first herpesvirus isolated in cultured cells, and in the following decade Epstein-
Barr virus (EBV) was shown to be associated with mononucleosis after being 
discovered in cells derived from a tumour from a patient with Burkitt’s Lymphoma 
(BL). As time progressed and technology progress with it, more human 
herpesviruses were discovered and studied, showing biological diversity and 
evolutionary similarities. Herpesviruses share many common genes (see Figure 
1.1 A ) suggesting a common ancestor 150 million years ago from which several 
herpesviruses diverged (Mocarski 2007).  
Members of the Herpesviridae family share common traits, such as a large size 
(130-250 kb) linear double stranded DNA genome. Structurally, the virions are 
spherical, with a diameter of approximately 200nm and consist of 3 main 
structures: Envelope, tegument, and nucleocapsid. The lipid envelope of the 
Herpesviridae viruses is embedded with viral membrane glycoproteins and 
cellular proteins of different function (Davison 2007). The tegument, a protein 
compartment, is surrounded by the envelope and in turn the tegument surrounds 
the nucleocapsid. The nucleocapsid consists of capsomeres which form an 
icosahedron joined via triplexes, the densely compacted linear double stranded 
2 
Figure 1.1 Herpesvirus. (A) Composite phylogenetic tree for 
herpesviruses showcasing genes that are shared in different species. 
Underlined in red EBV. Modified from (Verweij et al. 2015). (B) Herpesvirus 
virion structure. Taken from (Swiss Institute of Bioinformatics 2017). 
B
A
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DNA is packed in its core (See Figure 1.1 B) (F. Y. Liu and Zhou 2007). 
Initially, Herpesviruses were classified as such based on the shared biological 
properties, such as host range or broad pathogenic and epidemiological features 
of the disease; however, the type of cell infected was later used to subdivide the 
Herpesviridae family into three subfamilies: Alphaherpesvirinae, 
Betaherpesvirinae and Gammaherpesvirinae. Later, with the development of 
nucleic acid sequencing, the taxonomy of Herpesvirus also advanced; now  they 
are classified into an order called Herpesvirales, which consists of the 
Herpesviridae family, subdivided into 3 subfamilies Alpha- Beta- and Gamma- 
herpesvirinae which encompass 17 genera and 90 species (Davison 2010). 
Some studies have shown that Herpesviruses have evolved interesting 
mechanisms to modulate or evade the host reaction to the infection, and therefore 
establishing a very prolonged or even lifelong latent infection (Tellam et al. 2012). 
Severe symptoms of infection by Herpesviruses are usually shown only in 
immunosuppressed or very young individuals, the usual infection routes can 
range from aerosol spread to mucosal contact (Davison 2007). Although 
occasional inter-species transfers do occur, when studied in vitro, single species 
of virus from the Beta- and Gammaherpesvirinae subfamily are limited to infection 
of specific host cells from a single species, whereas some virus from 
Alphaherpesvirinae can target more than one species of hosts cells (Barton et al. 
2011). For instance the porcine pseudorabies virus (PrV) can infect its natural 
host cells as well as mouse cells in vitro (Menotti et al. 2000).  
Nine herpesviruses are known to infect humans; in the Alphaherpesvirinae 
subfamily: herpes simplex virus type 1 (HSV1, HHV1) and type 2 (HSV2, HHV2). 
In the Betaherpesvirinae subfamily: varicella-zoster virus (VZV, HHV3), human 
cytomegalovirus (HCMV, HHV5), human herpesviruses 6A, 6B, and 7 (HHV6A, 
HHV6B, HHV7). And in the Gammaherpesvirinae subfamily; Epstein-Barr virus 
(EBV, HHV4), and Kaposi’s sarcoma-associated herpesvirus (KSHV, HHV8) 
(Verweij et al. 2015). 
Found in all vertebrate species, the Gammaherpesvirinae subfamily of 
herpesviruses is divided into 4 genera, Lymphocryptovirus, Macavirus, 
Percavirus and Rhadinovirus (Davison 2010). The Gammaherpesvirinae species 
4 
are as varied as their multiple various hosts: mice, cows, horses, humans and 
other primates, these viruses were first distinguished by their tropism towards 
lymphocytes, inducing lymphoproliferation and cancer (Longnecker and Neipel 
2007). 
As with all other Herpesvirus, infection of cells by gamma herpesvirus places the 
previously linear viral DNA inside the host cell nucleus, where it circularizes as 
an episome that is not integrated into the cell genome. Then, two different 
situations can occur, latency is established or lytic cycle is followed. In latency, 
viral expression of genes is limited to a minimum and the production of new 
viruses is suspended; and in lytic cycle, the viral genome expresses all necessary 
proteins for the generation of new infectious viral particles (Barton et al. 2011).   
1.2 Epstein-Barr Virus 
1.2.1 EBV genome structure 
Mature EBV virions are 120-180 nm in diameter, the core of the viral particle holds 
inside the linear DNA, which has a large, nucleosome free, double stranded 
~172Kb DNA genome. It is flanked by terminal repeats, which bind and circularize 
after entry to the nucleus through homologous recombination; where it remains 
as an episome (Kieff et al. 1982; Kintner and Sugden 1979; Nonoyama and 
Pagano 1972; Shaw et al. 1979).  
When in latency, the viral episome is maintained in the nucleus and associated 
with histones, where it is replicated through the origin of replication (OriP) 
(Tempera and Lieberman 2010). When in lytic stage, the viral genome is 
replicated through the two origins of replication; OriLyt Left and OriLyt Right 
(Hammerschmidt and Sugden 1988) 
Fragments within the genome are named alphabetically based on the initial 
sequencing of EBV that digested the DNA with BamHI (See fig 1.2) (Baer et al. 
1984). 
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Fig 1.2 Schematic of the EBV genome. Letters correspond to BamHI 
digestion fragments. Origin of plasmid replication (oriP), the two origins of 
lytic replication (oriLyt) and the terminal repeats in blue. Lytic genes of pre-
latent phase are in orange. Coding exons for latency genes are shown in 
green. Latent mRNAs can be initiated from different promoters depending 
on latency type and time after infection: the W promoter (Wp), the C 
Promoter (Cp), the Q promoter (Qp, only in Latency I), and the LMP 
promoters are labelled. The non-spliced pre-mRNAs driven from these 
promoters is shown as a dashed line. Latency 0 miRNAs shown as red 
triangles. Taken from (Price et al 2014). 
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1.2.2 Viral Entry 
Initial entry of the virus into host cells occurs differently depending on the cell type; 
in epithelial cells it occurs by direct fusion of the viral envelope with the cell 
plasma membrane, whereas entry to B cells require endocytosis of the virus, 
which is followed by a subsequent membrane fusion event (Miller and Hutt-
Fletcher 1992; Nemerow and Cooper 1984). 
Several viral glycoproteins participate when EBV is entering B cells; gp350/220 
allows attachment by binding to the cell’s receptor CD21, gp42 binds to the cell’s 
major histocompatibility complex (MHC) class II to initiate both the entry event, 
and viral proteins gH/gL involved with the fusion of membrane (Fingeroth et al. 
1984; Nemerow et al. 1985).  
Once the virion enters the B cell and escapes endocytosis, viral proteins 
contained in the tegument are released into the host cell. Viral tegument protein 
BNRF1 binds to cellular protein Daxx and disrupts the Daxx-ATRX complex, 
which is known to supress transcription through histone methylation; this could 
mean that BNRF1 is therefore preventing the suppression of viral gene 
expression (Stanfield and Luftig 2017; Tsai et al. 2011; Xue et al. 2003). Recent 
research has suggested that upon fusion of the membranes, viral RNA transcripts 
that were contained in the virus are released into the host cell, undergo translation 
and modify the host cell response to infection (Jochum et al. 2012; Stanfield and 
Luftig 2017).  
1.2.3 EBV life cycle 
Depending on the expression pattern of EBV nuclear antigens (EBNAs) as well 
as latent membrane proteins (LMPs), and small non-polyadenylated RNAs called 
Epstein-Barr encoded small RNAs (EBERs) and BamHI-A rightward transcripts 
(BARTs) miRNAs; EBV latency can be subdivided into 4 patterns of expression: 
Latency 0, I, II and III (Abate et al. 2015; Rowe et al. 1992).  
In Latency 0, EBERs and BART miRNA transcripts are expressed, however they 
are also expressed in all other Latency programs. In Latency I, EBNA1 is 
expressed, in Latency II LMP1, LMP2A, and LMP2B are expressed in conjunction 
with what is expressed in Latency I, and finally, in Latency III all the latency genes 
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are expressed (EBNA1, EBNA2, EBNA3A, 3B, 3C, EBNA-LP, LMP1, LMP2A, 
LMP2B, BARTs, EBERs and BHRF1 miRNA).   
1.1.3.1 EBV latency cycle 
Immediately after the viral genome is deposed into the nucleus of the newly 
infected B cell, a short period where both lytic and latent genes are expressed 
occurs; this period is called Prelatency or Latency 0. In Latency 0 the expression 
program allows the infection to be persistent but without expression of proteins 
that aid cell proliferation. This program is typically present when the infected B 
cells are part of the memory pool; however it is important to clarify that EBERs 
and BARTs are also being expressed in all subsequent latency programs (Price 
and Luftig 2015). BART miRNAs are a product of alternative splicing, which can 
be grouped according to the introns of BARTs, they are very highly expressed 
and are believed to serve several different purposes related to latent replication 
(Edwards et al. 2008; Pfeffer et al. 2004). EBER1 and EBER 2 are small RNAs 
that also expressed at high levels; they are known to form RNA-protein 
complexes with cellular proteins and although their function is still debated, they 
are believed to hold a central role in cell transformation (Glickman et al. 1988; 
Lerner et al. 1981; Toczyski and Steitz 1991) 
In latency I, viral DNA replication is facilitated with EBNA1 by attaching the viral 
episome to host chromosomes and taking over the host cell’s replication 
machinery. EBNA1 is transcribed from promoter Q (Qp), and it also activates 
transcription of other EBNAs from viral C promoter (Cp) in Latency III. EBNA1 
decreases p53 tumour suppression activity, and activates nuclear factor κB (NF-
κB) which migrates to the nucleus and activates lytic gene promoters (see lytic 
reactivation) (Mogensen and Paludan 2001; Price and Luftig 2014; Reisman and 
Sugden 1986; Yates et al. 1985).  
Regarding proteins expressed in Latency II, LMP1 mimics B cell receptor CD40 
in vivo hampering communication with T cells, it also acts as an activated tumour 
necrosis factor receptor and activates signalling pathways that stimulates 
oncogenesis (Dawson et al. 2012; Kaye et al. 1993; D. Wang et al. 1985). LMP2A 
is a B cell receptor mimic that helps the infected cell evade apoptosis (Caldwell 
et al. 1998). LMP2B is still being studied and its function has not been entirely 
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elucidated, in a study where expression of LMP2A and LMP2B were knocked 
down in vitro, a critical loss of efficient activation and proliferation of EBV infected 
B cells was shown when LMP2A was not being expressed. In contrast, LMP2B 
did not appear to have an effect in those processes (Wasil et al. 2013). 
In latency III the EBNA transcripts are driven by viral promoters Cp or Wp. EBNA2 
has been shown to affect transformation of B cells in vitro, activates the 
expression of LMP1 and LMP2, and in recent studies EBNA2 has been shown to 
drive the formation of new binding sites for cell factors RBP-jκ and EBF1, as well 
as regulating RUNX1 and RUNX3 through distal super enhancers (Gunnell et al. 
2016; Hsieh et al. 1996; Lu et al. 2016; Rabson et al. 1982). EBNA3A and 
EBNA3C are essential for transformation in vitro of B cells, however, this 
proliferation fails in experiments where these EBNAs are rendered non-functional; 
adding to this, EBNA3B expression did not alter transformation when absent, 
however it may function as a tumour suppressor (Tomkinson and Kieff 1992a, 
1992b; White et al. 2012). Expression of EBNA-LP with EBNA2 was shown to 
induce cellular cyclin D2, and it is required for the efficient outgrowth of LCLs; 
subsequent studies confirmed this coactivation (Harada and Kieff 1997; Sinclair 
et al. 1994; Young et al. 2016). BHRF1 miRNAs are known to help in cell 
proliferation as well as aiding in the evasion of apoptosis (Feederle et al. 2011; 
Seto et al. 2010). 
Making the first association between EBV and human malignancies, EBV was 
first identified in cells derived from a patient in Africa with Burkitt’s Lymphoma. 
The pathology was described by Denis Burkitt in 1958, and the virus was isolated 
and identified using electron microscopy by tumour virologist Michael Anthony 
Epstein and Yvonne Barr (Burkitt 1958; Epstein et al. 1964). Later, a link was 
established between the presence of antibodies for EBV and patients with 
infectious mononucleosis (IM) (G. Henle and Henle 1966); these antibodies were 
also  found in 90% of tested individuals worldwide (de-The et al. 1975; G. Henle 
et al. 1969). Then, EBV was used to produce lymphoblastoid cell lines (LCLs), by 
causing immortalization of B lymphocytes in culture, establishing a new method 
of studying yet another important link between EBV and cell pathology in vitro. 
These were the first steps into the study of how EBV relates to disease (W. Henle 
et al. 1967; Nilsson et al. 1971).  
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1.1.3.2 EBV associated pathologies and latency 
The sequence of events in EBV infection follow a general outline. First, an initial 
infection exposure occurs typically in epithelial cells of the oral mucosa, followed 
by lytic replication of virus and shedding to neighbouring epithelial cells and, to a 
lesser extent, neighbouring B cells in the oropharynx. This is followed by 
proliferation of infected B cells in lymphoid tissues of the pharynx. Then, there is 
a downregulation of the proliferation program in the infected B cells, and entry 
into the memory B cell pool, giving way into a lifelong persistence as a truly latent 
infection. Finally some occasional latently infected cells switch to lytic cycle, 
starting new foci of virus replication and an intermittent low-level virus shedding 
(Taylor et al. 2015).  
There are two models to explain how EBV enters the memory B cell pool; the 
germinal centre model describes an initial infection of naive B cells that undergo 
latency III and proliferate, followed by entry to the germinal centre where 
expression defaults to latency II, subsequently the infected cells leave the 
germinal centre and enter the memory pool changing the program to latency 0, 
and ultimately in the switch from memory cell to plasma cell, virus is replicated 
and infection spreads; however, in the direct infection model, EBV infects B 
memory cells which supposes an intermediary latency III before going to latency 
0 and true persistence (Thorley-Lawson et al. 2013; Young et al. 2016). 
1.1.3.2.1 EBV malignancies related to B cell infection 
Burkitt’s Lymphoma 
As mentioned before, BL was first described as a lymphosarcoma prevalent in 
children in Africa, and years later EBV was discovered in cultures of BL cells. 
Children whom tested positive for the presence of EBV exhibited a higher risk for 
developing tumours (reviewed by (Thorley-Lawson and Allday 2008)). Tumour 
cells exhibited latent infection and carried the viral genome as an episome, 
expressing a putative tumour antigen in their nuclei termed EBNA (EBV nuclear 
antigen). Shortly prior to this, it was discovered that LCLs could be established 
by infecting primary B cells with EBV. This supported the idea that EBV was the 
defining factor in BL tumorigenesis, however, a very important discovery was 
made; the patterns of viral gene expression were restricted in cells from BL 
10 
tumours (Latency I) compared to the expression in the LCLs (Latency III) 
generated with cells coming from B cells of the same patients. This is what 
allowed to conceptualize latency being subdivided into different states (reviewed 
by (Rowe et al. 2009; Thorley-Lawson and Allday 2008)).  
In parallel, work by (Kohn et al. 1967), found abnormalities in the chromosomes 
of BL cells, and further research discovered that there was a translocation 
between chromosome 8 and 14, juxtaposing the MYC gene to one of the 
immunoglobulin G (IgG) enhancers. This region is highly active and increases the 
expression of MYC, thus driving the uncontrolled proliferation of BL cells. When 
considered jointly, the research showed the translocation of the gene MYC to be 
the common trait in the variants of BL (EBV positive vs EBV negative), which 
challenged the theory that EBV infection is the only factor leading to lymphoma 
(reviewed by (Boerma et al. 2009; Thorley-Lawson and Allday 2008)). 
Three different clinical variants of BL are used for classification: endemic, 
sporadic, and immunodeficiency-related. Endemic BL is present mainly in Africa 
and is associated with endemic occurrence of malaria, and EBV infection; 
whereas, sporadic BL occurs outside of Africa and is typically free from EBV 
infection. Immunodeficiency-related BL also occurs outside Africa, but is 
approximately 60% EBV-positive (Abate et al. 2015).The gene expression 
program of EBV in BL cells follows latency I; expression of EBNA1 and Epstein-
Barr virus-encoded small RNAs (EBERs).  
Hodgkin’s Lymphoma 
Hodgkin’s Lymphoma (HL) was first linked to EBV infection when Levine and 
collaborators found high levels of antibodies specific to EBV antigens in patients 
with HL; followed by experiments where DNA and RNA from the virus were 
detected in Hodgkin/Reed Stemberg (HRS) cells (Levine et al. 1971; Weiss et al. 
1989; Wu et al. 1990).  
HL can be classified into two types based on morphologic, immunophenotypic 
and clinical differences: classical HL (cHL) and nodular lymphocyte predominant 
HL (NLPHL). The disease is characterized by the presence of malignant cells 
called Hodgkin/Reed Stemberg cells, surrounded by non-neoplastic B and T cells 
(Reviewed (M. R. Chen 2011)). HRS cells are derived from B cells, however they 
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show a characteristic loss of a functional B cell receptor and are suspected to 
depend on acquiring anti-apoptotic functions from external sources. There’s a 
high level of Latent membrane protein-1 (LMP1) and 2 (LMP2) expression in 
EBV-positive HRS cells; these two proteins are used by the virus to evade 
apoptosis, and drive persistence in B cell memory pool (Vockerodt et al. 2014). 
The pattern of latency expression in HL is latency II. 
PostTransplant Lymphoproliferative Disease  
Posttransplant lymphoproliferative disease (PT-LPD) is manifest after medical 
intervention, where high EBV loads can be detected in saliva, following a solid 
organ transplantation or hematopoietic stem cell transplantation that was 
complemented with immunosuppressive therapy. Most cases of early onset of 
PT-LPD show EBV-transformed LCL-like cells expressing all of the latent cycle 
antigens, and even some cells entering lytic cycle. This phenomena can be seen 
in 1 to 11% of transplants peaking 2-3 months after the event depending on the 
degree of immune suppression. However, patients carry risk of late onset of PT-
LPD for life if they continue immunosuppressed. The risk for developing PT-LPD 
is increased in children that are EBV-negative receiving a transplant that is EBV-
positive compared to children that have been previously exposed to the virus; 
since the viral load is large in the transplanted organ, and the immune system of 
EBV-negative children can’t give a strong enough defence response. There is a 
correlation between loss of EBV-specific T cells and the development of PT-LPD, 
therefore new therapies involving receiving preparations of virus-specific 
cytotoxic T cells are arising and treating PT-LPD (Taylor et al. 2015).The pattern 
of latency expression in PT-LPD cells is type III, however some tumours display 
a Latency I/II pattern of viral expression (Rickinson 2014). 
EBV-positive diffuse large B cell lymphoma of the elderly  
Diffuse large B cell lymphoma (DLBCL) is a common malignant lymphoma, with 
a particular higher incidence in males of Asian countries, it presents as 
polymorphic or monomorphic B cell proliferation in patients without any known 
immunodeficiency or prior lymphoma.  If in situ hybridization for EBER confirms 
the presence of EBV, the prognosis of overall survival is affected negatively. A 
common trait seen in EBV-positive DLBCL of the elderly patients is an activated 
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B cell immunophenotype as well as an greatly activated NFκB (Jaffe and Pittaluga 
2011).  
Although it has been mostly studied in patients older than 50 years old, it can also 
affect younger patients in a similar way. Some cases show morphological overlap 
with Hodgkin’s Lymphoma. The EBV-positive tumours have a latency I or II 
pattern of expression, similar to what is observed in PT-LPD (H. J. Kim et al. 2017; 
T. X. Lu et al. 2015).
Infectious Mononucleosis 
Since the symptoms of IM are so easily discernible, IM has been used to study 
the events occurring in the primary exposure to the virus. IM was first recognized 
as a disease in 1880 by Nil Filatov, a Russian paediatrician; however, the name 
“infectious mononucleosis“ was coined in 1920 by Sprunt and Evans when 
noticing large numbers of atypical mononuclear cells in blood of patients 
exhibiting fever and pharyngitis (Balfour et al. 2015). 
As mentioned before, EBV was linked to IM by the Henle group in 1969. The 
disease has a particular set of symptoms that last 2 to 6 weeks; these are: a sore 
throat, cervical lymphadenopathy, fever, fatigue and sometimes inflammation of 
the spleen. Primary EBV infection produce two or more of the symptoms in over 
75% of cases (Luzuriaga and Sullivan 2010; Taylor et al. 2015). The IM infection, 
is characterized by activated Natural Killer (NK) cells, large increment in number 
of virus-specific CD8 T cells, responsive to latent antigens such as EBNA-2 and 
EBNA-3 (Latency III), and a smaller increment in number of virus-specific CD4T 
cells. This expansion of EBV-specific cytotoxic T cells destroy most infected cells. 
(Balfour et al. 2015; H. J. Kim et al. 2017; Taylor et al. 2015).  
1.1.3.2.2 EBV malignancies in atypical cells 
NK and T cell lymphoma 
Lymphomas commonly develop in the nose and upper parts of the aerodigestive 
tract, however they can occur in the skin, testis, gastrointestinal tract, and muscle; 
if untreated, the malignancy eventually leads to death. The defining feature of 
NK/T cell lymphoma is the presence of episomal EBV DNA making the detection 
of EBV infection necessary for diagnosis, achieved by in situ hybridization for 
EBV early RNA (EBER) is used to diagnose NK/T cell lymphoma. The affected 
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cells can be identified as large granular lymphocytes regardless of the localisation; 
they can alter the functionality of the liver, spleen and bone marrow, where the 
lymphoma cells can be found as cellular infiltrate (reviewed by (Tse and Kwong 
2017)).  
Cases of NK/T cell lymphomas are geographically found in Asian and South 
American populations, being rare in other places. The lymphoma is locally 
invasive and it can destroy the facial structure and even manifest hard palate 
perforation. Treatment usually involves chemotherapy and radiotherapy, but new 
therapies are targeting the overexpression of the programmed death protein 
ligand 1 (PDL1) by NK/T cell lymphoma cells, which upregulates expression 
through the MAPK/NFκB pathway, and inhibits T cell activity aiding to the evasion 
of immunosurveillance by lymphoma cells (reviewed by (Tse and Kwong 2017)). 
The expression program of NK/T cell lymphoma is Latency I or II with abundance 
of EBER followed by BARTs, expression of LMP2A 2B and EBNA1 are 
comparatively lower.  
Nasopharyngeal carcinoma 
Nasopharyngeal carcinoma (NPC) has a very unique pattern of geographical 
distribution, with the vast majority of cases diagnosed in Southeast Asia, and 
southern China. There seems to be a predisposition to NPC in certain ethnic 
groups, and in concordance to environmental factors like exposure to 
carcinogenic substances. NPC can be classified as non-keratinising and 
keratinising. Non-keratinising NPC is the most common in regions where NPC is 
endemic, constituting over 95% of the cases, and commonly associated with EBV 
infection(Chua et al. 2016).  
EBNAs are detected in cells coming from tumours but not in normal 
nasopharyngeal epithelium cells, suggesting that EBV is necessary for the 
pathogenesis of NPC. EBV latency expression in NPC cells seems to be an 
intermediary program between latency I and II with expression of LMP1, LMP2 
and EBNA1, and BART miRNAs and EBER (Kutok and Wang 2006).  
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EBV associated Gastric carcinoma 
EBV associated Gastric carcinoma (EBVaGC) forms tumours in the proximal 
stomach, these tumours manifest as multiple lesions not necessarily appearing 
at the same time. It is morphologically almost identical to EBV-negative gastric 
carcinoma, therefore, in situ hybridisation against EBER1 is necessary to identify 
EBVaGC. Another characteristic of EBVaGC is the presence of inflammatory 
infiltrate in the tumour, primarily lymphocytic, and with an abundance of B cells 
(Shinozaki-Ushiku et al. 2015). 
Gastric epithelial cells lack the EBV receptor CD21 (CR2) which is necessary for 
an EBV particle to attach to the host cell before endocytosis. This lack of CD21 
supports the idea that infection in epithelial cells happens through cell-to-cell 
contact, especially in inflammatory responses where B lymphocytes and gastric 
epithelial cells are involved, like gastritis (Shinozaki-Ushiku et al. 2015). EBVaGC 
shows Latency I or II, expressing EBERs, EBNA1, BARTS and BART miRNA, 
with some cases expressing LMP2A. 
A summary of the latency stage on several EBV-associated malignancies are 
shown in Table 1.1. 
1.1.3 EBV lytic stage 
Lytic Reactivation 
When lytic cycle is reactivated, EBV gene expression changes for the production 
of new viral particles and the infection to spread. The lytic gene expression 
pattern can be sub-classified into 3 subsequent lytic phases; immediate early (IE), 
early (E), and late (L). The two genes that are transcribed in the IE phase, BRLF1 
and BZLF1 are distinguished by the capacity of their produced proteins, Rta and 
Zta, to reactivate lytic cycle (Chevallier-Greco et al. 1986; J. Countryman and 
Miller 1985). Zta and Rta transactivate other lytic genes and begin the switch to 
full lytic production, E genes are activated and viral proteins required for the 
replication of the EBV genome are expressed, then L genes are transcribed, 
producing structural proteins as well as capsid agents and membrane proteins, 
which allow for viral genome encapsidation and ultimately new viral particles; 
however, this reactivation cannot occur without Zta or Rta (continues in page 16) 
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and they are both required for full expression of EBV proteins expressed in lytic 
cycle (Feederle et al. 2000). 
Differentiation of infected memory B cells into plasma cells promotes Lytic cycle 
reactivation; plasma cell associated transcription factors XBP1 and BLIMP1 
activate the promoter of BZLF1 (Zp) and BRLF1 (Rp). This also happens when 
the B cell receptor (BCR) is stimulated and cellular signalling pathways activate; 
for instance, with Protein kinase C (PKC) pathway active, transcription factors 
NF-κB and AP1 (activating protein 1) activate, which in turn bind to Zp and Rp 
and they in turn activate early genes (Goswami et al. 2012; Laichalk and Thorley-
Lawson 2005; Shaffer et al. 2002; Thorley-Lawson 2015).  
A similar activation caused by differentiation happens in epithelial cells, with 
BLIMP1 in conjunction with KLF4 coactivating Zp and Rp (Murata et al. 2013). 
Lytic reactivation can also be stimulated with the use of external agents: 12-O-
tetradecanolyphorbol-13-acetate (TPA) increases the concentration of calcium 
ions, which triggers PKC pathway activating NF-κB and AP1 which as mentioned 
above activates Zp and Rp; sodium butyrate inhibits histone deacetylase and 
therefore facilitates transcription and activation; and anti-Ig which mimics BCR 
stimulation and activates lytic cycle (Gao et al. 2001; H. Li et al. 2016a; Murata 
2014; Takada and Ono 1989; Westphal et al. 2000). 
Zta and Rta activate several different early genes encoding proteins required for 
replication, for instance BALF5 for DNA polymerase, BALF2 a single stranded 
DNA binding protein homologue, BMRF1 the DNA polymerase processivity factor, 
BSLF1 the primase homologue, BBLF4 an helicase homologue, BBLF2/3 formed 
from open reading frames of BBLF2 and BBLF3, which are suspected to function 
as a potential homologue of the third component of the helicase-primase complex 
(Fixman et al. 1992; Young et al. 2016). 
1.1.3 Zta 
As mentioned previously, one of the major players in lytic switch activation is gene 
BZLF1; several different methods of lytic reactivation involve the binding of 
cellular activation factors binding to its promotor Zp in order to produce Zta. The 
expression of Zta happens in the first 30 minutes after lytic activation and in turn 
initiates the signalling needed for expression of E and L genes. (Chevallier-Greco 
17 
et al. 1986; J. Countryman and Miller 1985; H. Li et al. 2016a; Sinclair 2003; 
Takada et al. 1986).  
Histone modifications have an interesting role in regulating activation of Zp and 
Rp. Histones H3 and H4, around Zp and Rp, are acetylated in distinct Lysine 
residues; H3K27ac, H3K9ac, and H4K8ac help establish an open chromatin 
configuration and allow access of transcription factors, like Zta which can auto-
regulate its own promoter Zp. In contrast, methylation modifications such as 
H3K27me3, H3K9me2/me3, and H4K20me3 correlate with inactivation of the IE 
promoters, maintaining latency; however H3K4me3 allows the virus to express 
Zta (J. K. Countryman et al. 2008; E. Flemington and Speck 1990a; Jenkins et al. 
2000; H. Li et al. 2016a). 
Structure and DNA binding 
Zta is composed of 245 amino acids with a total molecular weight of 35 KDa and 
4 distinct regions; an N-terminal transactivation domain, a basic DNA binding 
region, a dimerization “zipper” region, and a C-terminal region. Basic-leucine 
zipper (bZIP) proteins are characterized to have a basic DNA contact region and 
a dimerization “zipper” region which are present in Zta, giving Zta homology to 
AP1 transcription factors c-fos and c-jun. (Chang et al. 1990; Farrell et al. 1989; 
Flemington et al. 1992; Marschall et al. 1989; Seibl et al. 1986).  
The N-terminal correspond to amino acids 1 to 167 of Zta, it encompasses the 
transactivation domain (aa 27 to 78), where the pre initiation complexes bind to 
as well as other factors that form complexes to activate transcription (Chi and 
Carey 1993; Lieberman et al. 1990)  
The DNA binding domain of Zta corresponds to amino acids 175 to 196; it is 
necessary for the activation of lytic genes. If serine 186 is mutated, binding to Rp 
is altered, as well as the transcription activation of late genes through binding of 
Zta response elements (ZREs); in contrast, a substitution of cysteine 189 for 
serine maintained recognition to Rp but the transcription of late genes is affected. 
(Baumann et al. 1998; Bhende et al. 2005; P. Wang et al. 2005).  
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The leucine “zipper” dimerization domain correspond to amino acids 197 to 221. 
As stated before, Zta has a distinct non-leucine coiled-coil that is different from 
the typical leucine “zipper”; the C-terminal region of Zta is contiguous to the 
“zipper” region, folding the structure back towards the “zipper” region, giving 
stability to the homodimer (See Image 1.3). (McDonald et al. 2009; Petosa et al. 
2006; Sinclair 2006). This C terminal region is necessary for transcriptional 
activation, and is necessary for the interaction with DNA; however the formation 
of a homodimer is independent from the interaction with DNA (Hicks et al. 2001; 
Hicks et al. 2003).  
As mentioned before, Zta is a homolog of AP1 and binds to AP1 sites as well as 
sites that resemble AP1 binding motif, these 7bp sequences are called Zta 
response elements (ZREs) (Farrell et al. 1989; Urier et al. 1989). There are at 
least 32 variants of ZREs and can be classified into classes I, II and III; in class I 
there is no CpG motif, but there are CpG motifs in class II and III. In classes I and 
II there is no negative change on the binding of Zta when there is no methylation, 
but in class III the binding of Zta is negated when there is no methylation, and 
Fig 1.3 Zta dimerization and binding to DNA. Only the DNA binding region 
of Zta is displayed dimerised in green and in gold, the rest of Zta is not shown. 
The C terminal coil folding back to the “zipper” region can be seen on top, and 
the amino N’ terminal in the bottom. Adapted from (Petosa et al 2006). 
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finally, the effect on the binding of Zta to methylated ZREs is enhanced in class 
II (Flower et al. 2011; Karlsson et al. 2008).  
1.3 Computational methods for sequence analysis 
Sequence analysis has been used before to predict and identify variants of Zta 
response elements. Parting from well characterized Zta-responsive promoters 
from the EBV genome (Zp, Rp, BMRF1 promoter) an algorithm allowed for the 
generation of a position frequency matrix, followed by a viral genome-wide 
analysis and ultimately the identification of 32 variants of ZREs (Flower et al. 
2011). 
1.4 Zta interacting with the human genome 
Besides regulating the expression of cellular genes such as FOS, E2F1, EGR1, 
IL8, IL10 and IL13, Zta can inhibit the expression of core genes of interferon alpha 
receptor as well as impair the function of the interferon regulatory factor 7 (IRF7) 
whose role is to augment the production of type I interferons; Zta can also 
regulate cellular cytokine expression levels and inhibit the expression of MHC all 
of these mechanisms to alter or evade the natural defence response from the 
infected host (Bailey et al. 2009; E. Flemington and Speck 1990b; Heather et al. 
2009; Hsu et al. 2008; Kenney 2007; Morrison et al. 2004) 
The Zta interactions with the human genome were recently explored using 
chromatin immunoprecipitation coupled to next-generation DNA sequencing. 
This allowed to find Zta binding in proximity (≤ 2 kb) to the TSS of 278 regulated 
genes as well as Zta binding distally (≥ 4 kb) relative to the TSS of regulated 
genes. Also, the promoter sequence from upregulated genes FOSB and RASA3 
showed enhancer activity when placed distally from a Luciferase Reporter gene 
(Ramasubramanyan et al. 2015). 
1.5 Enhancers 
Enhancers are defined as cis-acting DNA sequences that can increase the 
transcription of genes, independently of orientation and distance from target 
promoter or promoters (Pennacchio et al. 2013). Identifying enhancers is 
challenging, they are scattered through the whole genome and their location 
relative to their target gene or genes is variable, upstream, downstream, or within 
introns. They also don't necessarily act on the closest promoter but can bypass 
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neighbouring genes to regulate distant genes. Sometimes a single enhancer 
regulates multiple genes (Mohrs et al. 2001; Pennacchio et al. 2013; Visel et al. 
2009) 
There is no consensus sequence found across all different enhancers, and even 
more, the enhancer activity might be restricted to a particular tissue or cell type, 
time point, or other particular conditions. Chromatin immunoprecipitation coupled 
to high throughput sequencing (ChIP sequencing) has helped define enhancers, 
by finding that enhancers have regions that are heavily enriched in closely spaced 
recognition motifs for sequence specific transcription factors. (Heinz et al. 2015; 
Koch et al. 2011; Pennacchio et al. 2013).  
Most enhancers are active in a cell type-specific manner, predominantly in 
regions of accessible chromatin, primed by lineage-determining transcription 
factors. This event is followed by the binding of signal-dependent transcription 
factors to the primed enhancers; therefore, enabling the enhancer cell type-
specific activity. The binding of transcription factors to enhancers can be aided 
with the binding of co-regulators, whose recruitment and transcription are 
accompanied by methylation or acetylation of histone tails; epigenetic marks like 
acetylation of lysine 27 in Histone H3 (H3K27ac) and methylation of lysine 4 
(H3K4me1) which have been useful in finding enhancers in mammals (Heinz et 
al. 2015). 
Depending on the activity found in regions corresponding to enhancers, they can 
be classified as inactive, primed, poised or active. Inactive enhancers are found 
in tightly compacted chromatin and without any bound transcription factors or 
histone modifications. Primed enhancers do have sequence-specific transcription 
factors bound to it, in an open chromatin conformation, but are still to be activated 
due to for instance a missing co-activator. Poised enhancers can be thought of 
as primed enhancers that also contain repressive epigenetic chromatin marks 
such as H3K27me3. Active enhancers are in an open chromatin conformation, 
with bound sequence-specific transcription factors activating them, with 
epigenetic markers of active histone (H3K27ac) with recruited RNA polymerase 
II enhancing the transcription of the target gene (Heinz et al. 2015; Shlyueva et 
al. 2014). 
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The first link between virus and an enhanced gene transcription was in 1981 
when two different labs found that the expression of reporter genes raised several 
hundred times over when a particular 72 bp sequence found upstream to the TSS 
of the simian virus SV40 gene, was present. This initial research served as a 
take-off point for subsequent investigation that focused on finding key 
components in DNA sequence that could serve to predict the presence of 
enhancers. Computational scanning of long DNA sequences and even genomes, 
have been used to find the motifs to which transcription factors bind after 
enrichment, however these studies can be limited by the contextual conditions of 
the study. Still, this approach is currently used and has found similarities between 
the sequence found in viral enhancers and host enhancers, supporting the notion 
that evolutionary convergence allowed virus to exploit and mimic the host 
enhancers as well as transcription factors (Arnone and Davidson 1997; Banerji 
et al. 1981; Kropp et al. 2014; Moreau et al. 1981; Yanez-Cuna et al. 2012).  
Due to the chromatin structure needed for an enhancer to exert its function over 
a target gene, following research focused on finding an open and accessible 
conformation that would allow binding of transcription factors. By crosslinking with 
formaldehyde and then employing DNase I coupled to deep sequencing, 
researchers have been able to find footprints of transcription factors that protect 
a stretch of DNA susceptible to DNase excision, in other words, open chromatin 
in the process of recruiting factors to initiate transcription, an indication of an 
enhancer sequence. However, the information that can be gathered does not 
focus exclusively on enhancers, since not all enhancers are in a state of open 
chromatin at all time, nor all stretches of DNA ready to undergo transcription 
correspond to enhancers (Giresi et al. 2007; Neph et al. 2012; Shlyueva et al. 
2014).  
Research that mapped epigenetic marks, found histone modifications on 
nucleosomes surrounding active and inactive promoters and enhancers. This 
allowed to find that active promoters presented H3K4me1 and H3K27ac, while 
active enhancers showed H3K4me1 and H3K27ac, whereas silent regions 
showed H3K9me3. (Heintzman et al. 2007; Kouzarides 2007; C. L. Liu et al. 
2005). Eventually a generalized custom developed of considering epigenetic 
marks for the prediction of enhancers, however there is no general agreement on 
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which epigenetic marks signal the presence of an enhancer; this is due to the 
variation of different marks found on different enhancers and on different data 
sets used to study such enhancers. It is also important to know that there is no 
histone modification or combination of modifications that flawlessly mark an 
enhancer; some active enhancers don’t even present epigenetic marks (Arnold 
et al. 2013; Bonn et al. 2012; Rada-Iglesias et al. 2011; Shlyueva et al. 2014).  
Other research has focused on a different method of predicting enhancers, by 
instead using ChIP-sequencing mapping the binding of transcription factors, co-
activators or other chromatin regulators like Pol II, Cohesin, or Mediator (Kagey 
et al. 2010; G. L. Li et al. 2012). The reason why these can work as an indicator 
of the presence of an enhancer is that the sequence of the enhancer undergoes 
transcription of non coding RNA, termed enhancer RNA (eRNA) (De Santa et al. 
2010; T. K. Kim et al. 2010).  
Although it is disputed whether the eRNAs have a particular function in the 
enhancing effect or they are just a temporal consequence of the proximity of Pol 
II to an active enhancer; currently, the detected transcription of eRNA has 
expanded the previous methods of finding potential enhancers besides locating 
histone modifications near the putative enhancer regions. For instance, recent 
research has postulated the possibility of altering the RNA surveillance 
mechanisms and therefore extending the period of detection of eRNA to reveal 
functioning enhancers without epigenetic marks (Andersson et al. 2014; W. Li et 
al. 2016b; Lubas et al. 2015; Shlyueva et al. 2014).  
Regions in the genome with a high density of enhancers bound by an array of 
transcription factors to drive transcription, like Mediator, are called super-
enhancers. These regions also present eRNA transcription, histone acetylation 
and other epigenetic regulation markers, and are typically cell type specific as 
well. Enhancers within a super-enhancer form 3D interactions to other enhancers 
within the same super-enhancer region, which is feature of the folded genome in 
the nucleus. The majority of these super-enhancers are formed with genes that 
are enriched for the biological processes that define the identities of the cell types 
(Dowen et al. 2014; Hah et al. 2015; Heinz et al. 2015; Hnisz et al. 2013; Z. J. Liu 
et al. 2014). 
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1.6 Chromatin looping events 
A major challenge in deciphering cell type-specific enhancer functions is 
connecting active enhancers to their target genes in vivo, however Chromosome 
conformation capture (3C) has helped show evidence of the formation of loops 
between enhancers and distal promoters in vitro (Heinz et al. 2015; Pennacchio 
et al. 2013). 
An interesting instance of expression control through 3D rearrangement of 
chromatin (looping) happens in the Hox gene cluster, which contribute to the body 
plan during vertebrate development. The Hox genes are found linearly, in a way 
that reflects the temporal and sequential expression of the genes, however as 
development of expression pattern advances, the Hox genes re-arrange spatially, 
in such a way that a cluster of Hox genes that are actively being expressed forms 
an “active array”. This “active array” gradually integrates clusters of previously 
inactive Hox genes, and as they spatially incorporate into the “active array”, they 
become active themselves. This re-arrangement is accompanied by a change of 
active histone epigenetic markers (Denker and de Laat 2016; Montavon et al. 
2011; Noordermeer et al. 2011). 
In the EBV genome, three-dimensional rearrangement has been documented in 
Latency I when OriP forms a loop with Qp mediated in part by EBNA1, or in 
Latency III when OriP forms a loop with cohesin to the LMP1 promoter (Arvey et 
al. 2012; Avolio-Hunter and Frappier 1998; Lieberman 2013; Tempera et al. 
2011). Similar events are also seen in the host cell genome, EBV has been known 
to upregulate MYC, driving cell proliferation and counteracting apoptosis by 
silencing BCL211 (bim). Interesting recent research showed that this is achieved 
by EBNA2 binding to enhancers of MYC, which induces a structural 
reorganisation of the MYC promoter to enhancer loops, which upregulates 
tumorigenesis. Part of their study also explored how EBNA3A and EBNA3C 
repress BCL2L11 by inactivating a long range enhancer hub recruiting H3K27 
methyltransferase EZH2 and silencing promoter-enhancer looping interactions. 
As mentioned previously, epigenetic regulation markers like acetylation or 
methylation of H3K27 was an important marker for the identification of the 
interactions they set to explore (McClellan et al. 2012; Wood et al. 2016).  
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1.7 Aims of project 
Viral transcription factor Zta is known to regulate cellular expression of genes. A 
previously performed genome wide ChIP-seq analysis in BL Akata cells showed 
a great proportion of the binding sites of Zta distal (≥ 4 kb) to promoter regions of 
cellular genes, and a smaller number of binding sites proximal (≤ 2 kb) to TSS of 
genes (Ramasubramanyan et al. 2015). The mapped binding sites could have 
enhancer properties, and perhaps when binding sites are distal, Zta regulation is 
occurring through chromatin looping. In order to research this the aims are: 
 To develop a method to test if Zta is binding to sequences with enhancing
properties. Potential sequences that could be conferring enhancing activity
will be identified. Components in the sequences that could work as
enhancers will be analysed. The sequences will be inserted into vectors
and its enhancing capabilities will be tested through Luciferase Assays in
EBV negative, epithelial and BL cells.
 To develop a method to discriminate possible Zta interactions that would
be good candidates for looping activity. Relating genes highly regulated
by Zta a selection criteria will aid to select which interactions to further
research.
 To design a 3C assay that would capture the interactions between distal
Zta interactions and promoter regions that are candidates to be looping in
EBV positive inducible LCL and BL cells.
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Chapter 2. Materials and Methods 
2.1 Materials 
2.1.1 Vectors 
Table 2.1. List of Vectors used. 
2.1.2 Cell lines  
Table 2.2. List of Cell lines used. 
Cell line 
Name 
Description Reference Application 
DG75 EBV- Burkitt’s 
Lymphoma cells 
(Ben-Bassat et al. 
1976) 
Zta enhancer 
analysis 
293T EBV- embryonic 
renal cells 
(DuBridge et al. 
1987) 
LCL#3 LCL, EBV+ 
Spontaneously lytic 
6 to 20%  
(Sinclair et al. 1994) Chromatin 
conformation 
capture 
Vector 
Name 
Design Backbone 
plasmid 
Application 
pcDNA3 Invitrogen pcDNA3 Control for Zta 
expression 
His-Zta Sinclair Lab  
(Bailey et al. 2009) 
pcDNA3 Zta expression 
CIITA 
(CIITA -
214+52) 
Sinclair Lab  
Nicolae Balan 
(Balan et al. 2016) 
pGL3-Control Zta enhancer element 
analysis 
BHLF1 Sinclair Lab 
(Ramasubramanyan 
et al. 2015) 
pCpGL-basic Zta enhancer element 
analysis 
BHLF1-Mut Sinclair Lab 
(Ramasubramanyan 
et al. 2015) 
pCpGL-basic Zta enhancer element 
analysis 
26 
GM2188 LCL, EBV+, Tightly 
latent 
(Stiff et al. 2005) 
Akata BL, EBV+, anti-IgG 
inducible 
(Takada and Ono 
1989) 
Akata-Zta BL, EBV+, BZLF1 
expression vector, 
Doxycycline 
inducible 
(Ramasubramanyan 
et al. 2015) 
2.1.3 Antibodies  
Table 2.3. List of Antibodies used. 
Antibody Description Supplier Dilution Application 
Zta 
antibody 
(BZ1) 
Zta primary 
mouse 
monoclonal 
Martin Rowe 
Lab, 
Birmingham. 
Described in 
(Young et al. 
1991) 
1:500 Western Blot 
(WB) 
β-Actin Rabbit 
polyclonal 
Sigma (A2066) 1:5000 WB 
IRDye 
680CW 
Anti-mouse 
secondary 
fluorescent Ab 
LI-COR 1:5000 WB 
IRDye 
800CW 
Anti-rabbit 
secondary 
fluorescent Ab 
LI-COR 1:5000 WB 
IgG Rabbit 
polyclonal 
Dako (A0423) 1:800 Akata cell line 
Induction 
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2.1.4 Primers (oligonucleotides) 
Table 2.4. List of primers used. 
Primer 
Name 
Sequence 5’-3’ Designed for 3C amplification 
of fragment containing 
1 GTCCCAAACCATCCGTCTTCA LHX1 promoter 
2 CTTGGACAGGCTCCATCCAG peak near LHX1 1 
3 TGGTCTCTCCTCCTCCAATCTT peak near LHX1 2 
4 GACTTCCAAGCCCTTGCTCA peak near LHX1 3 
5 GCAGAAGAGGGCAAGGGATTT LHX1 negative control in loop 
6 CCAGTTTCCAAACAAACCGGTAA LHX1 negative control out of 
loop 
7 GGAACCCTGGTTCTTTCCCA SLC6A7 promoter 
8 TGGCAGTAAGCCTGCATAACC peak near SLC6A7 1 
9 GTCCACCTGCCCATGTAACC  peak near SLC6A7 2 
10 TACCTGGCTTGATGAGCAGAA SLC6A7 negative control in loop 
11 AAAGAGGGAGCAAAGGAATGC SLC6A7 control out of loop 
12 GCTGTCTTTCCCTCAGCTCTTT FZD10 Promoter 
13 CTCTACGTCCCCTGCTTTCTC peak near FZD10 1 
14 ACAGTTGGTCCAAGCAGTAG peak near FZD10 3 
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15 AACGCCATCAAGGGAATGGG peak near FZD10 4 
16 TACAACCAGATGACGCCCTG FZD10 control 
out of loop 
17 AGCCCAACCTTTATTTGGCTG FZD10 negative control 
in loop 5’ 
18 GCAAGCATCCTTTCTTTTCCC FZD10 negative control 
in loop 3’ 
C1 AACATTCCTTGGAAGTACATGAGC Peak 898 near cluster VWF CD9 
C2 AAACTTACAAGAATCCACGCAGT Peak 899 near cluster VWF CD9 
C3 GGAAGGATGATGGACGGAAGATT cluster VWF CD9 negative 
control in loop  
C4 GACTGCTGATGGAAGTGAGTGG cluster VWF CD9 negative 
control out of loop  
C5 GGAATTAAGTCTTTTTTTAGAATA VWF promoter large 
C6 TCCTTAGGGCAAAAGAGGGAAAG CD9 promoter 
C7 cTAGAATTTTCATCCTTTGCAC VWF promoter short 
2.1.5 Solutions and buffers 
Table 2.5. List of solutions and buffers used. 
Name Composition Purpose 
Tris-acetate- 
EDTA (TAE) 
40mM Tris (pH 7.6), 
20mM acetic acid, 1mM 
EDTA 
Agarose gels, electrophoresis. 
Transfer 
Buffer 
25 mM Tris-HCl (pH8.3), 
192 mM, Glycine, 20% 
v/v methanol 
Western Blot 
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PBS tween 138 mM NaCl, 2.7mM 
KCl, 10mM NA2HPO4 
Western Blot 
Ponceau 
Stain 
0.1% w/v Ponceau in 5% 
v/v acetic acid 
Nitrocellulose membrane 
staining 
Lysis buffer 10mM TRIS-HCl pH 7.7; 
10mM NaCl; 5mM MgCl2; 
0.1mM EGTA; 1X 
complete protease 
inhibitor 
Chromosome Conformation 
Capture 
Ligation 
Buffer 
660mM TRIS-HCl, pH 
7.5; 50mM DTT; 50mM 
MgCl2; 10mM ATP 
Chromosome Conformation 
Capture 
2.1.6 Kits and reagents 
Table 2.6 List of kits and reagents used. 
Kit/reagent Supplier Purpose 
CutSmart buffer NEB Restriction digest 
SalHI NEB Restriction digest 
HindII NEB Restriction digest 
BamHI NEB Restriction digest 
EcoRI NEB Restriction digest 
PstI NEB Restriction digest 
rAPid Alkaline 
phosphatase 
Roche Digestion treatment 
PCR extraction 
kit 
Qiagen DNA products clean up 
T4 DNA ligase Invitrogen Sub-cloning 
5x T4 ligase 
buffer 
Invitrogen Sub-cloning 
Ampicillin Sigma Bacterial cell selection 
Zeocin Invitrogen Bacterial cell selection 
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Top10 competent 
cells 
Invitrogen Plasmid DNA transformation 
PIR competent 
cells 
Invitrogen Plasmid DNA transformation 
Luria Broth LifeSci school service 
department 
Bacterial cultures 
Miniprep Qiagen Small scale plasmid DNA 
extraction and purification 
Midi/Maxiprep Qiagen Large scale plasmid DNA 
extraction and purification 
RPMI 1640 
medium 
GIBCO, Invitrogen Cell culture 
DMEM medium GIBCO, Invitrogen Cell culture 
DPBS GIBCO, Invitrogen Cell culture 
Foetal Calf serum 
(FCS) 
GIBCO, Invitrogen Cell culture supplementation 
Penicilin, 
Streptomicin, L-
Glutamine (PSG) 
GIBCO, Invitrogen Cell culture supplementation 
Effectene 
transfection kit 
Qiagen Cell transfection 
2x protein sample 
Laemmli buffer 
Sigma Protein Gel electrophoresis 
MOPS SDS buffer NuPAGE Protein Gel electrophoresis 
NuPAGE Bis-Tris 
SDS-PAGE 12% 
Invitrogen Protein Gel electrophoresis 
Odyssey 
blocking buffer 
LI-COR WB 
SeeBlue Pre-
stained protein 
marker 
Invitrogen WB 
Reporter Lysis 
Buffer 
Promega Luciferase Reporter Assay 
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Luciferase 
Reagent 
Promega Luciferase Reporter Assay 
Bicinchoninic 
Acid Assay 
Pierce ThermoFisher Protein measurement 
T4 Ligase NEB 3C 
T4 Ligation buffer NEB 3C 
RNase Sigma 3C 
Proteinase K Sigma 3C 
Phenol 
Chloroform 
Sigma 3C 
Ethanol Sigma 3C 
Sodium acetate AnalaR Normapur 3C 
Phusion high 
fidelity 
polymerase 
NEB PCR 
Agarose Fisher bioreagents DNA electrophoresis 
GelRed Biotium DNA electrophoresis 
Hyperladder Bioline DNA electrophoresis 
2.2 Methods 
2.2.1 Molecular cloning by digestion-ligation 
Designed elements were synthetically produced through Invitrogen’s 
GeneStrings service. The sequence of the elements included restriction sites 
present in the plasmids aimed to be inserted at. In this way, when ligated after 
being mixed and digested, the fragments would be introduced into the targeted 
plasmids. The synthetic fragments were first reconstituted in nuclease-free de-
ionized water; then, the concentration was determined with the absorbance 
measure of UV light using a NanoDrop spectrophotometer (Invitrogen) for the 
designed elements as well as the employed plasmids. Digestions were prepared 
in a 30 µL volume, the components for each digestion consisted of 3 µL of 10X 
restriction enzyme buffer, 1 µL of restriction enzyme (10 Units), 250 ng of 
synthetic DNA or 1 µg of plasmid DNA, and enough nuclease-free de-ionized 
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water to reach 30 µL. The reaction was incubated for 1 hour at 37°C. Then, the 
temperature was increased to 65°C and maintained for 20 minutes in order to 
deactivate the restriction enzymes. The digested destination vector DNA was 
treated with 10 Units of rAPid alakine phosphatase (Roche) for 10 min at 37°C to 
reduce self-ligation; then the phostatase enzyme was inactivated by increasing 
and maintaining the temperature to 75°C for 2 minutes. The products were 
purified using a PCR extraction kit from (Qiagen).  
A ligation reaction was set with a 1:3 (vector : Insert) ratio,  typically 50 ng of 
vector DNA were used and 1 µL of T4 DNA ligase (Invitrogen) was added. The 
amount of insert DNA was calculated in the following way: 
𝑛𝑛𝑛𝑛 𝑜𝑜𝑜𝑜 𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑜𝑜𝑣𝑣 ∗ 𝐾𝐾𝐾𝐾 𝑠𝑠𝑠𝑠𝑠𝑠𝑣𝑣 𝑜𝑜𝑜𝑜 𝑠𝑠𝑛𝑛𝑠𝑠𝑣𝑣𝑣𝑣𝑣𝑣
𝐾𝐾𝐾𝐾 𝑠𝑠𝑠𝑠𝑠𝑠𝑣𝑣 𝑜𝑜𝑜𝑜 𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑜𝑜𝑣𝑣 ∗ 𝑚𝑚𝑜𝑜𝑚𝑚𝑚𝑚𝑣𝑣 𝑣𝑣𝑚𝑚𝑣𝑣𝑠𝑠𝑜𝑜 𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑜𝑜𝑣𝑣𝑚𝑚𝑜𝑜𝑚𝑚𝑚𝑚𝑣𝑣 𝑣𝑣𝑚𝑚𝑣𝑣𝑠𝑠𝑜𝑜 𝑠𝑠𝑛𝑛𝑠𝑠𝑣𝑣𝑣𝑣𝑣𝑣
Enough water was added for a final volume of 15 µL. The ligation samples were 
incubated in water with ice overnight. This was typically followed by a subsequent 
bacterial transformation. 
2.2.2 Bacterial Transformation 
Two strains of E. coli were used for the transformation of plasmid DNA containing 
the designed inserts; TOP10 E. coli cells were used for vectors PGL3 and 
pcDNA3 vectors, while PIR E. coli were used for constructs inserted in the pCpGL 
plasmid. A small concentration of plasmid DNA (<10 ng) was mixed with 50 µL of 
competent E. coli cells. The antibiotic resistance cassettes in the vectors allowed 
for the use of 100 µg/mL of ampicillin for selection of PGL3 and pcDNA3 vectors, 
whereas 25 µg/mL of zeocin was employed for selection of colonies with pCpGL 
vector. Competent cells were mixed with plasmid DNA, left on ice and then 
heatshocked at 42 °C for 45 seconds, immediately placing them back on ice for 
2 minutes. Sterile Luria broth (LB) (1 mL) was added to foster the recovery heat-
shocked competent cells, after which the sample was shaken in an orbital shaker 
at 225 rpm and 37 °C for 1 hour.   
After this, 10% of the mixture was spread in an agar plate containing the 
appropriate antibiotic for colony selection. The agar plates were then cultured at 
37 °C for 16 hours, after this, plates with colonies were stored at 4°C. Different 
colonies from a single agar plate were picked to inoculate different tubes with 
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5mL of LB culture supplemented with the appropriate antibiotic. These broth 
samples were kept in agitation at 37°C for 16 hours to increase the yield of 
transformed E.coli. If long term storage of the bacterial stocks was needed, 800 
µL of verified starter culture was mixed with 200 µL of sterile glycerol and stored 
at -80°C. 
To check that the intended DNA was present in the cultured bacterial cells, the 
plasmid DNA was extracted (see Plasmid DNA extraction), digested again with 
the appropriate restriction enzimes, and then visualised in an agarose gel (see 
Agarose Gel Electrophoresis). Bands of the appropriate molecular weight were 
excised from the gel and sequenced using the Eurofins service (MWG Eurofins, 
UK). 
2.2.3 Plasmid DNA extraction 
When aiming to obtain small amounts of plasmid DNA, the Mini-prep plasmid 
extraction kit (Qiagen) was used. Bacterial cells from 3 mL of LB broth starter 
cultures were pelleted, lysed and centrifuged in a DNA binding silica column, as 
directed in the protocol from the kit.  For higher yields of plasmid DNA, Midi-prep 
or Maxi-prep kits (Qiagen) were used, 500 mL of LB broth containing the selected 
antibiotic were used to culture cells, were incubated overnight at 37°C with 
agitation (225 rpm), the rest of the DNA extraction was executed following the 
protocol from the kit. 
2.2.4 Cell Culture 
Cells employed for the different experiments were kept at 37°C in aseptic 
conditions in a humidified incubator with 5% CO2 gas distribution. Counting of 
cells was performed using a Neubauer chamber, mixing 10 µL of cells in media 
with 10 µL of Trypan blue.  
Some experiments employed the EBV-negative Burkitt’s Lymphoma DG75 cell 
line (Ben-Bassat et al. 1976), the cells were cultured in suspension, maintained 
at a concentration between 3×105 and 3×106 cells/mL, fed with RPMI 1640 
medium (GIBCO, Invitrogen) supplemented with 10% (v/v) fetal calf serum and 
100 U/mL of penicillin, 100 µg/mL of streptomycin and 2 mM of L-glutamine 
(GIBCO, Invitrogen). The lymphoblastoid cell line 3, referred as LCL#3, is a B-
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cell transformed with B95.8 EBV strain (Sinclair et al. 1994); cell line GM2188 is 
a Lymphoblastoid EBV positive and tightly latent cell line. These cells were 
cultured in the same way as described for DG75 cells. 
The Akata cell line is an EBV positive, Burkitt’s Lymphoma derived cell line; 
inducible to lytic cycle after treatment with IgG (Takada and Ono 1989). It served 
as the base for the generation of the Akata-Zta cell line, which was designed to 
facilitate the study of cells in lytic cycle, since it contains a doxycycline inducible 
Zta expression vector (Ramasubramanyan et al. 2015). These two cell lines were 
also cultured with RPMI medium supplemented with fetal bovine serum, penicillin 
and streptomycin and L-glutamine, as described with the DG75 cell line. The 
Akata cells were harvested 48 hours after induction with IgG, and Akata-Zta cells 
were harvested 24 hours after induction with Doxycycline, a kind gift from Anja K. 
Godfrey. 
In some experiments, adherent 293T cells were employed, these are EBV-
negative, embryonic kidney, epithelial cells (DuBridge et al. 1987; Pear et al. 
1993). The cells were cultured in 75 cm2 flasks, were fed with DMEM medium 
supplemented with 10% (v/v) fetal calf serum and 100 U/mL of penicillin, 100 
µg/mL of streptomycin and 2 mM of L-glutamine (GIBCO, Invitrogen). Since they 
are adherent, they were rinsed and lifted with warm D-PBS, and subcultured with 
a ratio of 1:3 approximately every other day, or after confluency. 
When cells were harvested, they were counted and an appropriate volume 
reflecting the number needed for each experiment, was spun down 5 min at 1300 
rpm. The media was discarded, and the cell pellet washed with warm D-PBS. A 
new centrifugation ensured that the cell pellet was formed and the D-PBS was 
discarded. Cell pellets were immediately used or flash frozen in liquid nitrogen for 
later use, kept at -80°C. 
2.2.5 Cell Transfection 
Transfection of plasmid DNA was performed through electroporation for 
suspension DG75 cells. The cells were split 1:3 the day before transfection to 
ensure viability. For each transfection 1×107 cells in 250 µL of warm serum free 
medium were placed in a disposable 4mm polycarbonate cuvette; with 10 µg of 
total plasmid DNA (5 µg of either pcDNA3 (control) DNA or 5 µg of Zta expression 
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vector (HisZta-pcDNA3) + 5 µg of luciferase reporter vector). The electroporation 
was executed using a BIORAD Genepulser II using 250 volts with 975 µF of 
capacitance.  
Transfection of 293T cells was executed using the Effectene transfection kit 
(Qiagen). The protocol was followed as instructed by the kit, except changing the 
amount of Effectene reagent to 2.5 µL per each µg of DNA. Each transfection 
started by seeding 4×105 cells the day previous to the transfection. A maximum 
of 1 µg of plasmid DNA was added to each transfection (0.5 µg of pcDNA or 0.5 
µg of Zta expression vector + 0.5 µg of luciferase reporter vector). Cells were 
harvested 48 hours after transfection, scraped and washed with warm D-PBS. 
2.2.6 Protein gels and Western Blots 
After mixing with vortex in 250 µL of 2x Laemmli protein buffer, cell pellets were 
boiled for 5 minutes at 125°C, then they were spun down for 1 min at 13000 rpm. 
A volume of 10 µL was loaded per well for each sample, and a control sample of 
5 µL of SEE blue marker (Invitrogen), into commercially available pre-casted Bis-
Tris SDS-PAGE gels to separate proteins and conduct western blots (NuPAGE, 
Invitrogen). Gel electrophoresis was performed at 200 V for 50 min after covering 
the inner chamber of the tank with MOPS SDS buffer (NuPAGE). 
In order to transfer the proteins, after the electrophoresis, the gels were placed in 
contact to a nitrocellulose membrane and sandwiched between filter papers and 
sponges. The sandwich was then placed in a transfer cassette which was 
inserted in the transfer chamber of the tank, preceded by being filled with transfer 
buffer. Current was applied to migrate the proteins and transfer them to the 
nitrocellulose membrane (75V 90min). 
To check if the transfer was successful, after disassembling the sandwich, 50 mL 
of Ponceau S stain was added to the nitrocellulose membrane. After 2 minutes 
of rocking, the Ponceau stain was removed and washed with PBS-Tween buffer. 
After the transfer was completed, the nitrocellulose membrane was blocked for 
45 min with 5 mL of blocking buffer (LI-COR) and 5 mL of PBS-Tween buffer with 
a slow rocking motion. The blocking buffer was discarded and primary antibody 
was diluted in new blocking buffer, added to the membrane and incubated at 4°C 
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overnight with a slow rocking motion. The solution of primary antibody was 
discarded and the membrane was washed with PBS-Tween three times, for five 
minutes at room temperature, while rocked gently. This was followed with a new 
incubation of 45 minutes with secondary antibodies diluted in blocking buffer, at 
room temperature while rocked gently. After 3 subsequent washes with PBS-
Tween, the membrane was placed in the LI-COR imaging system and visualized 
under the 700 and 800 wavelength channels. Images were captured after a 10 
min exposure and imported at 600bpi quality. 
2.2.7 Luciferase reporter assays 
Pellets of 5×106 DG75 cells and 2×105 293T cells were resuspended in 250 µL of 
1x Reporter Lysis Buffer (Promega) by vortexing for 10 seconds, followed by a 
short 15 second spin down at 13000 rpm. The supernatant was transferred to a 
new tube and the cellular debris discarded. After this, 10 µL of lysate was loaded 
per well (manually, in triplicate) of a white 96 well plate; the plate was then placed 
in a plate reader machine (Promega GloMax multi-detection system) which 
added 50 µL of luciferase reagent (LAR reagent, Promega) to each well. After a 
2 second delay, the plate reader integrated a 10 second reading of the sample 
and moved on to do the same to the following well. To obtain a value of 
background noise, 3 wells were loaded with reporter lysis buffer that did not lysate 
any cells. The obtained values from each plate were automatically saved as a 
comma separated value (csv) file. The results reported the measured light as 
relative light units (RLU) for each well. The values of the transfected cells were 
subtracted the background noise values, and were then normalized with the 
values from the bicinchoninic acid assay (BCA, see BCA section and 
Normalization section).  
2.2.7.1 Bicinchoninic Acid Assay (BCA) 
To account for any possible differences in the concentration of protein across the 
different samples being compared in the luciferase assays, BCA assays were 
performed. In each clear plastic 96 well plate, a standard of known increasing 
concentration of Bovine Serum Albumin (Pierce ThermoFisher) was placed in 
triplicates 25 µL, and in parallel 25 µL of the lysate from the transfected cells was 
placed in triplicate in the plate. The following step was adding 200 µL of working 
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reagent (WR, Pierce ThermoFisher) in the wells, and reading the absorbance in 
the plate reader (Promega GloMax multi-detection system) at 560 nm using the 
default BCA program. Three wells which were devoid of BSA or lysate were used 
to obtain a value of background to be subtracted from the wells with BSA and 
lysate. The readings were automatically saved as a csv file accessible using 
Excel. Once the background value was averaged and subtracted to the readings 
of the BSA and lysate, a standard curve was generated with the average 
absorbance value from the wells with BSA, a linear regression allowed to find the 
protein concentration of the wells containing lysate from transfected cells. 
2.2.7.2 Normalization and Statistical Analysis 
The protein concentration values from the BCA assay were averaged and this 
value was used to normalize the triplicate RLU values (with the background 
subtracted) from the luciferase assays. This resulted in three values which were 
in turn averaged and named Normalized Luciferase Activity.  The obtained values 
were used to run a Student T-test used to attain p value for statistical significance 
between different conditions. The T-test was performed through Excel T-test 
function, set as double tailed, with equal variances and an alpha equal to 0.05. 
To test for equal variances across sample arrays, prior to the T-test, an F-test 
was performed in Excel with an alpha equal to 0.05. 
2.2.8 Polymerase Chain Reaction 
The amplification of products for the 3C experiments, was performed based on 
the protocol recommended by New England Biolabs for the use of their Phusion 
High-Fidelity DNA Polymerase. Each reaction was typically set for a 25 µL volume, 
the components were: 5 µL of 5x Phusion HF buffer, 0.5 µL of 10 mM dNTPs, 2.5 
µL of 10 µM primer pairs (forward and reverse), 0.25 µL of Phusion DNA 
Polymerase, DNA template (400 ng for cellular template, 10 fg for genestrings 
controls), and enough nuclease-free water for 25 µL. Several different 
concentrations of cellular template were tested, ranging from 10 fg to 800ng, 
however the results presented in following chapters are from assays performed 
with 400ng of template. Except where stated otherwise, the thermal cycling 
parameters were: 
Initial Denaturation of 30 seconds at 98°C 
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30 cycles of 
98°C for 10 second 
60°C for 30 seconds 
72°C for 30 seconds 
A final extension of 72°C for 2 minutes 
Hold at 4°C 
2.2.9 Agarose Gel Electrophoresis 
Gels were prepared to 1.2% (w/v) of Agarose and TAE buffer. Each gel was 
composed of 50 mL of 1x TAE and 600 µg of Agarose, the suspension was boiled 
to help agarose dissolve. Then, 4 µL of 12500X GelRed DNA stain (Biotium) was 
added to the cooled solution. The liquid was then left to be solidified in the casting 
tray fitted with a gel comb to generate wells. Gels were covered inside of an 
electrophoresis tank, with 1x TAE buffer. Loaded samples were mixed with blue 
DNA loading dye (Bioline), a marker was also loaded into the wells as a control, 
1kb DNA hyperladder (Bioline). The electrophoresis tank was closed, and the 
electrophoresis was performed at 90 volts for 90 minutes. Gels were imaged and 
visualized with the use of the LI-COR imaging system (600 channel). 
2.2.10 Chromatin conformation capture assay 
The cells were centrifuged for 1min at 400g at room temperature, the supernatant 
was discarded and the cell pellets were re-suspended in 500µL of 10% (v/v) 
FCS/PBS per 1x107 cells. Then this suspension of cells was filtered through the 
70µm cell strainer to make single-cell suspension. 
2.2.10.1 Formaldehyde crosslink and cell lysis 
Per each cell pellet of 1x107 cells, 9.5 mL of 1% formaldehyde/10% FCS/PBS 
was added, incubated while tumbling for 15 min at room temperature. The fixation 
was quenched by adding glycine to 0.125M. The tubes were centrifuged 8 min at 
225g at 4°C, and the supernatant removed. Pellets were taken up in 5mL of cold 
lysis buffer and incubated for 10 min on ice. Then, the cells were centrifuged for 
5 min at 400g at 4°C, and the supernatant was removed. 
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2.2.10.2 DNA digestion 
The nuclei were taken up in 0.5mL of restriction enzyme buffer 1.2X (cutsmart), 
and then SDS added to a 0.3% concentration at 37°C, incubating for 1 hour while 
shaking at 900 rpm. Then 50µL of 20% Triton X-100 was added. After this 400 U 
of the selected restriction enzyme was added to the sample, and incubated at 
37°C overnight while shaking at 900 rpm. 
2.2.10.3 DNA ligation 
Once the DNA was digested, 40µL of 20% SDS was added to the sample, it was 
then incubated for 25 min at 65°C, while shaking at 900 rpm. Then 6.125mL of 
1.15 X ligation buffer (New England Biolabs) was added, followed by 375µL of 
20% Triton X-100. A 1 hr incubation at 37°C was performed with gentle shaking. 
After this 100 U of ligase were added and incubated for 4 hrs at 16°C, followed 
by 30 min at room temperature. Then 300µg of Proteinase K were added, 
followed by an overnight incubation at 65°C to reverse cross link the sample. 
2.2.10.4 DNA purification 
After the ligation, 300µg of RNAse was added, and later incubated for 45 min at 
37°C. Then 7mL of phenol-chloroform was added, and mixed. After centrifugation 
for 15min at 2,200g at RT, the supernatant was saved, 7ml of water was added, 
followed by 1.5mL of 2M sodium acetate pH 5.6 followed by 35mL of ethanol for 
precipitation. The samples were stored overnight at -20°C, this was then followed 
by centrifugation for 15 min at 2,200g at 4°C. The supernatant was discarded and 
the DNA pellet was reconstituted in water. 
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2.2.11 Computational methods 
As word processors were needed to alter or analyse sequence, Word and 
Notepad (Microsoft Office) were employed; for the generation of figures Microsoft 
PowerPoint was used, and for calculations and correlations Microsoft Excel was 
employed. When finding ZREs in sequences, 3 different Macros were generated 
and programmed to be executed in Word, a different macro for each different 
class of ZREs: 
Sub HighlightTargetsZREsCLASS2() 
Dim range As range 
Dim i As Long 
Dim TargetList 
TargetList = Array("TGAGCGA", "TCGCTCA", "TGAGCGC", "GCGCTCA")  ' 
For i = 0 To UBound(TargetList) 
Set range = ActiveDocument.range 
With range.Find 
.Text = TargetList(i) 
.Format = True 
.MatchCase = False 
.MatchWholeWord = False 
.MatchWildcards = False 
.MatchSoundsLike = False 
.MatchAllWordForms = False 
Do While .Execute(Forward:=True) = True 
range.Underline = wdUnderlineDotted 
Loop 
End With 
Next 
End Sub 
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Sub HighlightTargetsZREsCLASS1() 
Dim range As range 
Dim i As Long 
Dim TargetList 
TargetList = Array("TGAGCCA", "TGGCTCA", "TTAGCAA", "TTGCTAA", "TGTGTAA", "TTACACA", "TGAGCAA", 
"TTGCTCA", "TGTGTCA", "TGACACA", "TGTGCAA", "TTGCACA", "TGAGTCA", "TGACTCA", "TGACTAA", 
"TTAGTCA", "TGTGTCT", "AGACACA", "TGGCACA", "TGTGCCA", "TGAGTAA", "TTACTCA", "GTTGCAA", 
"TTGCAAC")  ' 
For i = 0 To UBound(TargetList) 
Set range = ActiveDocument.range 
With range.Find 
.Text = TargetList(i) 
.Format = True 
.MatchCase = False 
.MatchWholeWord = False 
.MatchWildcards = False 
.MatchSoundsLike = False 
.MatchAllWordForms = False 
Do While .Execute(Forward:=True) = True 
range.Underline = wdUnderlineDouble 
Loop 
End With 
Next 
End Sub 
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2.2.11.1 Regulatory Sequence Analysis Tools 
Several of the tools that are freely available on the internet were used to generate 
different analysis, however they were all accessed from the main website as it 
was in the second half of 2013 (http://rsat.sb-roscoff.fr/).  
Sub HighlightTargetsZREsCLASS3() 
Dim range As range 
Dim i As Long 
Dim TargetList 
TargetList = Array("GGAGCGA", "TCGCTCC", "TTCGCGA", "TCGCGAA", "TAAGCGA", "TCGCTTA", "TGAGCGG", 
"CCGCTCA", "TGTGCGA", "TCGCACA", "TGAGCGT", "ACGCTCA", "CGGGCGA", "TCGCCCG", "AGAGCGA", 
"TCGCTCT", "CGAGCGA", "TCGCTCG", "TCAGCGA", "TCGCTGA", "TGCGCGA", "TCGCGCA", "TGGGCGA", 
"TCGCCCA", "TTAGCGA", "TCGCTAA", "CGCGCGA", "TCGCGCG", "CGTGCGA", "TCGCACG", "TGTGCGT", 
"ACGCACA", "TTTGCGA", "TCGCAAA", "TTGGCGA", "TCGCCAA")  ' 
For i = 0 To UBound(TargetList) 
Set range = ActiveDocument.range 
With range.Find 
.Text = TargetList(i) 
.Format = True 
.MatchCase = False 
.MatchWholeWord = False 
.MatchWildcards = False 
.MatchSoundsLike = False 
.MatchAllWordForms = False 
Do While .Execute(Forward:=True) = True 
range.Underline = wdUnderlineDotDashHeavy 
Loop 
End With 
Next 
End Sub 
43 
2.2.11.1.1 Sequence upstream from genes 
Sequences from EnsEMBL database were obtained through “RSAT – retrieve 
EnsEMBL sequence”. The parameters were set to obtain the upstream sequence 
(-2000 to +2), relative to the CDS.  
2.2.11.1.2 Consensus sequence 
The sequences were transferred from the previous analysis to the RSAT – oligo 
analysis tool; the parameters were set to mask non-DNA, to purge sequences, 
and to use the human genome as background model, no other parameter was 
changed from the default (van Helden et al. 1998). 
2.2.11.1.3 Matrix scan 
The obtained sequences were transferred to the RSAT – matrix-scan tool, where 
the DNA sequences were scanned with the profile matrices generated in the 
previous step, the analysis was performed with the default settings (Turatsinze et 
al. 2008). 
2.2.11.1.4 Matrix mapping 
The alignments obtained from the matrix scan were mapped with the RSAT – 
feature-map tool, with default settings. 
2.2.11.2 BLASTn alignment 
To analyse the alignments of fragments across sequences, Standard Nucleotide 
BLAST (https://blast.ncbi.nlm.nih.gov/Blast.cgi?PAGE_TYPE=BlastSearch) was 
used, checking the box to align two or more sequences, setting “Somewhat 
similar sequences (blastn)” program selection for a low level of stringency, and 
with a filter for species-specific repeats for Human, no other setting was changed. 
2.2.11.3 Primer design 
Primers were designed using NCBI Primer-Blast web tool, parameters were set 
to obtain primers of at least 20 bp in length and 60° C as optimal melting 
temperature, no other parameters were changed. The specificity of the primers 
was checked against human and EBV genomes (NC_007605.1) 
(www.ncbi.nlm.nih.gov/tools/primerblast).   
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Chapter 3. Enhancer capability of Zta binding sites 
3.1 Introduction 
In the Introduction, the process through which EBV inserts its DNA into the cell 
was reviewed; as well as the way in which the infection remains latent until Zta 
initiates a cascade of signals that switch the infection into a lytic state of gene 
expression. 
Zta binds to the AP1 like sites, known as Zta response elements (ZREs) 
(Hardwick et al. 1988; Lieberman et al. 1990). ZREs can be classified as 
unmethylated and methylated (Bergbauer et al. 2010). Zta can preferentially bind 
to ZREs with an integral CpG motif when they are methylated (Bhende et al. 
2004). It activates its own promoter as well as many other viral genes (Bergbauer 
et al. 2010; E. Flemington and Speck 1990a; Ramasubramanyan et al. 2012). 
Previous experiments performed in the lab mapped Zta binding sites to the 
human genome through ChIP-sequencing (Ramasubramanyan et al. 2015). The 
numerous interactions between Zta and the human genome provided a large 
number of regions to analyse for the exploration of Zta influence over gene 
expression.  
Although Zta has previously been characterized to be acting at promoter-proximal 
regions in the EBV genome (Adamson and Kenney 1998; Bhende et al. 2004; 
Packham et al. 1990; Ramasubramanyan et al. 2012), when studied in the human 
genome, some of the mapped peaks of Zta were found near promotor regions of 
genes; and interestingly, most other interactions are found in places not 
contiguous with promoters. 
This pointed towards an idea; sequences where Zta binds could have enhancer 
properties. In this work, I asked the question: Is Zta binding to sequences with 
enhancing properties? the exploration of this idea was executed, first by 
identifying potential sequences that could be conferring enhancing activity, then 
by trimming and editing components in the sequence that could work as 
enhancers, and lastly by inserting this sequence into vectors and testing its 
enhancing capabilities through Luciferase Assays.  
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To select which interactions to examine, previous research performed in the 
Sinclair Lab analysed the change of mRNA levels in the transcriptome of B cells 
(Ramasubramanyan et al. 2015). When the mRNA levels were compared 
between latency and lytic cycle, a list ranking the genes from highest fold change 
to lowest was generated. This helped prioritize which interactions to analyse. 
3.2 Results 
Aiming to discover if the sequences to which Zta binds had enhancing properties 
not analyzed before, an initial step was taken; selecting which genomic 
sequences were of interest. Two different methods of selection were used: the 
first to be presented focused on 6 specific sequences that due to their 
characteristics could be candidates to be considered enhancers. The second 
method of selection focused on a higher number of sequences which were 
associated with Upregulated genes (Figure 3.1 left and right, respectively). In the 
interest of clarity, first I will present the approach for the enhancers method, and 
then the Upregulated genes method. 
3.2.1 Enhancers method of identification of genomic sequences 
Initially, a simple and straightforward process of selection was used in the 
enhancers method. A previous master’s project analysis confirmed Zta binding to 
the promotor region of the FOSB gene using qPCR, as well as a many fold 
increase in the levels of expression of mRNA when compared to in latency. A 
similar change in the mRNA levels happens with AHNAK; also, they both showed 
Zta peaks within 2kb away to their transcription start site (TSS) (Figure 3.2 and 
3.3). The Zta peaks close to these genes are not isolated, but surrounded by 
smaller peaks, making them interesting potential enhancers. This, therefore, 
presented the opportunity to consider the sequences from prominent Zta peaks 
proximal to genes FOSB and AHNAK to be analyzed.  
3.2.2 Enhancers method of analysis of sequences and element design 
The sequences selected to be analyzed through the enhancers method were 
retrieved through the use of the UCSC Genome Browser. Sequence under three 
peaks in proximity (less than 20 kb away) to AHNAK were retrieved, as well as 
sequence under five peaks close to FOSB. (continues in page 50). 
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ELEMENT
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DESIGN METHOD Design Method
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Mapped
Matrices
occurrences
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Word/PPT curation
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Figure 3.1. Diagram of how the different elements were designed and
produced. UCSC acronym for University of California Santa Cruz genome
browser. RSAT acronym for Regulatory Sequence Analysis Tools. BLASTn
acronym for Basic Local Alignment Search Tool from NCBI. (See subsections
2.2.11.1 to 2.2.11.4 in Chapter 2.2.11 Computational methods).
46
Fi
gu
re
3.
2.
C
lu
st
er
s
of
pe
ak
s
pr
ox
im
al
to
FO
SB
ge
ne
pr
op
os
ed
fo
r
su
pe
r-
en
ha
nc
er
ac
tiv
ity
.
Th
e
al
ig
nm
en
t
of
th
e
FO
SB
co
ns
tru
ct
de
si
gn
ed
(la
be
le
d
fo
sB
),
ca
n
be
ap
pr
ec
ia
te
d
in
th
e
lo
w
er
m
id
dl
e
pa
rt
of
th
e
im
ag
e,
w
ith
th
e
st
re
tc
he
s
of
se
qu
en
ce
be
ne
at
h
th
e
pe
ak
s
us
ed
to
de
si
gn
sa
id
co
ns
tru
ct
.N
ot
e
th
at
th
e
ac
tu
al
FO
SB
ge
ne
is
on
ly
sh
ow
n
pa
rti
al
ly
in
th
e
lo
w
es
tr
ig
ht
m
os
ts
ec
tio
n
of
th
e
m
ap
.
47
Fi
gu
re
 3
.3
 C
lu
st
er
s 
of
 p
ea
ks
 p
ro
xi
m
al
 to
 A
H
N
AK
 g
en
e 
pr
op
os
ed
 fo
r s
up
er
-e
nh
an
ce
r a
ct
iv
ity
. T
he
 a
lig
nm
en
t o
f t
he
 A
H
N
AK
c
o
n
s
tr
u
c
t 
d
e
s
ig
n
e
d
, 
c
a
n
 b
e
 a
p
p
re
c
ia
te
d
 in
 t
h
e
 l
o
w
e
r 
m
id
d
le
 a
re
 o
f 
th
e
 i
m
a
g
e
 (
la
b
e
le
d
 “
a
h
n
a
k
”)
, 
w
it
h
 t
h
e
 s
tr
e
tc
h
e
s
 o
f 
s
e
q
u
e
n
c
e
be
ne
at
h 
th
e 
pe
ak
s 
us
ed
 to
 d
es
ig
n 
sa
id
 c
on
st
ru
ct
. T
he
 a
ct
ua
l A
H
N
AK
 g
en
e 
ca
n 
be
 a
pp
re
ci
at
ed
 in
 th
e 
lo
w
es
t p
ar
t o
f t
he
 fi
gu
re
.
48
Peak 732
>hg19_dna range=chr11:62305993-62306348 5'pad=0
3'pad=0 strand=+ repeatMasking=lower 356bp
GCCTACAGCCGTTTACATCCGGAAAGTATCAACAGTCAATCAATGCATGTATA
CCGGCTGCCTCCATATGCCCAACACTATACTTTGCACTACAGACGGAACCAGC
CAGGGATGGACACAGCTGGGCCCAGCACCTAATTACACGCTGCGTTAGACGGT
GACCTCACATCACTCACGCACCCATGTGCCAGACAGGGAGATTTAAGACTCAG
TTCCTGTCACAGATACATATGATGAGCAAAGTGCACTAGCTGTGACCGATTTT
GCCGCAGAATATTCCAGAAGGCTTGGGAGCCTTCTAGGGGAAATGAAATATAC
ATGGGGTCTTGAAGGTGCTACAGGTGACCTCTGAGGAT
Peak 733
>hg19_dna range=chr11:62310818-62310998 5'pad=0
3'pad=0 strand=+ repeatMasking=lower 181bp
CGCAGGCAGAGGTGACACATCCAGGCACGCCACAAGGGGAAGACCTTCATTCA
CAACCAGTGGGATACTCTCTCACAGGCAATGACACACATCTCACTCAGAGACA
AGCTGTGACATGGTGGTCACAAGGACCTAAAGCCACAGTGGGACGACACCTGC
AATGCTATCAGTGACCTACCTA
Peak 734
>hg19_dna range=chr11:62312555-62312701 5'pad=0
3'pad=0 strand=+ repeatMasking=lower 147bp
AGGTCTAAGGACCTGACTGACTTGGGAGGCTCCCACACTGCCTTTCCACAAAT
CCCCTCCACAGAGCAGGGCACTCTGCAGCGACCGCACGCTCCCTGGGAGCACC
TCACTGCCACGGTCGCCGCGGCGGGAGCCACACCCTGCGAA
Figure 3.4. Sequences corresponding to peaks proximal to AHNAK. The
DNA sequences are coming from the human assembly GRCh37, also known as
hg19. The range of the sequences is shown, coming from the 11th chromosome,
each from a different range. Any repetitive sequences would be shown in lower
case letters. (A) Sequence for peak 732. (B) Sequence for peak 733. (C)
Sequence for peak 734.
A
B
C
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(continues from page 45) Any repetitive sequence was excluded from the design 
process, therefore sequence under two peaks close to FOSB was discarded, 
leaving us with sequence under 3 peaks close to AHNAK (Figure 3.4) and 3 
peaks close to FOSB (data not shown). 
3.2.3 Upregulated genes method of identification of genomic sequences 
The other process of selection for which sequences to analyze, the Upregulated 
genes method, involved a different criteria. Instead of only considering nearby 
Zta peaks, the focus was on finding some shared or perhaps ubiquitous trait or 
component with enhancing capabilities, pervasive to several sequences; 
therefore, the analysis needed to encompass many sequences.  
Since previous ChIP-seq experiments provided many different genes that have a 
Zta interaction within 2 kb from their transcription site, the idea of ranking them 
based on the fold increase of mRNA levels, helped select sequences to analyze 
(Ramasubramanyan et al. 2015). A list was then generated, composed of the top 
30 genes with a higher than 5 fold increase of mRNA levels; which was used to 
retrieve the sequence 2 kb upstream from the transcription start site of those: 
ANXA2, FAM213A, WFIKKN2, AHNAK, LAMA3, C16orf73, GRIN1, LRP2, 
CD109, EMP1, PDGFB, BPIFB2, HAND1, EPHB3, FAM83C, GDF2, CRMP1, 
CTSW, USP50, RASGRF2, SCIMP, FCER1G, BCL2A1, FOSB, CPNE6, BOLA1, 
RASA3, GPRC5C, ARRB1, PDE1B.  
3.2.4 Upregulated genes method of analysis of sequences and element 
design  
In the Upregulated Genes method, the aforementioned list of 30 genes of interest 
was submitted to the Regulatory Sequence Analysis Tools (RSAT) website as 
described in the Materials and Methods section. The multiple sequences 
retrieved underwent three different analyses; through the use of the Basic Local 
Alignment Search Tool (BLASTn), matching short sequences across the 
analyzed sequences were found. The RSAT oligo-finder allowed to find a 
consensus sequence across the sequences conceptualized as matrices. The 
UCSC Genome Browser helped integrate the information found across platforms. 
Each will be expanded on, in the next section. 
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Given that previous research performed in a master’s project showed through 
qPCR that Zta was interacting with the promotor regions of FOSB, SCIMP, 
BCL2A1 as well as peaks 2574, 2575 and 2576 (close to FOSB), the 
comparisons made between the sequences and the recently mentioned targets 
became a focal point of the design.  
3.2.4.1 Derivation of matrices of Zta binding sites 
3.2.4.1.1 Identification of genomic sequence of proposed interactions 
Since the aim was to find interesting elements in the sequence upstream of the 
TSS of the genes, the sequences were requested to encompass from -2000 bp 
to +2 upstream of the TSS. The sequences came from the EnsEMBL database 
version 89, prompted by the RSAT – retrieve EnsEMBL sequence tool. The 
sequences were retrieved in FASTA format. 
3.2.4.1.2 Basic Local Alignment Search Tool 
Since part of the aim of analysis was to find some pervasive element found across 
all the different sequences, the sequences retrieved from the list of genes of 
interest were aligned against each other using BLASTn. This produced an 
extensive comparison between different sequences, resulting in finding various 
short segments of sequence to be found across sequences (Figure 3.5). 
Although the alignment scores were small, that is only a reflection of the size of 
the fragment, and not the Expect value, which takes into consideration the chance 
of getting a false positive given the background of the analysis. In other words, 
the smaller the alignment and the bigger the list of and size of sequences to 
compare, the larger the expect value. Alignments of a larger span give a smaller 
expect value, compared to alignments of a shorter sequence.  
This showed that there were indeed short pervasive sequences found across 
several of the different sequences analyzed. 
3.2.4.1.3 Regulatory Sequence Analysis Tools 
Although some alignments were found across several sequences through 
BLASTn, no ubiquitous and pervasive element was found in most of 
the sequences, therefore the analysis shifted towards (continues in page 54) 
Figure 3.5. BLASTn alignment of sequences with FOSB finds several
matches. The sequence for FOSB goes from -2500 to +2 in order to
incorporate the region corresponding to peak 2576. (A) Illustrative miniature.
The thick red line represents the query sequence against which the subject
sequences were compared. Black vertical squares/lines represent sequence
similarity or matches of a given region against the query, in this case FOSB.
Since the analysis was made between all sequences, the thin red line
represents an alignment of the sequence of FOSB against itself, therefore it is
shown in red, illustrating a very high alignment score. The color boxes represent
the coloration the sequences would get based on the alignment score; the
alignments found and used in subsequent analysis are in black showing that the
length and therefore alignment score is low. The yellow arrow added to the
figure points towards an element detected to be present in many of the
sequences analyzed. (B) One of several matching sequences found, referred to
in (A) with the yellow arrow, is found in the sequences of USP50, GRIN1,
LAMA3, MEIOB, SCIMP, BOLA1 (the rest of the matching sequences are not
shown).
A
B
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Matrix 1 
Consensus csyCAGGGrCTGrr
consensus.rc   YYCAGYCCCTGRSG
a 19 13 0 0 58 0 5 11 30 2 6 2 22 25
c 26 22 34 74 0 0 0 0 0 61 1 6 13 13
g 19 24 19 0 0 74 69 63 44 11 1 62 30 27
t 10 15 21 0 16 0 0 0 0 0 66 4 9 9
//
Matrix 2 
consensus rhTCAGGGRGrw
consensus.rc WYCYCCCTGADY
a 10 7 0 0 27 0 0 0 20 0 9 9
c 6 8 0 27 0 0 0 0 0 0 6 3
g 9 5 0 0 0 27 27 27 7 27 11 5
t 2 7 27 0 0 0 0 0 0 0 1 10
//
Matrix 3 
consensus vcCCACACASrca
consensus.rc TGYSTGTGTGGGB
a 22 15 12 0 44 0 63 0 64 0 23 11 27
c 21 25 45 64 13 64 1 63 0 46 6 34 13
g 16 14 2 0 7 0 0 1 0 18 35 10 15
t 5 10 5 0 0 0 0 0 0 0 0 9 9
//
A
B
C
D
E
F
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The sequences from the list of genes of interest were then analyzed through the 
motif discovery tool “Oligo Analysis” from RSAT. The analysis produced 3 
matrices generated from 77 different sites for Matrix 1 (Figure 3.6 A), 27 sites for 
Matrix 2 (Figure 3.6 C), and 64 sites for Matrix 3 (Figure 3.6 E). It is important to 
comment that the sequences of peaks 2574, 2575 and 2576 (close to FOSB) to. 
(continues from page 51) detecting a consensus sequence of an 
over-represented sequence, which was also added to the analysis used to 
find the Matrices. 
Then, in order to identify the places within the sequences that best reflected the 
consensus sequences of the generated matrices; the “Matrix scan” tool of RSAT 
was used. This found the incidences of each matrix present on any sequence. 
This analysis also gave each match with a “weight” score that reflects how much 
the matrix gets represented in the matched sequence outside of chance brought 
by the matrix composition or the background model.  
This analysis was performed scrutinizing the presence of the 3 matrices in the 
upstream sequences used to generate the matrices. Out of the found incidences 
of the matrices on the sequences, we focused on the ones found in the upstream 
sequence of FOSB (Figure 3.7), SCIMP, BCL2A1, and peaks 2574 and 2575. 
Figure 3.6. Three Matrices were generated through RSAT analysis. In order 
to obtain these matrices, the sequence 2 kb upstream of the transcription start 
site of the list of genes of interest wa  analysed. (A) logo plot of Matrix 1, followed
by its reverse complementation. The relative height of the letter represents the 
estimated probability of such base to be found in such position. (B) Matrix 1, each 
number represents the percentage of probability for the base to be found in a
particular position. (C) Logo plot of Matrix 2, followed by its reverse 
complementation. (D) Matrix 2. (E) Logo plot of Matrix 3 followed by its reverse 
pl mentation. (F) Matrix 3. 
Figure 3.7. Matrices incidences in FOSB (fragment). The incidences were 
found on the sequences used to generate the matrices. Each line corresponds 
to an instance of one of the matrices found against the sequence of FOSB. 
The sequence for FOSB goes from -2500 to +2 in order to incorporate the 
region corresponding to peak 2576. The weight value referring to how much 
the compared sequence resembles each matrix outside of chance, the higher 
the number the less probable the match happened by chance 
55 
The matrices incidences were also mapped against the sequences upstream of 
the genes of interest as part of the RSAT tools, resulting in a visual representation 
of the sequence and each time a sequence reflected one of the matrices. The 
results are shown for FOSB which clearly depicts several incidences of the 3 
matrices (Figure 3.8). 
3.2.4.1.4 Alignments and verifications 
In order to find components of interest within the retrieved sequences through the 
Upregulated Gene method, a macros command was programmed and executed 
on Word. Sequences were retrieved with a masking of repetitive sequence in 
lower case characters, and the sequence found to be part of a peak to be 
presented in bold text (Figure 3.9 A). This allowed to find interesting alignments 
of the matrices incidences mapped in close proximity to ZREs or sequence 
matches found through BLASTn (Figure 3.9 B). 
To unify the analysis obtained through BLASTn and RSAT as well as the visual 
advantages of the UCSC ChIP-seq map, the merging of the visual maps helped 
create an alignment of analysis across platforms. This was helpful to visualize 
where the interesting components of each analysis could fall in alignment relative 
to components of different analysis; strongly corroborating the presence of 
consensus sequence across platforms of analysis, some in areas of high 
conservation (See Figure 3.10, 3.11 and 3.12). 
3.2.4.2 Reporter genes with Zta binding sites 
The visual alignment of analyses, allowed to generate a table with the 
representations of each matrix according to its weight score, selected because of 
their pervasive presence across sequences, found at the upstream sequences of 
SCIMP, BCL2A1, FOSB and peaks 2574 and 2575 (Table 3.1). The weight score 
represents how much the matrix is represented and with resemblance in the 
sequence outside chance, the higher the number the less probable the match 
happened by chance. This illustrates that there were instances where some of 
matrices could not be found in some sequences, for instance no matrix had a 
match in the sequence for peak 2575. (continues in page 62)
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WYCYCCCTGADY 
R -2243 -2232 ACCCCTGTGAGC 1.5
AGTCACCTGTACCCCTG．．TGAGC．．．．．CA．．AGA．．．TTGCA．．．．．ACAGTACATG
A
B
>Homo_sapiens-ENSG00000125740-FOSB-ENST00000585836-
ENSP00000467497 ENSG00000125740-ENST00000585836-
ENSP00000467497; upstream from -2500 to 2; size: 2503;
location: chromosome:GRCh37:19:1:59128983:1 45969345
45971847 D
aactctgtctcaaaaaacaaaacagaacaaaacaaaaattagccaggtgtggtggcgcac
acctgtaatcccagctactcgggaggctgaggcaggagaatcacttgaacccaggagatg
taggctgcagtgagccgagattgtggcactgcactccagcctgggcaacagagtgagact
ctgtcaaaaaaaaaaaaaaaaaaCGTCAGATTCATGAACCCCATTTGCTAAGAAGATTTG
CTCAGGTAGTCACCTGTACCCCTG．．TGAGC．．．．．CA．．AGA．．．TTGCA．．．．．ACAGTACATGCTAAGAGCAGT
AAGAAGGAGATTGTAAAGCTTAGAAAGACCTGACAggccaggcgctgtggctcacgcctg
taatctcgacacttcgggaggccgaggcaggcggatcaccaggtcaggagttcaagacca
tcctgaccaatatggtgaaaccccgtctgtactaaacatataaaaattagcttgacgtgg
tggcccgcgcctgtagtccagcaactcgagaggctaaggtgaggcggaggttgcagtgag
ccgagatcgccactgcactccagcctggcggcagagcaagactccgtctcaaaaaaaaaa
aaaaaaaaaaaaaaaaaaaGACCTGACAAGTGAAAGCTACTAATATTGCCATTATCATTT
AAAAAAACCCCAGACACAGGTTTTTCAGGGAGTTTCATCCAACCAGGCAGGTCTCAGAAA
TCAGAAAAGAaatggaaagggtaggaaatctggagtttgacaattctgagtttgaatttc
ttgtgatgggatcttgggcaagtcatttaacctccctgagtatcatttttttcttttata
aaatgaagatttttctctcttaaccttccagagctgttttaaggattacaaatcttctac
tgaaaggcgtagcacaggagctgtgcttggcaagtgccaaatacaaggcattaattattA
TTATTAGAATTAATAATAATATCCCCTCCCTCTTACACATTCTTTGTCTCCGGGTGGATT
AAAAGGTGGAAGGAGAGGCTACCAACACCATCAGAAGAGAGGCTTCTCTCTAAGTTTCAT
TTCCCATCTCCTCCAAATCCGCATCCCTCCCAAACGCCGGACCTGTAAGGCCAGCAGGGT
CCAAGACACACATCCTTTGCCCAGCGGGGAAGATTAaagctaaagctcagagaggg．．．．．．．aaaa．．．．
catttcctaagctcgcacagcgaatcaggacagaaaccaggacgagcctcggaatccctC
CATTACCTCCACTTTCACCTGAGCATCACAGCCCGCTCGGGACTCAGTTTCCCCACCTAC
GTGACCACACCACACTAATCAGGGTCTCCTTTTGGAGATCTGCTCTTCTTCTCGAATGGG
GGCGCTGCACCATCGGTAGAACAGGGTAGGTGGGGGCGCCAGAGGTGAAGGGGACCTGCA
GGCTGGGGTCTTCCCCGCCCGGGTCAGCGGGGTCCCTGCGGGGCTAGTCTAAGCGCCTAT
TATTACCAGCCCCCGGGGCGGCGTTGCACTGCGCAggcgcgggcggggcgcgggcgcgcg
cgcgAGCGAGCGAGGGATTCCCTCTGACGTCATTGCTAGGATACCAAACAAACACTCCGC
CGCGCCGGCCGAGCTCCTTATATGGCTAATTGCGTCACAGGAACTCCGGGAAGGCGGGGC
CGGGATCCCCTCCCGCCGAGTGGCCCGGAACGCAACCCCCGAGACCCCCAGGGCCCCGAG
GGTCATGCAAGTGACCAGATCGAGTCTAGAACAGACCTCTTGCTGGACAGTGCGGGACTC
GATTTGGCGGGGCCGGAGATTTGGGGAAGTTTGTCCAGCAAGGGGCGGGTGACGTAAGCA
GGGGGGCGGGTCCCGGGCATATAAATACAGGCTGGCGGGTCTGTGCTTCATTCATAAGAC
TCAGAGCTACGGCCACGGCAGGGACACGCGGAACCAAGACTTGGAAACTTGATTGTTGTG
GTTCTTCTTGGGGGTTATGAAATTTCATTAATCTTTTTTTTTCCGGGGAGAAAGTTTTTG
GAAAGATTCTTCCAGATATTTCTTCATTTTCTTTTGGAGGACCGACTTACTTTTTTTGGT
CTTCTTTATTACTCCCCTCCCCCCGTGGGACCCGCCGGACGCGTGGAGGAGACCGTAGCT
GAAGCTGATTCTGTACAGCGGGACAGCGCTTTCTGCCCCTGGGG．．．．．．．．．．．．．GAG．．．CAACCCCTCCCTC
GCCCCTGGGTCCTACGGAGCCTGCACTTTCAAGAGGTACAGCGGCATCCTGTGGGGGCCT
GGGCACCGCAGGAAGACTGCACAGAAACTTTGCCATTGTTGGAACGGGACGTTGCTCCTT
CCCCGAGCTTCCCCGGACAGCGTACTTTGAGGACTCGCTCAGCTCACCGGGGACTCCCAC
GGCTCACCCCGGACTTGCACCTTACTTCCCCAACCCGGCCATAGCCTTGGCTTCCCGGCG
ACCTCAGCGTGGTCACAGGGGCCCCCCTGTGCCCAGGGAAATG 
57
58 
Figure 3.9. Annotation and alignment of sequence upstream of FOSB. (A) 
Sequence upstream of FOSB with annotations in text font. Sequence in bold 
corresponds to the bases that constitute the peak of interaction between Zta 
and the human genome. Sequence underlined with dashes, double lines, 
single lines and bold lines correspond to the sequence of known ZREs. 
Sequence underlined with dots marks sequence found to be shared across all 
the sequences found in the BLASTn analysis. Sequence boxed represent 
iterations of where the matrices were found in RSAT. Sequence in lower case 
represent repetitive sequence. (B) Direct alignment of matrix 2 with FOSB 
upstream sequence. The top line in red is the consensus sequence of Matrix 
1. The second line comes from the RSAT matrix scan analysis, where it found
an instance of sequence from FOSB upstream sequence, in the Reverse
strand, that spans from -2243 to -2232. The value at the rightmost part of the
second line is the weight value referring to how much the compared sequence
resembles matrix 2 outside chance, the higher the number the less probable
the match happened by chance. The third line is part of the sequence retrieved
from the UCSC genome browser. The boxed sequence represents the
alignment to the matrix, the sequence dotted represents sequence found to be
shared across the list of genes of interest through BLASTn (See Fig 3.5 and
Fig 3.10). The sequence for FOSB goes from -2500 to +2 in order to
incorporate the region corresponding to peak 2576.
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(continues from page 55) Two different designs were used to compile the 
incidences of the matrices. One design compiled the top 4 instances of each 
matrix (according to its weight score) found across SCIMP, BCL2A1, FOSB and 
peak 2574. This was referred as 4OEM as an acronym for 4 of each matrix 
(Figure 3.13 A). The other design compiled the top instance of each matrix, 
referred as 1OEM (Figure 3.13 B). 
3.2.4.3 Synthetic generation of elements through GENESTRINGS 
Aiming to produce a synthetic DNA sequence composed of the elements found 
in the previous analyses, synthesis of the designed elements was carried out by 
the GENESTRINGS service. In order to have the capacity to be inserted into 
different vectors, two pairs of restriction sites, as well as GC clamps, were added 
to the 5’ and 3’ ends of the sequences (Figure 3.13 and Figure 3.14).  
3.2.5 Element enhancing effect 
Once all 4 elements were designed with restriction sites to the ends of their 
sequence, they were synthetized through the GENESTRINGS service of Life 
Technologies. (continues in page 65) 
>4OEM
GGGCCCCTGCAGGGATCCCTGAGCCGCAGCAC．．．．TCCAGCC．．．．．．．ACTGCTGTCTC
CTTAGCGAGGCCGTGGGCC．．．TCGCTGGG．．．．．．．．AGTTCTGTCTCACAGTGAATTAA
TCACAG．．．GATGAGGAAGTGGC．．．．．．．．．．．．．．TT．．CTCTGAAACAGGACAGCGCTTTCTGCCC．．．．．．．
CTGGGG．．．．．．GAG．．．CAACCCCTCCACTCAGTCAAGCTCAGTGAGCA．．．．．．．．TTC．．．TCAGCA
CTAaagctaaagctcagagaggg．．．．．．．aaaa．．．．catttcctaaAGTCACCTGTACC
CCTG．．TGAGC．．．．．CA．．AGA．．．TTGCA．．．．．ACAGTACATGAGCAAAACTGCAGG．．．．ACTCAGT．．．．．．．
GAGTG．．．．．GTTTCTGTGGATCTAGGAATGCTCACGGCAAA．．．．．．．．．．．．CTC．．．GTCTGTGGGG
ACACCAAACCAGGCCCTGTTCTC．．．TGCCACCCAGGCT．．．．．．．．．．．．．G．TTTTGTAGTCACA
ACTCATCCCCAACACACACT．．．．．．．．．．CCCA．．．．ACACCCTGTGTAGATATG．．AATGTGTG．．．．．．．．
TG．．CAGTTGTGAGTCTGTCGACACTAGTGGGCCC
>1OEM
GGGCCCCTGCAGGGATCCGGACAGCGCTTTCTGCCCCTGGGG．．．．．．．．．．．．．GAG．．．CAACC
CCTCCAGTCACCTGTACCCCTG．．TGAGC．．．．．CA．．AGA．．．TTGCA．．．．．ACAGTACATGAGG
CCCTGTTCTC．．．TGCCACCCAGGCT．．．．．．．．．．．．．G．TTTTGTAGTCGTCGACACTAGTGGGC
CC 
Figure 3.13. Compiled Matrices instances into 4OEM and 1OEM.
These sequences were found to be the most pervasive matrix
instances. Sequence is annotated as in Figure 3.9. As spacers, there
are 10 nucleotides to each side of the either boxed sequence, (it
being the matrix alignment (RSAT)) or dotted sequence (shared
sequence fragments (BLASTn)). Sequence highlighted in blue is a
GC clamp, sequence highlighted in red marks a PstI restriction site,
sequence highlighted in green marks a BamHI restriction site,
sequence highlighted in purple marks a SalI restriction site and
sequence highlighted in orange marks a SpeI restriction site. (A) The
4 top instances found for matrix 1, 2 and 3 compiled into 4OEM. (B)
The top instances found for matrix 1, 2 and 3 compiled into 1OEM.
A
B
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Figure 3.14. Elements designed from the peak clusters proximal to FOSB
and AHNAK genes. Any repetitive sequence found in the peaks was excluded.
The sequence in blue represents a GGGCCC clamp added. On the 5’ end,
sequence in red marks a PstI restriction site, while sequence in green marks a
BamHI restriction site. On the 3’ end, sequence in purple marks a SalI restriction
site and sequence in orange marks SpeI restriction site. (A) Sequence of FOSB
element. (B) Sequence of AHNAK element.
>FOSB
GGGCCCCTGCAGGGATCCGGGCGAATCTCCGAGCAGAGAGAAGAAATTGAGTG
TGTGACAGTGTGAATGGATGTGACTATAGGTGAGCAACAGTCGGTGACAATGT
GCACATCTGGTATTTCCTGTGTGAGAGCAAAACTACAGGACTCAGTGAGTGGT
TTCTGTGGTTTGCACTTGTGTATCTGGGTGTATGGGAGTGTGTAGCCCTGCTG
ACTGTGTAGATATGAATGTGTGTGCAGTTGTGAGTCTTGCATGTGGTCATCTA
TGTGAAACAATGCCTGTATAAGTACCCATGGATGTGCACGGTTTTGCCTCTAG
CCGTGCATTTCTGGTTCTGTGTGTGTGTGTTTCTGGGACATTCTTCAAGTCCA
CAACTCTGAGGGTATCACTGTGAGAGCAGGGGTCCTAGCTCTACCCATTTGTG
TGTGTGTGGAGATGTGTAAGTCTATGTAGACAAAAGTGTGTGTCATTTACTGT
GTTTGGGGTGTGAACACCTATGTGATGTGTTTGCACAACTGCACGTGTTTTGT
TCTGTGTGTGTGATCGTGTGTTCAAATAAGTCATCTTGTCTAGTCATCAGGTG
CCTGCACAGACAAAGGTGAAAGGTGTCTGCCTGTTGAGATCTGTGGATAGGGT
GTATATATGGACATCTCAGCCTGTCTACGTGTGTATCTGTCTCTGTCCTCACG
GCAAAAGAGAGGTCGACACTAGTGGGCCC
>AHNAK
GGGCCCCTGCAGGGATCCGCCTACAGCCGTTTACATCCGGAAAGTATCAACAG
TCAATCAATGCATGTATACCGGCTGCCTCCATATGCCCAACACTATACTTTGC
ACTACAGACGGAACCAGCCAGGGATGGACACAGCTGGGCCCAGCACCTAATTA
CACGCTGCGTTAGACGGTGACCTCACATCACTCACGCACCCATGTGCCAGACA
GGGAGATTTAAGACTCAGTTCCTGTCACAGATACATATGATGAGCAAAGTGCA
CTAGCTGTGACCGATTTTGCCGCAGAATATTCCAGAAGGCTTGGGAGCCTTCT
AGGGGAAATGAAATATACATGGGGTCTTGAAGGTGCTACAGGTGACCTCTGAG
GATCGCAGGCAGAGGTGACACATCCAGGCACGCCACAAGGGGAAGACCTTCAT
TCACAACCAGTGGGATACTCTCTCACAGGCAATGACACACATCTCACTCAGAG
ACAAGCTGTGACATGGTGGTCACAAGGACCTAAAGCCACAGTGGGACGACACC
TGCAATGCTATCAGTGACCTACCTAAGGTCTAAGGACCTGACTGACTTGGGAG
GCTCCCACACTGCCTTTCCACAAATCCCCTCCACAGAGCAGGGCACTCTACAG
CGACCGCACGCTCCCTGGGAGCACCTCACTGCCACGGTCGCCGCGGCGGGAGC
CACACCCTGCGAAGTCGACACTAGTGGGCCC
A
B
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3.2.5.1 Transfections and Reporter Assays 
Three different vectors with different properties were used aiming to test different 
aspects of the possible enhancer activity. The vectors used were: 
1. A vector composed of a pCpGL-basic backbone and a BHLF1 promoter
region was selected to be used (Hammerschmidt and Sugden 1988;
Ramasubramanyan et al. 2015). This choice was made, since previous
empirical research, proved that Zta upregulates the activity of the BHLF1
gene through its interactions with ZREs present in the BHLF1 promoter
sequence. For this reason, the vector was employed to test if any
enhancer activity of the elements reflected changes in luciferase activity
(Figure 3.15 A).
2. Another vector composed of a pCpGL basic backbone but containing a
mutated BHLF1 promoter (BHLF1-Mut) sequence inserted was also
selected to be used (Klug and Rehli 2006; Ramasubramanyan et al. 2015).
This choice was made, since previous experiments showed that when the
ZREs in the sequence are mutated, a loss of the activation caused by the
interaction with Zta can be observed. Therefore, this tested if the supposed
enhancer activity of the designed elements are present on a promoter not
regulated by Zta (Figure 3.15 B).
3. A third vector composed of a pGL3 enhancer backbone and a minimal
promoter sequence of the gene CIITA was selected (CIITA -214+52). This
choice was made since previous research showed that the CIITA promoter
activity does not greatly change when Zta is present in EBV negative BL
DG75 cells, however if ZREs are inserted in tandem distally from the TSS,
then activation by Zta is observed (Ramasubramanyan et al. 2015).
However, in EBV negative Akata  cells, this same vector shows repression
when Zta is present (Balan et al. 2016). The restriction sites BamHI and
SalI are distant to the transcription start of the luciferase gene, therefore,
to test if the proposed enhancer sequence can change the level of
repression by Zta when inserted far away from the luciferase transcription
start site, this vector (addressed from here onwards simply as CIITA) was
used (Figure 3.15 C). (continues in page 69)
Figure 3.15 Three vectors were used to test the effect of the presence of 
the elements. (A) Schematic of the BHLF1 vector. The Luciferase gene 
is represented as a red arrow and the Zeocin resistance cassette in green. In 
dark grey the sv40 polyA terminator. In purple the promoter sequence of 
BHLF1. Restriction sites in dark blue for HindIII and PstI. (B) Schematic of the 
BHLF1-Mut vector. As above, the luciferase gene and the Zeocin resistance 
cassette are represented in red and in green respectively. In dark grey the 
sv40 polyA terminator. In orange the promoter sequence of BHLF1 with 
mutated ZREs. Restriction sites in dark blue for HindIII and PstI. (C) 
Schematic of the CIITA vector. Same as above, except the Ampicilin 
resistance cassette in green, and in dark grey the sv40 enhancer downstream 
of the luciferase gene. In blue the promoter sequence of CIITA. Restriction sites 
in dark blue for BamHI and SalI.
SV40 pABHLF1-Mut Luciferase ZeocinHindIII
PstI
B
SV40 pABHLF1 Luciferase ZeocinHindIII
PstI
A
BamHI
SalI
SV40
enhancerLuciferase AmpicilinCIITA -214+52
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(continues from page 65) The elements were digested and ligated with the 
vectors, then transformed into E. coli competent cells as described in Materials & 
Methods. The cells were plated in selective agar and the selected samples were 
re-cultured in LB broth overnight, to extract DNA through a QIAGEN MINIPREP 
extraction kit. The samples were sequenced and compared against the designed 
elements (Figure 3.16).  
Following the sequence verification, the samples were then cultured at a larger 
scale to extract larger amounts of DNA. The vectors containing the elements were 
transfected into EBV negative, BL DG75 suspension cells as well as in to EBV 
negative 293T epithelial adherent cells. A summary of the element transfections 
can be found in Table 3.2.  
The transfections of constructs into each cell type and consecutive luciferase, 
BCA and western blot analyses were initially performed once. After that, 2 more 
transfections were attempted for a total of 3 different repetitions for each condition. 
However, when analysing the second and third repetitions, the values of the 
control conditions showed highly irregular behaviour, as well as finding data 
points off scale in most tested conditions. This lead us to think that human error 
occurred in the repetitions, due probably to the high number of samples for each 
experiment; therefore, the data and subsequent analysis of repetition #2 and #3 
are omitted from the present document, and only the data for the first transfection 
is shown and discussed.  
Each transfection was executed using either an expression vector for His tagged 
Zta (referred to simply as Zta) or an empty vector as a control (pcDNA). Western 
blots were performed verifying the expression of Zta for each transfection, the 
harvested cells were divided into two. One half was used to perform the 
Luciferase assays, measuring Relative Light Units, a reflection of the constructs 
activity; each sample was read by triplicate. The BCA assays were also 
performed from the same half of the sample as the luciferase assays by triplicate. 
The BCA assay reflects the protein content in the samples; the values from this 
assay were averaged and used to normalize the values from the luciferase 
assays (See section 2.2.7.2 in Materials and Methods). The other half of the 
samples was used for Western blots assays. 
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3.2.5.1.1 Is element AHNAK an enhancer in DG75 cells? 
Due to the composition of the images and in the interest of the most possible 
clarity and the least confusion, figures 3.17 to 3.32 will be found at the end of the 
results section (pp 76-107), before the discussion of this chapter in page 104. 
The luciferase activity for BHLF1, increased 1.53 times when AHNAK was 
present compared to when it was absent (Figure 3.17 C first column). BHLF1 was 
activated by Zta as expected (155 times) (Figure 3.17 C second column), 
however the presence of AHNAK reduced activation by Zta to 38 times (Figure 
3.17 C third column).  
There is a significant reduction (0.38 times) in activity when we compare the 
activity of Zta when AHNAK is present (Figure 3.17 C last column). This reduced 
activation could be due to differences in Zta expression levels as there is slightly 
more Zta in cells with less luciferase activity (Figure 3.17 D and E). 
In the context of BHLF1-Mut Zta has no activation, as expected (Figure 3.18 C 
second column). The presence of AHNAK in BHLF1-Mut made no difference on 
this lack of activation by Zta (Figure 3.18 C third column).  
But the addition of AHNAK to BHLF1-Mut, enhanced promoter activity 5.28 fold 
(Figure 3.18 C last column). Although there is no significant change in the 
luciferase activation by Zta when AHNAK is present, the Zta band signal detected 
in the Western blot shows that the Zta levels in BHLF1-Mut AHNAK are slightly 
lower than the control sample (Figure 3.18 D and E).  
3.2.5.1.2 Is element AHNAK an enhancer in 293T cells? 
The luciferase activity in 293T cells for BHLF1 when AHNAK is present is 5.56 
times higher than when it is absent (Figure 3.19 C first column).  
The activation by Zta when there is no AHNAK element, is 518.72 (Figure 3.19 C 
second column) but when AHNAK is present in BHLF1, activation by Zta 
increases to 1654.08 (Figure 3.19 C third column).  
When AHNAK is present in BHLF1, the activity with expression of Zta is 17.75 
times higher than when AHNAK is not present (Figure 3.19 C last column). There 
is a little more Zta present in the sample (25.41 / 13.65 = 1.86 times more) in the 
Western blot assays compared to in the control sample (Figure 3.19 D and E). 
71 
However, when the ZREs are mutated, the enhancing effect disappears. The 
luciferase activity is slightly reduced when AHNAK is present in BHLF1-Mut 
(Figure 3.20 C first column).  
There is a modest (0.67) activation by Zta when AHNAK is present in BHLF1-Mut 
(Figure 3.20 C last column), this is different from what is observed in DG75 cells. 
Expression of Zta in the Western Blot assay is similar.  
3.2.5.1.3 Is element FOSB an enhancer in DG75 cells? 
The possible enhancer effect of FOSB was tested by after transfections in DG75 
cells through luciferase assays. The impact off adding FOSB to BHLF1 is a slight 
(0.35) decrease in activity (Figure 3.21 C first column).  
As previously observed in section 3.2.5.1.1, Zta increases the activity of BHLF1 
(155.53 fold). Albeit slightly less (117.9), this is also observed when FOSB is 
present (Figure 3.21 C third column). The abundance of Zta is the same in these 
experiments (Figure 3.21 D and E). 
For BHLF1-Mut, the luciferase activity increased 1.94 times when the FOSB 
element was present compared to when it wasn't (Figure 3.22 C first column). Zta 
decreased activity in BHLF1-Mut (0.27) which was not expected (Figure 3.22 C 
second column). The presence of FOSB makes no difference over the activation 
of Z (1.10) (Figure 3.22 C third column). 
The luciferase activity when Zta was expressed increased 7.9 times when FOSB 
was present compared to when it wasn't (Figure 3.22 C last column). However, 
the difference shown in the signal of the Zta bands in the Western blot is 1.5 times 
higher in the sample with the FOSB element than compared to the control (Figure 
3.22 D and E), signaling for a higher presence of Zta in the sample which would 
be reflected in the increased luciferase activity. 
3.2.5.1.4 Is element FOSB enhancing in 293T cells? 
FOSB enhances promoter BHLF1 activity 2.37 times (Figure 3.23 C first column). 
Zta increases the activity of BHLF1 (431.63), however when FOSB is present 
with BHLF1 the activation by Zta is 336.19 (Figure 3.23 C second and third 
column). 
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With Zta being expressed, the activity gets 1.73 times better when FOSB is 
present than without (Figure 3.23 C last column). The signal from the Zta band in 
the Western blot is 1.86 stronger in the sample with FOSB than the control 
sample; which could account for the difference in activity (25.4/13.64 = 1.86) 
(Figure 3.23 D and E). 
For BHLF1-Mut the luciferase activity is 10.97 times higher with FOSB (Figure 
3.24 C first column). 
Luciferase activation by Zta, is 5.44 in BHLF1-Mut (Figure 3.24 C second 
column); but when FOSB is present it lowers to 2.90 (Figure 3.24 C third column), 
despite increased levels of Zta (Figure 3.24 D and E). This might point towards 
FOSB lowering the ratio of Zta activation 0.53 times compared to when the 
element is not present (2.90/5.44 = 0.53). 
The luciferase activity when Zta is expressed, increases 5.85 times with the 
presence of the FOSB element (Figure 3.24 C last column). However, the signal 
from Zta in the Western blot is 4.35 times higher in the sample with FOSB than 
the control sample (73.31/16.82 = 4.35) (Figure 3.24 D and E).  
3.2.5.1.5 Is 1OEM enhancing in DG75 cells? 
The potential enhancing effect of 1OEM was tested through luciferase assays in 
DG75 cells. The luciferase activity of promoter BHLF1 is slightly reduced when 
1OEM is present (Figure 3.25 C first column).  
The activation of by Zta without 1OEM is 63.97 times higher than when Zta is not 
being expressed (Figure 3.25 C second column). This changes with the presence 
of 1OEM to 43 (Figure 3.25 C third column).12, yet with similar Zta levels in the 
western blot (Figure 3.25 D and E).  
The luciferase activity when Zta is expressed is lowered 0.36 times when 1OEM 
is present compared to when it is absent (Figure 3.25 C last column). 
The effect of 1OEM over the luciferase activity was also measured when the 
ZREs of the BHLF1 promotor were mutated. The luciferase activity found in 
BHLF1-Mut when the 1OEM element is present, is 1.97 times higher with 1OEM 
(Figure 3.26 C first column).  
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The luciferase activation by Zta in BHLF1-Mut is not changing (0.91, N.S. Figure 
3.26 C second column), consistent with the mutation of the ZREs in BHLF1. 
However, when 1OEM is present with BHLF1-Mut, this is halved (0.51 Figure 
3.26 C third column). Importantly, the signal detected in the bands of the WB 
(Figure 3.26 D and E); show a lower level of expression of Zta in the sample 
containing the 1OEM element. 
The luciferase activity, when Zta is expressed, does not change in BHLF1-Mut 
with or without 1OEM (Figure 3.26 C last column).  
When 1OEM is analysed on the promoter CIITA in DG75 cells, the luciferase 
activity is similar (0.75) than when the element is not present (Figure 3.27 C first 
column).  
As expected and reflecting what was observed by Ramasubramanyan et al, there 
is no activation by Zta of CIITA (Figure 3.27 C second column). There is also no 
luciferase activation by Zta when 1OEM is present (Figure 3.27 C third column).  
The luciferase activity when Zta is expressed is 0.43 times lower when 1OEM is 
present (Figure 3.27 C last column).  
The Western blot shows a higher signal for Zta in CIITA 1OEM than in CIITA 
(Figure 3.27 D and E). 
3.2.5.1.6 1OEM enhances in 293T cells? 
There is 34.34 times more luciferase activity of promoter BHLF1 when 1OEM is 
present than compared to when it is absent (Figure 3.28 C first column).  
There is activation by Zta in BHLF1 (71.59) as expected (Figure 3.28 C second 
column). When 1OEM is present, the activation by Zta is 45.66 (Figure 3.28 C 
third column), however it is important to see that there is a higher Zta signal in 
the WB sample that contains 1OEM (Figure 3.28 D and E). This can also be 
related to the 21.90 fold change of activation by Zta when 1OEM is present 
(Figure 3.28 C last column). 
For BHLF1-Mut the luciferase activity when Zta is not being expressed increases 
3.41 times when 1OEM is present (Figure 3.29 C first column).  
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Activation of BHLF1-Mut by Zta without 1OEM is similar (5.61) to when the 1OEM 
element is present (5.80), almost not changing (Figure 3.29 C second and third 
column).  
In EBV negative 293T cells, when 1OEM is analyzed on the promoter CIITA, the 
luciferase activity is similar (0.98) to without 1OEM (Figure 3.30 C first column).  
When Zta is present, the activity of CIITA is repressed (0.38) as expected and 
reflecting the findings from Balan et al (Figure 3.30 C second column). This 
repression by Zta is reversed when 1OEM is present (3.04) (Figure 3.30 C third 
column). Showing that when 1OEM is in the sequence, the activation by Zta 
increases 8 fold (3.04/0.38 = 8). 
Luciferase activity when Zta is being expressed is considerably higher (7.92) in 
the control sample (Figure 3.30 C last column).  
3.2.5.1.8 Is 4OEM enhancing in DG75 cells? 
The luciferase activity of CIITA is 0.55 times lower in the sample with the 4OEM 
element (Figure 3.31). 
The activation by Zta when there is no element, is 0.81 (reflecting the findings of 
Ramasubramanyan et al) (Figure 3.31 C second column), and the activation by 
Zta is almost the same to when the element is there (Figure 3.31 C third column). 
The luciferase activity when Zta is expressed is decreased discreetly 0.80 when 
the element 4OEM is present. Overall, no impact can be observed when 4OEM 
is present (Figure 3.31 C last column). 
3.2.5.1.9 Is 4OEM enhancing in 293T cells? 
The luciferase activity of CIITA is slightly higher (1.84 times) when the 4OEM 
element is present (Figure 3.32 C first column).  
As expected and reflecting the findings by Balan et al, there is a 0.38 repression 
by Zta to CIITA (Figure 3.32 C second column). There is no repression by Zta 
when 4OEM is there (Figure 3.32 C third column). However, when taking into 
consideration the signal of Zta in the Western blot, we can see a stronger band 
for Zta in CIITA 4OEM than compared to the control, this points again towards 
4OEM not altering the ratio of activation caused by Zta.  
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The luciferase activity with Zta is 5.19 times higher when 4OEM is there 
compared to when it is absent (Figure 3.32 C last column). Here is important to 
keep in mind that this might be an artificial increase of luciferase activity reflected 
in the higher signal of Zta found in the sample with the 4OEM construct in the 
Western blot assay. 
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Figure 3.17 Influence over BHLF1 activity by AHNAK in DG75 cells.
Comparison of normalized luciferase activity in DG75 cells with and without
the AHNAK element. “BHLF1” represents (Figure legend continues…)
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the control sample which contains ZREs. “BHLF1 AHNAK” represents the
sample containing the construct AHNAK as well as ZREs. (A) Luciferase
activity normalized to BCA levels. Dark grey bars represent the normalized
luciferase value for samples transfected with plasmid DNA not containing
the Zta gene. Light grey represent the value for samples transfected with
plasmid containing the Zta gene. Error bars calculated from the Standard
deviation from 3 readings for each sample. (B) Table of values for (A). (C)
Table showing the difference in the fold change between samples and its
significance; values from (B). Student’s T-test provided P value, with an
α=0.05, in equal variances. (D) Western blot of transfected samples
presented in (A). (E) Signal from the bands corresponding to Zta in (D).
The signal of the Zta band corresponding to the sample with the AHNAK
element is 1.7 times the value of the sample without the element.
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Figure 3.18. Influence over BHLF1 activity by AHANK when ZREs are
mutated in DG75 cells. Comparison of normalized luciferase activity in
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(cont…) after with and without the AHNAK element in absence of ZREs.
“BHLF1-Mut” represents the sample without ZREs, used as control. “BHLF1-
Mut AHNAK” represents the sample without ZREs yet containing the construct
AHNAK. (A) Luciferase activity normalized to BCA levels. Dark grey bars
represent the normalized luciferase value for samples transfected with plasmid
DNA not containing the Zta gene. Light grey represent the value for samples
transfected with plasmid containing the Zta gene. Error bars calculated from the
Standard deviation from 3 readings for each sample. (B) Table of values for (A).
(C) Table showing the difference in the fold change between samples and its
significance; values from (B). Student’s T-test provided P value, with an α=0.05,
in equal variances. (D) Western blot of transfected samples presented in (A). (E)
Signal from the bands corresponding to Zta in (D). The signal of the Zta band
corresponding to the sample with the AHNAK element is 0.71 times the value of
the sample without the element.
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(Cont…) “BHLF1” represents the control sample which contains ZREs.
“BHLF1 AHNAK” represents the sample containing the construct AHNAK
as well as ZREs. (A) Luciferase activity normalized to BCA levels. Dark
grey bars represent the normalized luciferase value for samples
transfected with plasmid DNA not containing the Zta gene. Light grey
represent the value for samples transfected with plasmid containing the Zta
gene. Error bars calculated from the Standard deviation from 3 readings for
each sample. (B) Table of values for (A). (C) Table showing the difference
in the fold change between samples and its significance; values from (B).
Student’s T-test provided P value, with an α=0.05, in equal variances. (D)
Western blot of transfected samples presented in (A). (E) Signal from the
bands corresponding to Zta in (D). The signal of the Zta band
corresponding to the sample with the AHNAK element is 1.86 times the
value of the sample without the element.
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Figure 3.20. Influence over BHLF1 activity by AHNAK in 293T cells 
when ZREs are mutated. Comparison of normalized luciferase activity in 
293T cells (Figure legend continues)
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(Cont…) after transfection of the AHNAK element in absence of ZREs.
“BHLF1-Mut” represents the sample without ZREs, used as control.
“BHLF1-Mut AHNAK” represents the sample without ZREs yet containing
the construct AHNAK. (A) Luciferase activity normalized to BCA levels.
Dark grey bars represent the normalized luciferase value for samples
transfected with plasmid DNA not containing the Zta gene. Light grey
represent the value for samples transfected with plasmid containing the Zta
gene. Error bars calculated from the Standard deviation from 3 readings for
each sample. (B) Table of values for (A). (C) Table showing the difference
in the fold change between samples and its significance; values from (B).
Student’s T-test provided P value, with an α=0.05, in equal variances. (D)
Western blot of transfected samples presented in (A). (E) Signal from the
bands corresponding to Zta in (D). The signal of the Zta band
corresponding to the sample with the AHNAK element is 1.48 times the
value of the sample without the element.
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Figure 3.21. Influence over BHLF1 activity by FOSB in DG75 cells.
Comparison of normalized luciferase activity in DG75 cells with and
without (Figure legend continues…)
84
(cont…) the FOSB element. “BHLF1” represents the control sample which
contains ZREs. “BHLF1 FOSB” represents the sample containing the
construct FOSB as well as ZREs. (A) Luciferase activity normalized to BCA
levels. Dark grey bars represent the normalized luciferase value for
samples transfected with plasmid DNA not containing the Zta gene. Light
grey represent the value for samples transfected with plasmid containing
the Zta gene. Error bars calculated from the Standard deviation from 3
readings for each sample. (B) Table of values for (A). (C) Table showing
the difference in the fold change between samples and its significance;
values from (B). Student’s T-test provided P value, with an α=0.05, in equal
variances. (D) Western blot of transfected samples presented in (A). (E)
Signal from the bands corresponding to Zta in (D). The signal of the Zta
band corresponding to the sample with the FOSB element is 1.04 times the
value of the sample without the element.
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Figure 3.22. Influence over BHLF1 activity by FOSB in DG75 cells
when there are no ZREs available. Comparison of normalized luciferase
activity in DG75 cells with and without the FOSB element in absence of
ZREs. (Figure legend continues…)
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(cont.…) “BHLF1-Mut” represents the sample without ZREs also used as a
control. “BHLF1-Mut FOSB” represents the sample without ZREs yet
containing the construct FOSB. (A) Luciferase activity normalized to BCA
levels. Dark grey bars represent the normalized luciferase value for
samples transfected with plasmid DNA not containing the Zta gene. Light
grey represent the value for samples transfected with plasmid containing
the Zta gene. Error bars calculated from the Standard deviation from 3
readings for each sample. (B) Table of values for (A). (C) Table showing
the difference in the fold change between samples and its significance;
values from (B). Student’s T-test provided P value, with an α=0.05, in equal
variances. (D) Western blot of transfected samples presented in (A). (E)
Signal from the bands corresponding to Zta in (D). The signal of the Zta
band corresponding to the sample with the FOSB element is 1.46 times the
value of the sample without the element.
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Figure 3.23. Influence over BHLF1 activity by FOSB in 293T.
Comparison of normalized luciferase activity in 293T cells with and without
the FOSB element. (Figure legend continues…)
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(cont.…) “BHLF1” represents the control sample which contains ZREs.
“BHLF1 FOSB” represents the sample containing the construct FOSB as
well as ZREs. (A) Luciferase activity normalized to BCA levels. Dark grey
bars represent the normalized luciferase value for samples transfected with
plasmid DNA not containing the Zta gene. Light grey represent the value
for samples transfected with plasmid containing the Zta gene. Error bars
calculated from the Standard deviation from 3 readings for each sample.
(B) Table of values for (A). (C) Table showing the difference in the fold
change between samples and its significance; values from (B). Student’s T-
test provided P value, with an α=0.05, in equal variances. (D) Western blot
of transfected samples presented in (A). (E) Signal from the bands
corresponding to Zta in (D). The signal of the Zta band corresponding to
the sample with the FOSB element is 1.86 times the value of the sample
without the element.
89
0100
200
300
400
500
600
700
800
900
BHLF1-Mut BHLF1-Mut
FOSB
N
or
m
al
iz
ed
 L
uc
ife
ra
se
 A
ct
iv
ity
C
A B
P<0.05
 Actin
 Zta
Transfection SignalValue
BHLF1-Mut Z 16.82
BHLF1-Mut
FOSB Z 73.31
BHLF1-Mut
pcDNA
BHLF1-Mut
pcDNA
BHLF1-Mut
FOSB
pcDNA
BHLF1-Mut
Z
BHLF1-Mut
FOSB
pcDNA
BHLF1-Mut
Z
BHLF1-Mut
FOSB
Z
BHLF1-Mut
FOSB
Z
Fold
change 10.97 5.44 2.90 5.85
Sig. P<0.05 P<0.05 P<0.05 P<0.05
Transfection
AVERAGE
pcDNA Z
BHLF1-Mut 23.49 127.75
BHLF1-Mut
FOSB 257.73 748.01
D E
Figure 3.24. Influence over BHLF1 activity by FOSB when ZREs are
mutated in 293T cells. Comparison of normalized luciferase activity in
293T cells with and without (Figure legend continues…)
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(Cont.…) the FOSB element in absence of ZREs. “BHLF1-Mut” represents
the sample without ZREs also used as a control. “BHLF1-Mut FOSB”
represents the sample without ZREs yet containing the construct FOSB.
(A) Luciferase activity normalized to BCA levels. Dark grey bars represent
the normalized luciferase value for samples transfected with plasmid DNA
not containing the Zta gene. Light grey represent the value for samples
transfected with plasmid containing the Zta gene. Error bars calculated
from the Standard deviation from 3 readings for each sample. (B) Table of
values for (A). (C) Table showing the difference in the fold change between
samples and its significance; values from (B). Student’s T-test provided P
value, with an α=0.05, in equal variances. (D) Western blot of transfected
samples presented in (A). (E) Signal from the bands corresponding to Zta
in (D). The signal of the Zta band corresponding to the sample with the
FOSB element is 4.35 times the value of the sample without the element.
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Figure 3.25. Influence over BHLF1 activity by 1OEM in DG75 cells.
Comparison of normalized luciferase activity in DG75 cells with and without
the 1OEM element. “BHLF1” represents the control sample which contains
ZREs. (Figure legend continues…)
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(Cont.…) “BHLF1 1OEM” represents the sample containing the construct
FOSB as well as ZREs. (A) Luciferase activity normalized to BCA levels.
Dark grey bars represent the normalized luciferase value for samples
transfected with plasmid DNA not containing the Zta gene. Light grey
represent the value for samples transfected with plasmid containing the Zta
gene. Error bars calculated from the Standard deviation from 3 readings for
each sample. (B) Table of values for (A). (C) Table showing the difference
in the fold change between samples and its significance; values from (B).
Student’s T-test provided P value, with an α=0.05, in equal variances. (D)
Western blot of transfected samples presented in (A). (E) Signal from the
bands corresponding to Zta in (D). The signal of the Zta band
corresponding to the sample with the 1OEM element is 1.05 times the
value of the sample without the element.
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Figure 3.26. Influence over BHLF1 activity by 1OEM in DG75 when
ZREs are mutated. Comparison of normalized luciferase activity in DG75
cells with and without the 1OEM element in absence of ZREs. “BHLF1-
Mut” represents the sample (Figure legend continues…)
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(cont…) without ZREs also used as a control. “BHLF1-Mut FOSB”
represents the sample without ZREs yet containing the construct FOSB.
(A) Luciferase activity normalized to BCA levels. Dark grey bars represent
the normalized luciferase value for samples transfected with plasmid DNA
not containing the Zta gene. Light grey represent the value for samples
transfected with plasmid containing the Zta gene. Error bars calculated
from the Standard deviation from 3 readings for each sample. (B) Table of
values for (A). (C) Table showing the difference in the fold change between
samples and its significance; values from (B). Student’s T-test provided P
value, with an α=0.05, in equal variances. (D) Western blot of transfected
samples presented in (A). (E) Signal from the bands corresponding to Zta
in (D). The signal of the Zta band corresponding to the sample with the
1OEM element is 0.27 times the value of the sample without the element.
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Figure 3.27. Influence over CIITA activity by 1OEM in DG75 cells.
Comparison of normalized luciferase activity in DG75 cells with and without
the 1OEM element. “CIITA” represents the sample used as a control.
“CIITA 1OEM” represents the sample containing the construct 1OEM. (A)
Luciferase activity normalized (Figure legend continues…)
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(cont.…) to BCA levels. Dark grey bars represent the normalized luciferase
value for samples transfected with plasmid DNA not containing the Zta
gene. Light grey represent the value for samples transfected with plasmid
containing the Zta gene. Error bars calculated from the Standard deviation
from 3 readings for each sample. (B) Table of values for (A). (C) Table
showing the difference in the fold change between samples and its
significance; values from (B). Student’s T-test provided P value, with an
α=0.05, in equal variances. (D) Western blot of transfected samples
presented in (A). (E) Signal from the bands corresponding to Zta in (D).
The signal of the Zta band corresponding to the sample with the 1OEM
element is 1.86 times the value of the sample without the element.
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Figure 3.28. Influence over BHLF1 activity by 1OEM in 293T cells.
Comparison of normalized luciferase activity in 293T cells with and without
the 1OEM element in absence of ZREs. “BHLF1-Mut” represents the
sample without ZREs also used as a control. “BHLF1-Mut FOSB”
represents the (Fig legend continues…)
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(Cont.…) sample without ZREs yet containing the construct FOSB. (A)
Luciferase activity normalized to BCA levels. Dark grey bars represent the
normalized luciferase value for samples transfected with plasmid DNA not
containing the Zta gene. Light grey represent the value for samples
transfected with plasmid containing the Zta gene. Error bars calculated
from the Standard deviation from 3 readings for each sample. (B) Table of
values for (A). (C) Table showing the difference in the fold change between
samples and its significance; values from (B). Student’s T-test provided P
value, with an α=0.05, in equal variances. (D) Western blot of transfected
samples presented in (A). (E) Signal from the bands corresponding to Zta
in (D). The signal of the Zta band corresponding to the sample with the
1OEM element is 2.21 times the value of the sample without the element.
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Figure 3.29. Influence over BHLF1 activity by 1OEM in 293T when
ZREs are mutated. Comparison of normalized luciferase activity in 293T
cells with and without the 1OEM element in absence of ZREs. “BHLF1-
Mut” represents the sample (Figure legend continues…)
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(cont.…) without ZREs also used as a control. “BHLF1-Mut FOSB”
represents the sample without ZREs yet containing the construct FOSB.
(A) Luciferase activity normalized to BCA levels. Dark grey bars represent
the normalized luciferase value for samples transfected with plasmid DNA
not containing the Zta gene. Light grey represent the value for samples
transfected with plasmid containing the Zta gene. Error bars calculated
from the Standard deviation from 3 readings for each sample. (B) Table of
values for (A). (C) Table showing the difference in the fold change between
samples and its significance; values from (B). Student’s T-test provided P
value, with an α=0.05, in equal variances. (D) Western blot of transfected
samples presented in (A). (E) Signal from the bands corresponding to Zta
in (D). The signal of the Zta band corresponding to the sample with the
1OEM element is 0.49 times the value of the sample without the element.
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Figure 3.30 Influence over CIITA activity by 1OEM in 293T. Comparison
of normalized luciferase activity in 293T cells with and without the 1OEM
element. “CIITA” represents the sample used as a control. “CIITA 1OEM”
represents the sample containing the construct 1OEM. (A) Luciferase
activity (Figure legend continues…)
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(Cont.…) normalized to BCA levels. Dark grey bars represent the
normalized luciferase value for samples transfected with plasmid DNA not
containing the Zta gene. Light grey represent the value for samples
transfected with plasmid containing the Zta gene. Error bars calculated
from the Standard deviation from 3 readings for each sample. (B) Table of
values for (A). (C) Table showing the difference in the fold change between
samples and its significance; values from (B). Student’s T-test provided P
value, with an α=0.05, in equal variances. (D) Western blot of transfected
samples presented in (A). (E) Signal from the bands corresponding to Zta
in (D). The signal of the Zta band corresponding to the sample with the
1OEM element is 0.53 times the value of the sample without the element.
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Figure 3.31. Influence over CIITA activity by 4OEM in DG75 cells.
Comparison of normalized luciferase activity in DG75 cells with and without
the 4OEM element. “CIITA” represents the sample used as a control.
“CIITA 4OEM” represents the sample containing the construct 1OEM. (A)
Luciferase activity normalized (Figure legend continues)
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(cont.…) to BCA levels. Dark grey bars represent the normalized luciferase
value for samples transfected with plasmid DNA not containing the Zta
gene. Light grey represent the value for samples transfected with plasmid
containing the Zta gene. Error bars calculated from the Standard deviation
from 3 readings for each sample. (B) Table of values for (A). (C) Table
showing the difference in the fold change between samples and its
significance; values from (B). Student’s T-test provided P value, with an
α=0.05, in equal variances. (D) Western blot of transfected samples
presented in (A). (E) Signal from the bands corresponding to Zta in (D).
The signal of the Zta band corresponding to the sample with the 4OEM
element is 1.25 times the value of the sample without the element.
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Figure 3.32. Influence over CIITA activity by 4OEM in 293T.
Comparison of normalized luciferase activity in 293T cells with and without
the 4OEM element. “CIITA” represents the sample used as a control.
“CIITA 4OEM” represents the sample containing the construct 4OEM. (A)
Luciferase activity normalized (Figure legend continues…)
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(Cont…) to BCA levels. Dark grey bars represent the normalized luciferase
value for samples transfected with plasmid DNA not containing the Zta
gene. Light grey represent the value for samples transfected with plasmid
containing the Zta gene. Error bars calculated from the Standard deviation
from 3 readings for each sample. (B) Table of values for (A). (C) Table
showing the difference in the fold change between samples and its
significance; values from (B). Student’s T-test provided P value, with an
α=0.05, in equal variances. (D) Western blot of transfected samples
presented in (A). (E) Signal from the bands corresponding to Zta in (D).
The signal of the Zta band corresponding to the sample with the 1OEM
element is 3.55 times the value of the sample without the element.
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3.3 Discussion 
Research performed previously in our lab showed that Zta binds to the human 
genome across many regions. Some of these interactions can be found proximal 
(< 2kb) to the transcription start site of genes that have been shown to be 
upregulated in lytic cycle when analyzed through RNA-Seq analysis, and ranked 
based on the change in upregulation (Ramasubramanyan et al. 2015). This 
suggested that there might be elements in the sequences to which Zta is bound, 
which enhance its activity; sequences apart from ZREs. Therefore, the 
sequences upstream of the top 30 upregulated genes (found in the previous 
research by Ramasubramanyan et al), were studied, and short regions that are 
shared across the analyzed sequences were found. Two elements (1OEM and 
4OEM) were designed and synthetized based in this, and their ability to enhance 
expression was studied. 
Parallel to this, Zta peaks from the ChIP-Seq analysis were tested to be 
enhancers; the sequence of these peaks was close to genes known to be 
upregulated in lytic cycle, therefore two elements were designed with the 
sequence of these peaks and named after the gene close to those peaks (FOSB 
and AHNAK).  
Different analyses of the aforementioned sequences were carried out to generate 
plasmids that would be composed of the elements with a potential enhancing 
activity. The exploration on this enhancer activity was performed by testing in vitro 
the change in activity in Luciferase assays.  
It is important then to consider that different molecular environments exist in the 
cell lines used for the experiments, and this in turn can be observed in the activity 
of the control samples. In DG75 cells, there was no repression of CIITA by Zta 
which is something observed as well by Ramasubramanyan et al (2015) in the 
same cell line. When Balan et al (2016) tested the capacity of Zta to repress the 
activation of CIITA in EBV negative BL Akata cells, a clear repression was 
present in the promotor even when there were no ZREs available; the same was 
found in this research in 293T cells. A similar cell line difference can be seen in 
the lack of activation by Zta of BHLF1-Mut in DG75 cells (Figs 3.18, 3.22 and 
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3.26), and a small activation by Zta of BHLF1-Mut in 293T cells (Figs 3.20, 3.24 
and 3.29). 
Regarding the designed elements enhancing activity; when the AHNAK element 
was incorporated into promoters and transfected, an enhancer effect was found 
in both DG75 and 293T cells when the element was adjacent to the BHLF1 
promoter. There was no additional increase in expression with AHNAK when Zta 
was expressed in DG75 cells, but a small Zta driven enhancement was seen in 
293T cells. 
The FOSB element showed cell specific enhancer activity in 293T cells when 
placed next to BHLF1-Mut, but this was not the case in DG75 cells; there was no 
additional change when Zta was expressed. In contrast, the element showed 
repression in DG75 cells. 
The 1OEM element had little impact on the BHLF1 promoter in DG75 cells. 
However, in 293T cells the element acted as an enhancer on the BHLF1 
promoter, independently of Zta, and was able to reduce the Zta driven repression 
of the CIITA promoter in these cells. 
Element 4OEM was also able to overcome the repression of the Zta promoter by 
Zta in 293T cells. 
Overall, these findings show that the elements representative of peaks where Zta 
is binding to (for AHNAK and FOSB), as well as the elements representative of 
conserved sequences and motifs (for 1OEM and 4OEM), both have cell specific 
enhancer ability; however, if the effects of each element are considered 
collectively across the experiments, the enhancing activity found is minor and not 
substantial. Albeit this, the computational approach devised to generate the 
elements worked as an appropriate tool for the design and analysis of sequences 
involved with enhancing activity, given that 4 different constructs were designed 
and tested.  
It is also important to acknowledge that the experiments were not successfully 
repeated and therefore the observed behavior of the enhancers was not 
reproduced, however, the activity of the controls in the presented data mirror 
findings from the works of Balan et al as well as Ramasubramanyan et al.  
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It bears considering that the analysis used to generate the two of the elements 
tested, did not consist of sequences exclusively beneath Zta peaks (in 1OEM and 
4OEM). This means that the consensus sequences found to be pervasive might 
be representing an enhancer sequence that responds to other transcription 
factors than Zta. This speculation could address the increases in luciferase 
activity when there were lower levels of Zta being expressed (Fig 3.26 and 3.29), 
or with no expression of Zta at all (Fig 3.18 and 3.22); or when the presence of 
an enhancing element in 293T did not enhance in DG75, perhaps other 
transcription factors are occupying the element sequence but not increasing 
activation (Fig 3.17 and 3.21). 
Further analysis could be carried out by testing if the enhancer capability remains 
after removing components of the elements 1OEM and 4OEM; since those 
elements are composed of compilations of the most representative sequences 
reflecting the matrices, it would be useful to test the enhancer capability of single 
matrix instances free from ZREs, similar to how Balan et al showed how Zta had 
an effect over CIITA promoter without key ZREs. 
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Chapter 4. Potential looping interactions of Zta with promoters 
4.1 Introduction 
The knowledge and number of the different factors that play an important role in 
transcriptional regulation in general has been increasing and expanding as 
technology facilitates the study of different models of regulation. Although it has 
been a subject of research in the last decades, the full extent of knowing how 
enhancers work and regulate gene expression has not been reached. 
The understanding of the importance of; cis acting transcription factors, protein-
protein modifications to TFs, the composition of binding motifs near to TSS, has 
been complemented with the advent of findings showing a higher level of 
complexity in the transcriptional regulation by; acetylation or methylation of 
histones, DNA looping or inter-chromosomal interactions (reviewed by (Lelli et al. 
2012) and (Mercer and Mattick 2013)). 
Chromosome conformation capture is one of the new techniques that have 
expanded the understanding of the three-dimensional events taking part in 
transcriptional regulation; it was first used to study interactions between distant 
regions in in Saccharomyces cerevisiae (Dekker et al 2002). It requires the 
production of a template DNA library and a control DNA library which will be used 
to compare and test for the presence of particular PCR products of a set length 
(this is expanded in the introduction of chapter 5). However, since the first 
necessary step is to postulate which interactions are occurring, in this chapter we 
will focus solely in these potential interactions. 
Genomic elements that are located far away from each other come in close 
contact by the formation of chromatin loops, these loops can be detected by 3C 
experiments (reviewed by (Denker and de Laat 2016)). Since in previous analysis 
it was found that Zta can regulate gene expression distally (Ramasubramanyan 
et al. 2015), I asked whether Zta binding at distal sites promotes the formation of 
chromatin loops to neighbouring promoters. 
Previously, using data from ChIP-seq analysis as a point of departure, research 
by McClellan et al showed binding sites of EBNA2 and EBNA3 genes to be 
looping to promoter regions in EBV positive BL tumour cells (MutuIII) (McClellan 
et al. 2012; McClellan et al. 2013). Over 25% of the binding sites of EBNA2 and 
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EBNA3s were found to be shared; high levels of acetylation of the 27th lysine 
residue of histone 3 (H3K27ac) helped distinguish EBNA2 binding sites as active 
enhancer sites, while low levels of acetylation showed low level of gene activation. 
This is something that resonated through the analysis of Wood et al, where they 
found that EBNA2 targets tumour-associated super-enhancers at MYC. These 
super-enhancers are large lineage-specific regulatory elements typically 
comprising multiple transcription factors binding sites; and the super-enhancers 
upstream of MYC were distinguished by marks of acetylation in H3K27, regions 
which were both occupied by EBNA2 and looped to the promotor region of MYC 
(McClellan et al. 2013; Wood et al. 2016). 
The mark of H3K27ac has also been linked to an active EBV C promoter (Cp) 
stimulated by EBNA2 (reviewed by (H. S. Chen et al. 2013)). Perhaps more 
importantly, these marks of acetylation were consistent with looping events 
between regions found through 3C experiments, making it clear that marks of 
H3K27ac are important when considering potential loops (McClellan et al. 2013; 
Wood et al. 2016).  
Although the 3C technologies have evolved recently, the technique is still used 
to explore “one to one” type of interactions (reviewed by (Denker and de Laat 
2016)). The initial step was to select “one to one” interactions of Zta to promoters 
that could potentially be forming loops (this will be expanded in Section 4.1.1). 
When selecting which interactions to explore, the position of restriction sites had 
to be regarded, this since it is one of the most important considerations of the 3C 
experiment design. If the fragment sizes were smaller than 1Kb or greater than 
10 Kb in length, differences in the efficiency of ligation/amplification could bring 
biases to the data. In a similar way, the position of the restriction sites should not 
digest within the sequence of the promoter or potential enhancer (reviewed by 
(Naumova et al. 2012)).   
Finally, as the analysis progressed, the idea arose of selecting which interactions 
to include in the 3C experiments based on grouping the genes into possible 
clusters. This idea borrows from diverse studies that detected groups of genes to 
be found in relative proximity to each other, while sharing a specific regulated 
activity (Fraser and Bickmore 2007; McClellan et al. 2013; Montavon and 
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Duboule 2013; Osborne et al. 2004; Shopland et al. 2003). Part of the analysis 
employed data previously generated in the Sinclair lab, mRNA-seq analysis 
found genes to be highly regulated in lytic cycle in Akata cells 
(Ramasubramanyan et al. 2015); this allowed to rank the genes based on the fold 
change in regulation levels. 
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4.2 Results 
4.1.1 Identification of potential looping targets between Zta binding sites 
and promoters 
The Zta peaks found in the ChIP-seq experiments were sometimes found distally 
from genes; this helped formulate the question; Is Zta forming loops to promoter 
regions of genes known to be upregulated in lytic cycle? Which Zta interactions 
could be candidates for looping events? 
In order to answer the first question, it is necessary to answer the second one. 
Aiming to discriminate possible Zta interactions that would be good candidates 
for looping activity, two different strategies were implemented. One selection 
criteria analysed the Zta interactions with the highest regulated genes. Then, 
another selection criteria grouped the aforementioned upregulated genes into 
clusters. 
4.1.1.1 Selection Criteria 
4.1.1.1.1 Highest regulated genes 
Initially, the Zta interactions considered to be looping were selected by a direct 
and simple criteria. Genes found to be upregulated more than twofold in previous 
mRNA-seq analysis (Ramasubramanyan et al. 2015) were sorted in a list based 
on the fold change of transcription in lytic cycle.  
From this list of genes, the 30 genes that are most regulated were visualized 
through the UCSC genome browser, with a view that included; any Zta peaks 
found from 2kb to 200 kb away from the canonical TSS, the promoter sequence 
of each gene, and the restriction sites for BamHI and HindIII. Acetylation of 
histone 3 in the 27th lysine residue was also included to help consider potential 
enhancers regions if Zta peaks were found in alignment with such feature. 
Following this, three genes were selected based on restriction sites not 
fragmenting promoter sequences or peaks, and the particular characteristics of 
each gene:  
Gene LHX1, upregulated 5546 fold in lytic cycle, with 3 Zta peaks found in NPC 
cells, two of them in places with marks of acetylation, and no gene between the 
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peaks and LHX1 promoter. The peak closest to LHX1 was detected in NPC cells, 
while the farthest two from LHX1 was detected in both NPC and BL cells, however 
Figure 4.1 A shows all the peaks considered for the selection, in NPC cells. 
Gene SLC6A7, upregulated 2510 fold in lytic cycle, with two Zta peaks found in 
both NPC cells and BL cells, one of them over a modest mark of acetylation 
(Figure 4.1 B). 
Gene FZD10, upregulated 1420 fold in lytic cycle, found with no other genes in 
relative proximity to it, and with 3 Zta peaks found in both NPC cells and BL cells 
surrounding it, one of them aligned to acetylation marks (Figure 4.1 C). 
4.1.1.2.1 Upregulated gene clusters 
Subsequently, a different selection criteria was devised for selecting the Zta 
interactions to identify potential loops. Using the 500 highest regulated genes, a 
BED file (Browser Extensible Data) was retrieved from the UCSC genome 
browser; this file was composed of each gene’s canonical name, chromosomal 
position, position start, and position end (Figure 4.2).  
This BED file was very useful to group the genes in clusters of two or more, with 
a maximum distance between them of 100 kb; this choice was made considering 
any distance larger than 100 kb too distant to have a shared influence or activity. 
This discrimination was accomplished by first sorting the genes by chromosomal 
position, then by gene start position. After this the value of the end position of 
gene A (Figure 4.2 B, “b”) was subtracted from the value of the start position of 
gene B (Figure 4.2 B “c”); if the resulting value was less than or equal to 100 kb 
(c-b ≤ 100 kb), the genes were considered a cluster. This analysis resulted in 
finding 29 clusters, 6 of them with a distance between genes closer than 10 kb 
and 23 clusters with a distance between 10 and 100 kb between genes. (Figure 
4.2 C). 
Even though this last analysis helped greatly to focus which genes to study, a 
subsequent analysis was devised to search if there were any Zta peaks in 
proximity (up to 100 kb away) to the clusters. After obtaining the BED file which 
mark the location of the Zta peaks in the genome (Akata BL 
(Ramasubramanyan et al. 2015)), the same sorting (continues in page 118)
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(continues from page 115) of features was programmed as in the previous 
section. The position of each single Zta peak was listed in a vertical list, 
sorted by ascending order of chromosome position, then, in the same sheet 
the previously found clusters were listed horizontally by ascending order 
of chromosome position (Figure 4.3). The resulting shared area 
contained cells that were programmed to perform an “if” logical test checking 
for the Zta peak chromosome position to match the chromosome position of 
the cluster on top. If they were indeed the same, then another “if” logical test 
was performed, if the midpoint of the peak could be found within the span 
(±100kb) of a gene cluster (e > peak midpoint < f) then the cell would be filled 
with the “HERE” message, otherwise it would be left blank; cell content 
=IF(AND(peak chromosome = cluster chromosome, e>peak midpoint, peak 
midpoint<f),"HERE",""). Then each cluster column was filtered in order to 
display only cells signalling for a match, in order to explore the peaks near the 
cluster in the genome browser (Figure 4.3).  
This selection criteria helped focus the Zta interactions suspected to 
be interacting with gene clusters to only eight gene clusters (Table 4.1). To 
select which cluster genes to carry further in the analysis, the peak height, the 
alignment with acetylation and the presence of the Zta peak in ChIP-seq in 
a different cellular environment than BL cells was considered. Three different 
clusters were selected: SIRPA and PDYN, PDGFRB and SLC6A7, and VWF 
and CD9 (Figure 4.4). None of the other genes visualized in Figure 4.4 are 
regulated by Zta. (continues in page 121) 
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(continues from page 118) The restriction sites HindIII, BamHI, EcoRI and 
AciI were displayed in the UCSC genome browser. I examined all peaks and 
promoter regions to find a restriction digestion that would generate fragments 
smaller than 10 kb in size, without cutting the Zta peaks or the promoter 
sequence of the genes composing the cluster (visualized in Chapter 5). This 
proved successful only for cluster VWF and CD9 when digested with EcoRI, 
therefore it was selected to be analysed by 3C (Table 4.2).  
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4.3 Discussion 
In summary, 3 genes highly regulated by Zta and 29 clusters of genes regulated 
by Zta were identified. This analysis obtained targets to be followed by 3C 
experiments, testing for possible looping events happening between Zta and 
promoter regions of genes FZD10, SLC6A7, LHX1 as well as cluster VWF and 
CD9. Different restriction enzymes were analysed and digestion regimens were 
selected for the subsequent 3C experiments. 
The method presented in this thesis of finding gene clusters as well as searching 
for Zta peaks to be encompassed within a cluster span (±100kb) is a simple 
method of scrutinizing and relating BED data files. This process would have been 
tedious and very time consuming if only using the UCSC genome browser; and 
although Galaxy provides a similar service, the input files require a particular 
format that limits the accessibility of the service. 
It has been shown that Zta can bypass methylation of CpGs, although not 
H3K27me; and many of the lytic promoters of genes in EBV are repressed by 
H3K27me (Woellmer et al. 2012), therefore, it would be plausible for Zta to 
bypass H3K27me silencing. Perhaps in future analysis of which potential loops 
to follow, H3K27me would be an interesting mark to gather information about and 
then consider. 
The gene SLC6A7, is reported to share several enhancers with PDGFRB 
(GeneCards), which was found as a cluster of regulated genes in our results. It 
also presents transcription factor binding sites for AP1 and c-Jun in vicinity to its 
promoter region (GeneCards). The presence of the AP1, c-Fos, c-Jun TF sites is 
also true for gene LHX1, and given that Zta shares homology to AP1 and c-Fos 
and that it binds to the canonical site of AP1 (Farrell et al. 1989; Lieberman et al. 
1990) it would seem plausible that Zta could be binding and regulating these 
genes; and since there are no Zta binding peaks in the promoter sequence of 
these genes it is plausible for this regulation to be happening through looping to 
distal regions. Finally, cluster VWF and CD9 is an interesting target, since those 
two genes share several enhancers (GeneCards), making a stronger case for a 
possible co-regulation by Zta. 
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To finalize, it seems that the targets found are adequate for an initial exploration 
of possible looping between Zta and promoter regions. 
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Chapter 5. Chromatin Conformation Capture for the proposed Zta loops 
5.1 Introduction 
Linked to Chapter 4, the possibility of Zta distally enhancing the expression of 
genes could be studied by testing the presence of looping events between 
regions. In this chapter we will focus on the design and execution of 3C 
experiments devised to explore the previously proposed Zta loops.  
The design of 3C experiments is a complex process, many different critical steps 
in the design have to be carefully considered and finely tuned in order to obtain 
solid results. In the original work by (Dekker et al. 2002) a novel approach that 
analysed frequencies of interactions in Saccharomyces cerevisiae between pairs 
of genomic sequences, also validated known qualitative features of chromosome 
organization. This 3C protocol consisted of cross linking DNA, digesting it, and 
re-ligating the cross-linked fragments, followed by a reversal of cross linking and 
subsequent amplification of the ligated products by PCR; then finally the detected 
products of PCR were compared to products coming from control template 
(Dekker et al. 2002). The design of the 3C experiments presented here follows 
the original concept presented by Dekker et al, and the particular protocol for the 
generation of the 3C libraries was based on the protocols used by; (McClellan et 
al. 2013) to study loops formed with EBNA2 and 3s in EBV positive latency II BL 
Mutu cells, and by (Tempera et al. 2011) to study loops formed between OriP and 
promoters of Qp and Cp in the EBV genome in EBV positive Mutu I cells. Overall, 
the schematic of the generation of the 3C libraries can be seen in (Figure 5.1). 
The central part of the 3C technique is the detection of the PCR amplified 
products; however, this corresponds only to the last part of the assay; which in 
turn, is a reflection of an adequate experiment design. This design should take 
into account considerations like; choosing regions of interest and a control region, 
selecting a digestion regimen for an adequate fragmentation, choosing an 
appropriate restriction enzyme and a desired resolution, proper position of 
restriction sites, digestion efficiency, primer design in region of interest, primer 
design in control region, and production of a control template (reviewed by 
(Naumova et al. 2012)).  
Figure 5.1. Schematic of 3C detection library. The horizontal blue line
represents DNA. Small vertical red lines represent binding sites of a specific
restriction enzyme. Small black arrows represent where primers would bind to,
pointing to the 3’ direction of their own sequence. The orange diagonal bars
represent Zta as a dimer binding to DNA. The blue box represent a gene of
interest. (A) Design of primers between a region that binds to the protein of
interest and a region containing the promotor sequence of a gene of interest
(anchor). (B) Loop formation and Crosslinking, the formed loops are chemically
fixed in place. (C) Enzymatic digestion carried out with the specific restriction
enzyme. (D) Possible ligation products are shown. (E) In this step proteins are
digested, the crosslink reverted and finally the DNA is purified. (F) Then DNA
can be amplified, and subsequent detection can occur. (G) For the generation of
synthetic controls, the sequence that would result from the linking of the
proposed sequence interactions caused by loopings was generated. Sequences
were composed by two segments united at the restriction site; the reverse-
complemented sequence targeted by the primer in the anchor (i) and the
sequence targeted by the primer in the proposed looping fragment (ii).
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One of the initial considerations in the design is an adequate fragmentation, the 
position of restriction sites for different restriction enzymes had to be analysed, 
this was mostly presented in Chapter 4, where the selection of the targets had to 
consider the fragment size and keeping Zta peaks and promoter regions 
undigested.   
Once the fragments were identified, primers had to be designed. The 
amplification target of the primers must be the sequence 80 to 150bp away from 
the restriction site, “inside” of the restriction fragment of interest, if the primers are 
too close or far from the restriction site, the amplification might not be efficient. 
All of the different primers are designed in the same strand making sure that any 
amplification comes from a “head to head” ligation of the intended fragments, 
otherwise, the primers could amplify a product that is not representative of a 
looping event in the case of an incomplete digestion, giving a false positive 
interaction. 
Regarding ligation, if it happens between regions different than the proposed 
ones in the looping, there will not be a primer pair formed for amplification; the 
same would happen if the halves swapped in orientation, if self-circularization 
occurs or if the ligation is incomplete, there will be no amplification of a product. 
If an incomplete digestion occurs, the subsequent ligation could unite fragments 
of sequence that separate the primers demanding a longer amplification step in 
the PCR, and therefore could be undetectable. 
Typically, for the generation of control libraries, bacterial artificial chromosomes 
(BACs) containing all possible ligation products relevant for genomic regions of 
interest were originally used, to assess PCR efficiency, in particular primer 
efficiency (Palstra et al. 2003; Tolhuis et al. 2002); however generating a BAC 
library template for each target would be complex and time consuming, instead 
we opted to synthetically generate controls from the sequence hypothesized to 
result from the amplification of each primer pair.  
In order to increase the chance of testing chromatin that is representative of 
looping events pertaining to lytic cycle, different cell lines were used, both to 
generate a comparison of cellular environmental backgrounds and to compare if 
any possible looping event captured is present only in lytic cycle (Table 5.1). 
Cell
lines
used
Attributes Induction Reference
3C experiment
Highest fold
mRNA
Cluster
SL
C
6A
7
LH
X1
FZ
D
10
VW
F 
& 
C
D
9
Ba
m
H
I
H
in
di
ii
Ec
oR
I
LCL#3 LCL, EBV+,
Spontaneou
sly lytic 6%
to 20%
None Sinclair et
al 1994 + + + -
GM2188 LCL, EBV+,
Tightly
latent
None Stiff et al
2004 + + + -
Akata BL EBV+,
Anti IgG
inducible
Mouse anti-
IgG
Takada et
al 1989 + - - +
Akata-
Zta
BL EBV+,
BZLF1
expression
vector
Doxycycline
inducible
Doxycycline Ramasubr
amanyan
et al 2015 + - - +
Table 5.1. Cell lines used to generate 3C library.
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On the first column the name of the cell line is displayed. On the Attributes
column, any pertinent details of the corresponding cell lines are displayed. On
the induction column, the method of induction, if any, is displayed. In the column
with the header “3C experiment” we can find the genes tested depending on the
method of design, either from top ranking genes with a high fold change in
mRNA seq, or through cluster formation of up to 100kb of distance between
genes and Zta peaks. Beneath the genes names, the restriction enzyme needed
to generate the library can be found. A + symbol represents that such library
was created in that cell line, a – symbol represents that no library was created in
that cell line for those genes.
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5.2 Results 
Following the idea that Zta could be regulating gene expression distally by looping 
to the promoter region of genes, a design for an assay of Chromatin conformation 
capture had to be devised. The selected targets were the promoter region of 
genes SLC6A7, LHX1, FZD10 as well as clustered genes VWF and CD9. 
5.2.1 Preparation of the Template 
5.2.1.1 Lytic Cycle confirmation 
Since the potential looping events were based on the interactions found in the 
ChIP-seq of lytic cells, the cells used to generate the 3C template needed to 
reflect this. Four different cell lines were used aiming to generate two different 
comparisons; and each was verified to be in lytic cycle. Cell lines LCL#3 and 
GM2188 are compared in a western blot, showing Zta as expected in lytic LCL 
and an absence of it in GM2188 (Figure 5.2. Data showing lytic cycle. A). In a 
similar way, we can see a higher viral genome load, reflective of lytic cycle, in the 
induced cells of the Akata line (Figure 5.2. Data showing lytic cycle. B). The 
Akata-Zta cells were a kind gift from Anja Godfrey, (Data not shown).  
5.2.1.2 Enzymatic digestion of Chromatin 
As discussed in Chapter 4, in order to obtain the fragments proposed to be 
looping, the fixated chromatin had to be digested with different restriction 
enzymes. After an overnight digestion, the chromatin was analysed in agarose 
gels, where a smear running down reflects digestion of chromatin (Figure 5.3. 
Enzymatic Digestion of Chromatin analysed on 1.2% Agarose Gel.). The 
template from induced and non-induced Akata and Akata–Zta cells can be seen 
in (Figure 5.3 A) for the digestion of BamHI and (Figure 5.3 B) for the digestion 
of EcoRI. The main band on top of each lane is above the markers band of 10 kb 
and with a tight band on top. While some lanes present minimal smear, others do 
show a smear running down the lane; this is a reflection of the quality of the 3C 
DNA template, indicative of a template of good quality when there is no smear, 
and of passable quality when the smear is more prevalent (Naumova et al. 2012). 
The quality of the template coming from LCL#3 cells and GM2188 is lower (Figure 
5.3 C and D).
Figure 5.2. Expression of Zta only in lytic cell lines and higher
expression of EBV viral load in induced cell lines. (A) Western blot
staining showing bands of an expected size corresponding to Actin and Zta in
LCL#3 cells and no band in the latent GM2188 cells. (B) Relative amount of
Viral load from Akata IgG induced and non induced (control) cells, this was
obtained through qPCR.
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Figure 5.3. Enzymatic Digestion of Chromatin analysed on 1.2% Agarose
Gel. (A) Digestion of the induced and non induced cells by BamHI. (B)
Digestion of the induced and non induced cells by EcoRI. (C) Digestion of
LCL#3 cells by HindIII and BamHI. (D) Digestion (“D”) and ligation (“L”) of
GM2188 and LCL#3 cells by HindIII and BamHI.
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5.2.2 Zta and promoter sequence of SLC6A7 
Based on the interactions of Zta found in the vicinity of SLC6A7 in Chapter 4, four 
potential loops were considered; two loops from fragments with Zta peaks to the 
promoter of SLC6A7 (Loop A and loop B), and two loops from fragments without 
Zta peaks to the promoter of SLC6A7 (Loop C and loop D). These last two loops, 
were designed to be considered negative (not looping) controls (Figure 5.4). 
The sequence of the fragments was used to produce primers through Primer-
blast. The primers were selected if they amplify towards the restriction site, so 
that if looping events were happening the primers would amplify towards each 
other (Figure 5.5).  
The hypothesised resulting amplified sequences were assembled together 
virtually, using the sequences from the fragments, so that they could be 
synthetically generated to be used as positive controls. This resulted in 4 positive 
controls, one corresponding to each loop (Figure 5.6). 
Aiming to test both the primers and the synthetic controls as template, an initial 
PCR was set up with and without polymerase, at 60 °C, controlling for external 
contamination. This temperature was chosen since the design of the primers 
set the Tm to 60°C. (Continues in page 138) 
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Figure 5.4 Maps of potential looping regions at SLC6A7. (A) Red arrows
represent the potential loops forming across regions. The track labelled as “Zta –
acyclovir QC” shows the stacked reads of Zta alignments to the hg19 release of
the human genome. This data was previously generated in the lab, from ChIP-
sequencing in Akata cells. The track labelled “Zta common NPC BL”
corresponds to the peaks called by MACS from previous ChIP-Seq experiments
performed in both HONE1 NPC cells and Akata BL cells. The genes displayed
come from the UCSC Genes database. The following track shows circled in red,
the alignments and names of the primers designed to amplify possible loops.
The track labelled as “Restr Enzymes” shows the sites where BamHI aligns to.
The track labelled as “Layered H3K27Ac” shows the regions with heavy
acetylation on cell lines GM12878, H1-hESC, HSMM, HUVEC, K562, NHEK,
NHLF, signalling for active enhancing regions. (B) Local map of the region
containing the promoter region of gene SLC6A7 (anchor region). (C, D) Local
maps of regions containing a Zta peak that could be looping to the region with
the promoter of SLC6A7. (E, F) Local maps of regions with low Zta signal, used
to design negative controls of regions not looping.
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Figure 5.5. Sequences used to design primers for SLC6A7. These were
obtained from the UCSC Genome browser and correspond to the upstream and
downstream sequence relative to the restriction site that flanks each fragment
of interest. The sequence was analysed by primer-BLAST to generate primers
downstream of the restriction site which would amplify towards the restriction
site and that would align to sequence with no repetitive elements. Primers that
would align ~80 to ~150 bp away from the restriction site were selected. The
sequence highlighted in green corresponds to BamHI. (A) Sequence in red
corresponds to primer 9, designed for amplification of potential loop B (B)
Sequence used to obtain primer 7 in anchor region, designed for amplification
of all potential loops in SLC6A7. Sequence highlighted in green corresponds to
BamHI. Sequence in blue corresponds to primer 7. (C) Sequence used to
obtain primer 8, designed for amplification of potential loop A. Sequence
highlighted in green corresponds to BamHI. Sequence in pink corresponds to
primer 8. (D) Sequence used to obtain primer 10, designed for amplification of
loop C. Sequence highlighted in green corresponds to BamHI. Sequence in teal
corresponds to primer 10. (E) Sequence used to obtain primer 11, designed for
amplification of loop D. Sequence highlighted in bright green corresponds to
BamHI. Sequence in dark green corresponds to primer 11.
CCGTGCTGGCGGTGGCCAACCCGAGGTCTGGCTGCCTGGCCCCAGGCTGGACACGCCCTCCCC
ACCCTGGCCCTCTCTAATTTTAGCCCCATGCTGCTGCGGAGGTCATGTGTCAGCCCTGCCTAC
TCACTCCGGACAGCTGCAGGCTGCGTCTTGCCAGTGACAAGAAGCAGATGCCCCCACTGGGGC
CCACCCTGCCAGAGCACCCATCCCCTGCCTCTCTCCTCAGGCCATATAGGCCTCCCCAACCTC
AGACTCCAGAGCCCCATATTGGCACTGGCTATGGCCCGGGTGGCAGGGACAACCAGAGCAACA
GCTCTTTGGGGGCTTCCCCTGCTGTCATTTCCCCTTACCTCCCTCCTCACCTCCTGGCCAGAG
CCCTGGAAGTGGGCATCAGCCAGGAAATGGCCTGAATGTCCAGCCCTGCCCACAGGCATCCGG
CTGCTTCAGACTTAAGCAAATACCttaaatgaaacaaggtatctgtgaagtacttagcaaagc
acctgacccataagccgcacatgctcaggaaatggtagcCATGATAAGACTTCTCCTGGTGGC
CTTGAGAGGGGGAGTTGGGAGGAGGGTCATATGAGCCACTGATGCCCCAGGGGCTCTGAGGCA
TGGGGCTCATGGCAGGTCACCTTCCCAGTCACCCCCACATTTCCACCTATGACCCCTTCGAGG
CTCTCATTCCAAGTTCCCTACTTGCAAACCAAGGCAGGGGCCACCTCTGGATCCCGAAGCTGA
CAGGAATGGCTGTCCATTCACCACAGGCTTTGGAGGGTTGGACTAGGATGTGCAGTGGGGCAG
ggggagtgctttctcctcgagcctcaaggtagacgcccctctcagctccagcctactgtcaca
ggatcgtgggtccagtgaggccacagcgtctaattttcaagagacgacagcaatctggggttt
tctatgaaatttcctaatttttaagtgttagaaactcattcaaaaaaatttttaaaacacccc
tacctccacaaagcatatcaagagattcaatccagctcacaggccgccattttgtgagctcAG
GACTAGAGTTCTTTAGGGTGCTTCAGTTGTTAAAAAAAGACTCTGACTATCTGGGTAGCTCAT
CTTTCAGTTTACGGAATGGCAGGATCCTTGTCCAGGGAGAGGGTGGGAAGGCAGTTTAACGAG
GTAGGAAAAGCCCAGTCAGAAGTTCTAGTATCTGCCCACCTCTGGGTCTCACTCCTCCCAACT
GGTTACATGGGCAGGTGGACCCACTCAATGCAGCCAGCTGCCCCCTTCTCAGAGCTGCCCTCT
TGCTGTGGTGCTGGCCACAAATCTGCAGCAGCTTTCTCGGCTGGCCCCAGCCCCAGTCAGAGG
GCCCCTCGGGTGAGCTTTGCTCTATCTGCTATCTATATCTCCTCTACTGCCTGCCAGCGGCCT
GCGCTCCCCAGAAGGAAGCCTCTGGAGGGCACTGGCCCCAGCCCTCTCTGATGTGCCAAGAGG
AGCTTCTTGCTAAACCCTGACAATAATCCCTTCCCCTTCTCTCTGCAAAGCCACATGCCTCAG
GTGATTGGGCACTCCCTGCCTTAACCAGCCCAGTTTGGCCAAGGGCCTGGGACGCTCCTGCCC
TGGACTCACTGGTGACCCAATCCAGTTaaaggcacttgccctgggtttggtcaaacctgtgct
gaatgcaggctctgcctctctagccatgtgacctgggacaagtcagagctcaccttcctgagc
ttctgcttcctcatcccagaaatagggatggcagcacccccatcatcccctctgctgccttgt
catgtaggccacctgagtggaagcacgggactgcttagcacagggcTCCAATCATGGTGGGCA
ATATTGTTACTCCC
A
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ttgataggtaaaattttatgtatttatcatgtacaacatgatgttttgaagcatatgtacctg
ggggaactgttaaatctagctaattagcatatgtattatctcacataattatcatttttgtag
tgagaacacttaacatccactctcttagcattctccaagaatacgatatattgtcactaactg
catattatacTtcatttattattattaacaatcatggaaacactatcctcattttacagagga
ataaactgaggctcaaaagggttcttatcaagcttacggtcatacagctaggggatcgaagaa
cagggatcccagcccagatttgtgtgactgtaaaccccAAGGAGGGCATTAGTGACAATGGTG
ATAACAATGGTACTGACAGCtaatgttaatatttattgactggggactgtgcctgaccttgcc
ctagtgttttacatgcatgtgtgtagtgatttaacccaccctcctcccatgaagtaggcacta
ttcctatcccctcgttacagatagggatcctgcggtccagaggggtgacctggcttgttcagg
ctgcacagctagaaaatggtgaagctggggtccaaatccaggtgccaggattccagaAAGGAA
GTAAAGGGGTTATGCAGGCTTACTGCCAATACAAATCTCCTGCACACTTTACATTAGGCTCTG
TGTCCTtcagaactggaccaagcttagagaccatcttctagatcctgggtgggaaactgaagc
ccgcagaggggaagggacttgcccatgtcccaccgtgtaaatgttgggggaggctttgctcct
ggtccacgtcacttgtgagccaggctcatgaccacgccatccctcGTGACCACGCCATCCCTG
GAGCTGTCACACCATCTTCATTCACTGCCTTCCTTCTCTGTCCTTGACCATCCGCACACCCTC
CCTTTCCATCCTTCCCGGCACAGGTGTGGATTGAAGCTGCTCTTCAGATCTTCTATTCCCTGG
GTGTGGGCTTCGGGGGGCTCCTCACCTTTG
C
GAATGCATTCAGAGTCCATGTGGTCTGGGCAGCTGGAGCAGGAGAGAAGCCACAAAGCCCCCC
TCAGGGTCTGACTTCAGGGGTCCTGAATtgctctgcagaagtccccagtccagtggggaagac
tgctatgcacacagatgacactaatataacaggataagggccaatctgagcgtcaggggagcc
agggcatccaacgagagcagagcacatgcctagcttatcctggaaggcttcctggagtaggta
atgtttgaactgagactgaaaaggactagcgagtatggatcaggccaagaagggaataaagga
gaaaaggaacttgagcaatatggactgaaagtataaTTTTTTTTGAACTCGGGAGTCTACTAC
CCGGGGCCTTCTCTCCCCGGGGGCTCTGGTGCCAGCTGCCTGCCCCTCTGTTTACTGTTCTGG
GAGGTGGCCAGGCCATAAAAAGTGTGCACAGCCTGCCTGACATCGCCCTTTGCTCCCATGATA
ACAGTGCACAAGGTGGATCCTGGCCTGGCACAGGCCCCTGAAGTGCAGCAGGCACTTCTCTCT
CTCCTCCTACCAGTGGCCTGGGAGACAGCGGGCATTCATTAGTAATGGTGGACACCTGAGGCT
TGGGAAAGAACCAGGGTTCCAAGAGTAGAGGGGGAGGGGCTGGTGAAAAGGCGGCTGGCCCGG
ACTGAATAGAGTTTTCTGATCTTCAAAAAAATATgctctgtgaccctagggtaactgcttccc
ctctttgggcccgcattgccccatctgtaaacttggggaagttgTCTACCAGAAAGAAATAAC
TCtggtcaagtaagtttgggaaatcctgctgaagccacttctctgatagagtcacagtgggcc
attagcacatcaaagtctctgacaagccccacagcaaagaaaccccttgaattttctttcatc
tggccttccccgtgctttgctacctaggaggcccctactcacacctccgagcatcccactgaa
ctCCACACACTC
B
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Agtttcactctgttgcccaggctggagctctgtggctcgatcatagctcactgcagcctcaa
actcctggctcaagccttcaagctgtgagatctgacgttatctctaggtaaatatagtgttc
aaattgaatcggagggcaccagattcgtgtctgctgcagaatctgaacaattggttgattgc
ttggtgtatggggaaatatgccccatcctctacatctggggtcagaagtattttgtgttgtg
agactataggagaaacggagtttgttttcttCCTGTATACAGGTTGGTCTGGGAGAGCCTGA
TAATATTGGCaataagcttccttttacaggacatttactagccaaaccttttacattcactg
tctcctttagtactgcaaaactttatgtaggtaagtactattgtcattctcatttcacagat
gggaaaactaaagctcagagagatcaaatgccttaagcttgtccatagtcaaacagctacca
aatggtggagataggatttggatcccagcagtctggttataaaacTATCTTTTGTGCGTTAC
TTACATTGTTTATTTATTTTTACAAAGAATCTAATTGTTCTGCATAATTCTTAAAATATATA
GCATTCctttgctccctcttttcctggaggcaattgcttttacctcttttagttgattcgct
tagtattttacttcttatctctaaagaacatggtcatttcttcttctttttttctttttttt
tttctgagacagggtttggttctgtcacccaggctggagtgcagtagtgtgatctcggctca
ctgcaacctccacctcccggactcaagccatcctcctacctcatcctcctgagtagttggga
ctacaggggcatgtgccaccattcctagcaaatttctgtatttttggtagacatggggtttc
accatgttgtccaggctggtctcaaacccctgagctcaagtgattcgcataccttggcttcc
caaagtactgggattataggtatgagcc
E
CCTGGGGCCCTGCCCGTCACCCTGCTGTGCCATCCAGCAGGACATGGAACGAGAGCAGACAA
CAGGCACCACAGAGAGAAGGAATTGCTCACGGTTTTCAAAATAGAATCGATGGAAGTCCAGG
CCCTCAACCAGGTTCCCCAGGGCCTCAGGTTCGAAGGCTGTCATGCCAGGGTCGCACATCTT
CCTGGGGGAAAGAAGCCAGAGGGAAGAGGGACTGGGGCGGCTTCTCATTGGACCCTTGGAGG
GTGAGCctgtgaaataggaatgattgcacctacctcacaggatcattgaagttagtagatgg
gaAGGGGCCAGGGGCTTGCAAGTTATAAAGTATGGGATATCACTGACTGGTTGGTGCCatct
agatccgggaagcctgggttcaggccctggctctgccaatggctgtgagaccccaagcaagt
ggcttaatccctttaagcaagagcaccatgaatagtgtacagggctgtgcagtgcactaaag
gtgctggtggggaggaaattcagcttgctctctactctccaaattgtactccctggttcagg
gcagtggatccagagggggctttttctaatttgTCTTCCTGTGGGGTCGGGATGGGGGACAC
TGCCTTTTCCTTCACATAAAAGTGACTTCTGCTCATCAAGCCAGGTATATACCTggaagggg
cgagttttctaatttgaacaaaggtgccctattgttaacagcagccttgGctgtgagcctca
gtttcctcttctgtaagatgagaaaaatagcattagatgaGGTAATATCTGGGAGGAGAAGC
ACAGGGCATGACGGAGGCTGTGTATTTTCAGCTGTTATTCCCTTCCAGGTCTTAGTCTTCTC
GGAGATCCTGACAGCCAGGCAGGGGAAGGGAACAAGCTGTCTTTCCCATCTCCAGGTCTGTG
GGATCTTTTGTGGTATAACATGGACCCCTGTGACAATAGCAATGAAGCCAGGGGCAGGAAAT
GTCCCAGGACAAGCAAAGCTCCCAACCCAGGGTAGAATTGGAGACACCCAGGAGAAGGTGTC
AGGCCCAGCACCGTCTGAGCTGGAGAAAGCATTCACAGGGTGCACTGTCCCTGCTCTGTCCT
TTCTGTTTGGGTGACCCCAGACAACTTGCTTCTCTACTCATGACCCCAAATTCTCCAGATGG
CTTAAGCCTGGGGCTGGGGGACTGTGCTCAGACCAAACGGGATGCCCAGGACCCTTCCAGCT
CCAGAATCCCCCAAGAGTGGGGGTCTGGACATGTGGGAGACTGAGCGCCCCCACTGAAGAAG
CCCCAACCCTGGAGGCACCTGGGTGTTCCTGCCTCCTAGAGTgaagggacttggaggccatc
tgccccaactccattgtacatatggggaaactgaggctcagagagatgaaggaacatgttca
agattacacagGGCATCCTGGACCCCAGAGGTCATGACAAGGGGTCAGAACCTAGAGCAGGC
TGCAGATGTCAGAGGAGGTGACATCACATAGGTGGGAGGGGTTCCCCAGGACCC
D
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Figure 5.6. Sequences used as template for synthetic controls of SLC6A7.
These were generated by uniting at the restriction site; the reverse-
complemented sequence of the anchor amplification target, and the sequence
from the proposed loops amplification targets. Sequence highlighted in green
represents BamHI. Sequence highlighted in blue represents primer 7 from the
anchor region. (A) Cyan represents primer 8. (B) Red represents primer 9. (C)
Teal represents primer 10. (D) Dark green represents primer 11.
Promoter Vs Potential Enhancer1
>A
cagttaccctagggtcacagagcATATTT
TTTTGAAGATCAGAAAACTCTATTCAGTC
CGGGCCAGCCGCCTTTTCACCAGCCCCTC
CCCCTCTACTCTTGGAACCCTGGTTCTTT
CCCAAGCCTCAGGTGTCCACCATTACTAA
TGAATGCCCGCTGTCTCCCAGGCCACTGG
TAGGAGGAGAGAGAGAAGTGCCTGCTGCA
CTTCAGGGGCCTGTGCCAGGCCAggatcc
tgcggtccagaggggtgacctggcttgtt
caggctgcacagctagaaaatggtgaagc
tggggtccaaatccaggtgccaggattcc
agaAAGGAAGTAAAGGGGTTATGCAGGCT
TACTGCCAATACAAATCTCCTGCACACTT
TACATTAGGCTCTGTGTCCTtcagaactg
gaccaagcttagagaccatcttctagatc
ctgggtgggaaactgaagccc
A
Promoter Vs Potential Enhancer2
>B
cagttaccctagggtcacagagcATATTT
TTTTGAAGATCAGAAAACTCTATTCAGTC
CGGGCCAGCCGCCTTTTCACCAGCCCCTC
CCCCTCTACTCTTGGAACCCTGGTTCTTT
CCCAAGCCTCAGGTGTCCACCATTACTAA
TGAATGCCCGCTGTCTCCCAGGCCACTGG
TAGGAGGAGAGAGAGAAGTGCCTGCTGCA
CTTCAGGGGCCTGTGCCAGGCCAGGATCC
TTGTCCAGGGAGAGGGTGGGAAGGCAGTT
TAACGAGGTAGGAAAAGCCCAGTCAGAAG
TTCTAGTATCTGCCCACCTCTGGGTCTCA
CTCCTCCCAACTGGTTACATGGGCAGGTG
GACCCACTCAATGCAGCCAGCTGCCCCCT
TCTCAGAGCTGCCCTCTTGCTGTGGTGCT
GGCCACAAATCTGCAGCAGCTTTCTCGGC
TGGCCCCAGCCCCAGT
B
Promoter Vs Negative Control1
>C
cagttaccctagggtcacagagcATATTT
TTTTGAAGATCAGAAAACTCTATTCAGTC
CGGGCCAGCCGCCTTTTCACCAGCCCCTC
CCCCTCTACTCTTGGAACCCTGGTTCTTT
CCCAAGCCTCAGGTGTCCACCATTACTAA
TGAATGCCCGCTGTCTCCCAGGCCACTGG
TAGGAGGAGAGAGAGAAGTGCCTGCTGCA
CTTCAGGGGCCTGTGCCAGGCCAggatcc
agagggggctttttctaatttgTCTTCCT
GTGGGGTCGGGATGGGGGACACTGCCTTT
TCCTTCACATAAAAGTGACTTCTGCTCAT
CAAGCCAGGTATATACCTggaaggggcga
gttttctaatttgaacaaaggtgccctat
tgttaacagcagccttgGctgtgagcctc
agtttcctcttctgtaagatgaga
C
Promoter Vs Negative Control2
>D
cagttaccctagggtcacagagcATATTT
TTTTGAAGATCAGAAAACTCTATTCAGTC
CGGGCCAGCCGCCTTTTCACCAGCCCCTC
CCCCTCTACTCTTGGAACCCTGGTTCTTT
CCCAAGCCTCAGGTGTCCACCATTACTAA
TGAATGCCCGCTGTCTCCCAGGCCACTGG
TAGGAGGAGAGAGAGAAGTGCCTGCTGCA
CTTCAGGGGCCTGTGCCAGGCCAggatcc
cagcagtctggttataaaacTATCTTTTG
TGCGTTACTTACATTGTTTATTTATTTTT
ACAAAGAATCTAATTGTTCTGCATAATTC
TTAAAATATATAGCATTCctttgctccct
cttttcctggaggcaattgcttttacctc
ttttagttgattcgcttagtattttactt
cttatctctaaagaacatggtcatttctt
cttctttttttcttttt
D
137
138 
(continues from page 131) Subsequently, the PCR products were loaded in 
an agarose gel, and an electrophoresis was run, resulting in clear bands of 
the intended size in lanes containing primers, template and 
polymerase. No amplification was observed in the lanes with primers and 
template, but without polymerase; indicative of no contamination (Figure 5.7). 
Trying to find an optimal temperature of amplification, a gradient of temperatures 
was used in PCR using the template from LCL#3 cells and the primers for loops 
A and B. The products were loaded in an agarose gel, and after an 
electrophoresis was run, it was observed that lower temperatures resulted in non-
specific amplification, and higher temperatures reversed this (Figure 5.8). 
Synthetic positive controls were amplified at the closest temperature to 60°C, 
found in the gradient 
Aiming to test if the presence of products representing looping events was 
observed, the PCR for amplification of loops between Zta and promoter region of 
SLC6A7 were performed at 64 °C, since this temperature showed no non-specific 
bands in the previous gradient of temperatures. The template from induced 
and non-induced Akata cells showed no amplification (continues in page 140) 
Figure 5.7. Amplification of PCR products from synthetic positive controls 
for loops with promoter of SLC6A7. A set of PCR reactions were performed 
using the synthetic positive control as template at 60°C. The reactions were 
performed with and without Phusion polymerase to corroborate that there was no 
contamination in any of the components of the reaction, the expected size of 
amplification to be correct, and that such polymerase would function as expected. 
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Figure 5.8. Temperature gradients used to optimise melting temperatures
for loops with SLC6A7. Using template from LCL#3 cells, four gradients were
tested. Black triangle on top represents the increasing temperature in the
gradient. (A) Performed at a 15.4°C gradient with 60°C as a midpoint testing for
loop A. (B) Performed at a 11.5°C gradient with 54°C as midpoint testing for loop
A. (C) Performed at a 15.4°C gradient with 60°C as a midpoint testing for loop B.
(D) Performed at a 11.5°C gradient with 54°C as midpoint testing for loop B. Each
control was amplified at whichever temperature closest to 60°C was found in the
gradient.
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(continues from page 138) of a product of similar size as the control (Figure 5.9 
A and C). In a similar way no product amplification could be detected in latent 
cells GM2188 or lytic LCL#3 (Figure 5.9 B and D). The positive controls were run 
in the same PCR reaction at the same temperature, time and day as the tested 
samples. 
5.2.3 Zta and promoter sequence of LHX1 
Based on the interactions of Zta found in the vicinity of LHX1 in Chapter 4, five 
potential loops were considered; three loops from fragments with Zta peaks to 
the promoter of LHX1 (Loops E, F, G), and two loops from fragments without Zta 
peaks to the promoter of LHX1 (Loop H and I). These last two loops, designed to 
be considered negative (not looping) controls (Figure 5.10). 
The sequence of the fragments was used aiming to produce primers through 
Primer-blast. The primers were designed to amplify towards the restriction site, 
so that if looping events were happening the primers would amplify towards each 
other. The hypothesised resulting amplified sequences were assembled together 
virtually, using the sequences from the fragments, so that they could be 
synthetically generated to be used as positive controls. This resulted in 5 positive 
controls, one corresponding to each loop (Figure 5.11). 
Aiming to test both the primers and the synthetic controls as template, an initial 
PCR was set up with and without the polymerase at 60°C, controlling for external 
contamination. This temperature was chosen since the design of the primers set 
the Tm to 60°C. Subsequently, the PCR products were loaded in an agarose gel, 
and an electrophoresis was run, resulting in clear bands of the intended size in 
lanes containing primers, template and polymerase. No amplification was 
observed in the lanes with primers and template, but without polymerase; 
indicative of no contamination (Figure 5.12). 
In a PCR with a gradient of temperatures using the template from LCL#3 cells, a 
band of similar size to the positive control of loop E could be appreciated (Figure 
5.13 A). Aiming to reproduce this, a subsequent PCR assay was performed with 
template from latent and lytic cells at 55°C. The products were loaded in an 
agarose gel, and after an electrophoresis was run, the band of similar size was 
observed (Figure 5.13 B). Asking whether the amplified (continues on page 149)
Figure 5.9. Chromosome conformation capture analysis of the SLC6A7
promotor region. Image captures of 1.2% Agarose gels after electrophoresis of
PCR amplification products. PCR amplification was performed at 64°C. Each
panel (A-D) is composed of sections (lanes) coming from the same gel. (A) The
image shows no band of similar size to the synthetic positive control for loop A
in lanes with the Akata and Akata-Zta templates. (B) The image shows no
product amplification of comparable size to the synthetic positive control for loop
A in lanes with LCL#3 and GM2188 templates. (C) The image shows no band of
similar size to the synthetic positive control for loop B in lanes with the Akata
and Akata-Zta templates. (D) The image shows no product amplification of
comparable size to the synthetic positive control for loop B in lanes with LCL#3
and GM2188 templates. The same experiments were performed for negative
controls C and D, not showing amplification (data not shown).
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Figure 5.10. Maps of potential looping regions at LHX1. (A) Red arrows
represent the potential loops forming across regions. The track labelled as “Zta
– acyclovir QC” shows the stacked reads of Zta alignments to the hg19 release
of the human genome. This data was previously generated in the lab, from
ChIP-sequencing in Akata cells. The track labelled “Zta common NPC BL”
corresponds to the peaks called by MACS from previous ChIP-Seq experiments
performed in both HONE1 NPC cells and Akata BL cells. The genes displayed
come from the UCSC Genes database. The following track shows circled in red,
the alignments and names of the primers designed to amplify possible loops.
The track labelled as “Restr Enzymes” shows the sites where HindIII aligns to.
The track labelled as “Layered H3K27Ac” shows the regions with heavy
acetylation on cells lines GM12878, H1-hESC, HSMM, HUVEC, K562, NHEK,
NHLF, signalling for active enhancing regions. (B) In the track labelled “NPC-
CHIP1”, ChIP data from HONE1 NPC cells displays two more Zta peaks which
were promising targets due to their proximity to the promoter region of the gene
of interest and their alignment to a region with heavy acetylation. This is also
reflected in the track labelled “Zta NPC data” in which the peaks from ChIP in
NPC were called by MACS, therefore two more potential loops were considered.
(C) Local map of the region containing the promoter region of gene LHX1. (D, E)
Local maps of regions containing a Zta peak that could be looping to the region
with the promoter of LHX1. (F) Local map of a region with both a Zta peak used
to generate a potential loop and a region with low Zta signal, used to design a
negative control. (G) Local map of a region with a low Zta signal, used to design
another negative control.
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Figure 5.11. Sequences used as template for synthetic controls of LHX1.
These were generated by uniting at the restriction site; the reverse-
complemented sequence of the anchor amplification target, (figure legend
continues…)
Promoter Vs Potential Enhancer1
>E
GCAGGGAGGGGGGAGAGACTATAATAAAA
GAGGGTGAAGGCGGCCCCAGGAGGCTGGG
CCTCGTCCCAAACCATCCGTCTTCATTGT
CTCCGTGTGTGCAAAGGCAACTCTGGCAT
AAGGAAAACCCACTATTGGAGCCGAGGCT
TTATTTTATATCCTATACATCAGGAGGGA
GGCAAAGCTTGGGTGGGGGGCGGATTCTG
GGGTCAGTCTGAGGAGGCCTTGGGGAAGA
AGTGAGCGCTAAGCAAGGCTCCCAAGAGG
AATGGAAGGGCCTGAACCAAAGCTGGCTT
GCCCTCAGCCAGGGGGCAGTGCCCACAGA
TGCCCTGGATGGAGCCTGTCCAAGGCGTC
CTGTGTCTGCTAGTCTGAGCCAGGGATGA
GCCTGAACGGGCCTCCCATGCTATCCATC
TTTCTGTCTGATGGGCTGTTGTCAGTATC
CTCAAT
A
Promoter Vs Potential Enhancer2
>F
AACCCAGAAAGGAAAGAAAGTGAAGAAGA
AAGAAAAAGGCAGGGAGGGGGGAGAGACT
ATAATAAAAGAGGGTGAAGGCGGCCCCAG
GAGGCTGGGCCTCGTCCCAAACCATCCGT
CTTCATTGTCTCCGTGTGTGCAAAGGCAA
CTCTGGCATAAGGAAAACCCACTATTGGA
GCCGAGGCTTTATTTTATATCCTATACAT
CAGGAGGGAGGCAaagcttggggttgata
ctgaaagcagcagggaaacgttttttaaa
tagaagaatgatatagtttacagacagtt
tactccaggacctggcaaacagcaggcat
ttaataaatacctcttgagtgaatgaatg
aatcaagattggaggaggagagaccaatt
aggcggccacttcagcgacccaggtatcc
catcatgagggctgaacccagggcagctg
ccatggagTTTTGGGGGGACCCTCAGCCA
GGCACTGGGC
B
Promoter Vs Negative Control1
>H
AACCCAGAAAGGAAAGAAAGTGAAGAAGA
AAGAAAAAGGCAGGGAGGGGGGAGAGACT
ATAATAAAAGAGGGTGAAGGCGGCCCCAG
GAGGCTGGGCCTCGTCCCAAACCATCCGT
CTTCATTGTCTCCGTGTGTGCAAAGGCAA
CTCTGGCATAAGGAAAACCCACTATTGGA
GCCGAGGCTTTATTTTATATCCTATACAT
CAGGAGGGAGGCAAAGCTTTTTATCAGTC
AGCTTTAAAGATCAGCATTCCTTAGAGGC
TGctccatcttcctctctctctgtttctc
tctcgcatcccctccttctcctggtctct
ctatctcccttcccatctcacggtccctt
tttcGGCACCGCATTTGTCTGTGTGGTTT
TTCTGCTCCTGGAAATCCCTTGCCCTCTT
CTGCCTCACTGCTCGCTGACAACAGGCCA
GGCCCTGCTCCGTGTCTCCAGGTGGCCGT
GGGGACAGAGAGGGGAGAGGGCAGGGGCA
AGACTGGCAGAGCCACC
Promoter Vs Potential Enhancer3
>G
AGAAGGGCATATAAAAGGCAAATCCAACC
CAGAAAGGAAAGAAAGTGAAGAAGAAAGA
AAAAGGCAGGGAGGGGGGAGAGACTATAA
TAAAAGAGGGTGAAGGCGGCCCCAGGAGG
CTGGGCCTCGTCCCAAACCATCCGTCTTC
ATTGTCTCCGTGTGTGCAAAGGCAACTCT
GGCATAAGGAAAACCCACTATTGGAGCCG
AGGCTTTATTTTATATCCTATACATCAGG
AGGGAGGCAAAGCTTATCCAAGGAAGTTA
GTGGCTGGCCCTGGACCCTAAGGCCTGAC
TGAGCTAGGGGGTCCCTCCGGCCTGCTAT
GCCAGAGGAAGGCCGGCCTCAcgtgatgg
aggggagtgagcaagggcttggaagtcaa
acagccttgggttcaaatcctggctttta
tgagccttgtaacctcaagcaagtcattg
cccttgctgagcatctgacgggctcctcc
ttggccaatagggatgataggaccaactt
cacaggg
C D
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Promoter Vs Negative Control2
>I
AATCCAACCCAGAAAGGAAAGAAAGTGAAGAAGAAAGAAAAAGGCAGGGAGGGGGGAGAGACT
ATAATAAAAGAGGGTGAAGGCGGCCCCAGGAGGCTGGGCCTCGTCCCAAACCATCCGTCTTCA
TTGTCTCCGTGTGTGCAAAGGCAACTCTGGCATAAGGAAAACCCACTATTGGAGCCGAGGCTT
TATTTTATATCCTATACATCAGGAGGGAGGCAAAGCTTTATTTTCATAGAACCAGAAAAAGTA
TTTTGTGTTAGAAAGTAATTTTTTTCCTTAGAAGGCAAATGATTTATTGAGCTTTTGTTACTT
AAACAATTCTAATGAAAAAATTAGCTTTATAGTTTTGTTACCGGTTTGTTTGGAAACTGGAAT
TGCTGAAAGCATGAAGTATAGCCAATGGTGAAGGTTTTATGAGAGAAACTGTTCATCTGCTTC
AGAAAAGCATTGCAGGATTTTACTTCCAAACAGA
E
(Fig legend continues…) and the sequence from the proposed loops
amplification targets. Sequence highlighted in yellow represents HindIII.
Sequence highlighted in cyan represents primer 1 from the anchor region. (A)
Purple represents primer 2. (B) Gray represents primer 3. (C) Gold represents
primer 4. (D) red represents primer 5. (E) Dark gray represents primer 6.
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Figure 5.12. Amplification of PCR products from synthetic positive
controls for loops with promoter of LHX1. A set of PCR reactions were
performed using the synthetic positive control as template at 60°C. The
reactions were performed with and without Phusion polymerase to corroborate
that there was no contamination in any of the components of the reaction, the
expected size of amplification to be correct, and that such polymerase would
function as expected.
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Figure 5.13. Non specific amplification of a false positive. (A) Initially, a
gradient temperature PCR (11.5°C gradient with 54°C as midpoint) showed
amplification of bands of similar size to the positive control in using LCL#3
template. (B) The PCR was performed with both LCL#3 and GM2188, at 55°C
still showing a band of similar size to the control in both templates. The bands
where excised and the product sequenced. The retrieved sequence (225bp) was
labelled “sequenceX” and then aligned (BLAT) to the UCSC genome browser (C)
where it was found not corresponding to the anchor region or restriction fragment
intended to be amplified. (D) Alignment of sequences through ClustalOmega on
Jalview. Black boxes in the Consensus track represent alignments of sequences.
The sequenced product was labelled as “sequenceX” (circled in red). The region
where the amplification of the sequenced product aligned-to (BLAT) was
retrieved adding 100bp upstream and downstream “Background”. The sequence
of primer 1 “Primer1” and the reverse-complemented sequence of primer 2
“Primer2” are also in the alignment (See Figure 5.11 A). We can see a partial
alignment from bp 60 to 80 of Primer 1, and on 359 to 371 we can see a partial
alignment of Primer 2. This would explain why there is an amplification of a
similar size to the positive control in both LCL#3 and GM2188 when the PCR
amplification is performed at 55°C. It was because of this event, that every PCR
was performed at 60°C to minimise any possibility of non-specific amplification.
La
dd
er
N
o 
te
m
pl
at
e
LC
L#
3
G
M
21
88
+C
trl
 E
600 bp →
400 bp →
200 bp →
B
+C
trl
 E
La
dd
er
600 bp →
400 bp →
200 bp →
A
54°C
↓
C
146
D147
148
Figure 5.14. Chromosome conformation capture analysis of the LHX1
promotor region. Image captures of 1.2% Agarose gels after electrophoresis of
PCR amplification products. The PCR amplification was performed at 64°C.
Each panel (A-E) is composed of sections (lanes) coming from the same gel.
(A) The image shows no product amplification of comparable size to the
synthetic positive control for loop E in lanes with LCL#3 and GM2188 templates.
(B) No product amplification of comparable size to the synthetic positive control
for loop F in lanes with LCL#3 and GM2188 templates. (C) No product
amplification of comparable size to the synthetic positive control for loop G in
lanes with LCL#3 and GM2188 templates. (D, E) No product amplification of
comparable size to the synthetic negative controls H and I.
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(continues from page 140) product was the intended sequence or unintended 
amplification, the band was excised and sequenced.  
Using the BLAT tool, the sequence retrieved was aligned in the genome browser, 
showing to be found at chromosome 12, a different location than the sequences 
considered when the 3C experiment was designed (Figure 5.13 C “sequenceX”). 
The sequence of the primers for the amplification of loop E (Primer 1 and Primer 
2) were aligned to the sequence from the excised band, showing a partial 
alignment in the flanks of sequenceX (Figure 5.13 D). These results show that 
the band found is a product of non-specific amplification, probably due to the 
temperature used, and not the actual fragment of loop E. 
Based on the previous experiment, all subsequent PCR experiments were 
performed with an amplification of 64 °C since this temperature showed no non-
specific bands in previous gradient of temperatures. When executed with the 
latent and lytic template of GM2188 and LCL#3 cells, no bands of similar size to 
the positive control were found in the products of the PCR experiments (Figure 
5.14). The positive controls were run in the same PCR reaction at the same 
temperature, time and day as the tested samples. 
5.2.4 Zta and promoter sequence of FZD10 
Based on the interactions of Zta found in the vicinity of gene FZD10, six potential 
loops were considered; four loops from fragments with Zta peaks to the promoter 
of FZD10 (Loops J, K, L, and M), and two loops from fragments without Zta peaks 
to the promoter of LHX1 (Loop N and O). These last two loops, designed to be 
considered negative looping controls (Figure 5.15). 
The sequence of the fragments was used aiming to produce primers through 
Primer-blast. The primers were designed to be 20 nucleotides in length and to 
amplify towards the restriction site, so that if looping events were happening, the 
primers would amplify towards each other. The hypothesised resulting amplified 
sequences were assembled together virtually, using the sequences from the 
fragments, so that they could be synthetically generated to be used as template 
for positive controls. This resulted in 6 positive controls, one corresponding to 
each loop (Figure 5.16). (continues in page 152) 
Figure 5.15. Map of potential looping regions at FZD10. (A) Red arrows
represent the potential loops forming across regions. The track labelled as “Zta –
acyclovir QC” shows the stacked reads of Zta alignments to the hg19 release of
the human genome. This data was previously generated in the lab, from ChIP-
sequencing in Akata cells. The track labelled “Zta common NPC BL” corresponds
to the peaks called by MACS from previous ChIP-Seq experiments performed in
both HONE1 NPC cells and Akata BL cells. The genes displayed come from the
UCSC Genes database. The following track shows circled in red, the alignments
and names of the primers designed to amplify possible loops. The track labelled
as “Restr Enzymes” shows the sites where HindIII aligns to. The track labelled as
“Layered H3K27Ac” shows the regions with heavy acetylation on cells lines
GM12878, H1-hESC, HSMM, HUVEC, K562, NHEK, NHLF, signalling for active
enhancing regions. (B) Local map of the region containing the promoter region of
gene FZD10 (anchor). (Figure legend continues…)
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(cont…) (C, D, E) Local maps of regions containing a Zta peak that could be
looping to the region with the promoter of FZD10. (E, F, G) Local maps of
regions with a low Zta signal, used to design negative controls.
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Figure 5.16. Sequences used as template for synthetic controls for FZD10.
These were generated by uniting at the restriction site; the reverse-
complemented sequence of the anchor amplification target, and the sequence
from the proposed loops amplification targets. Sequence highlighted in yellow
represents HindIII. Sequence highlighted in bright green represents promoter
primer 12 from the anchor region. (A) Teal represents primer 13. (B) Blue
represents primer 14. (C) Cyan represents primer 15. (D) dark green represents
primer 16. (Figure legend continues…)
Promoter Vs Potential Enhancer1
>J
GTCCCCCGCTGCTCAGCCCTGGCTGGCAA
CCGACCCCCCTCTGGCAAATGTTATGGAG
AATTGGGAGGAATTTTATGGCTGTCTTTC
CCTCAGCTCTTTTTTCTTTTGTCTTCTTT
GAAGAATGACTTTAGACATTTTATTTACA
TATTTAACCATGGATGAAAGACGGAAAAG
AAAGCTTAGGCCACCAGCCAATGGTTTTC
TTTCTAAAGGAAAGGAGAGGAGAGGCGAA
CCTTAAAACGCCGTCTCACGGCTGATCTG
CCCTGCTTCCAGGTCAAGCCCAAGCGAGG
GCATGAGGGAGAAAGCAGGGGACGTAGAG
ACAGCCTGGCAAGAGCTGAGGCAGGAGGA
AACGAGCACCTCTTTCTCCTTCCTGAGCA
TT
A
Promoter Vs Potential Enhancer3
>K
AGCCGGGGTCCCCCGCTGCTCAGCCCTGG
CTGGCAACCGACCCCCCTCTGGCAAATGT
TATGGAGAATTGGGAGGAATTTTATGGCT
GTCTTTCCCTCAGCTCTTTTTTCTTTTGT
CTTCTTTGAAGAATGACTTTAGACATTTT
ATTTACATATTTAACCATGGATGAAAGAC
GGAAAAGAAAGCTTTTGAGGGCAAGGACT
GAATTTTTTACATTTATGCATGGAAGATG
GGAAAATGTTGAATATATTCACTTCAATA
AATGCCAAGAATACAGCAGTACCATAGCC
TGATACTCAAACTACTGCTTGGACCAACT
GTGGTAGATAAAAAATGACTACACATTct
ttgctccctctcccattgagaggtggaat
taaattccctttctcttgaacatgagctg
gccttggtgatgatt
B
Promoter Vs Potential Enhancer4
>L
AGCCGGGGTCCCCCGCTGCTCAGCCCTGG
CTGGCAACCGACCCCCCTCTGGCAAATGT
TATGGAGAATTGGGAGGAATTTTATGGCT
GTCTTTCCCTCAGCTCTTTTTTCTTTTGT
CTTCTTTGAAGAATGACTTTAGACATTTT
ATTTACATATTTAACCATGGATGAAAGAC
GGAAAAGAAAGCTTGCCATGCGCCCCGCG
TCATCCTGGCGTCTGCCTCCTTTGGCAGG
GGAATTAATGGTTTTTTAGAGGTTAATAA
CTTGTTGGTGTTTCCCCATTCCCTTGATG
GCGTTGTCATCTTCCATCTTTTTTCATTT
CCTAAGGAGGAAAATAACTTCTGCGGAAC
AAAGGCTGGGCAACTGCGCCAAAGGCAGC
CCTCAGAACCTTATCAAA
C
Promoter Vs Negative Control1
>M
AGCCGGGGTCCCCCGCTGCTCAGCCCTGG
CTGGCAACCGACCCCCCTCTGGCAAATGT
TATGGAGAATTGGGAGGAATTTTATGGCT
GTCTTTCCCTCAGCTCTTTTTTCTTTTGT
CTTCTTTGAAGAATGACTTTAGACATTTT
ATTTACATATTTAACCATGGATGAAAGAC
GGAAAAGAaagcttaagtaacttcccagg
gtcacctaagtagaaagtgtcaggacagg
aatcccaggcaggctttctagctcttgaa
tctgtgctctgagctgcaatgtcatcctg
tCTCTTGCAGGGCGTCATCTGGTTGTATC
TAACCAGGTGCATGAGACCGTGATCATCC
CATAAACCAAATAACATACAGCTTAGGAA
TGTTTCTCTTcaattcttttttattatcc
agttccctttc
D
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Promoter Vs Negative Control2
>N
AGCCGGGGTCCCCCGCTGCTCAGCCCTGG
CTGGCAACCGACCCCCCTCTGGCAAATGT
TATGGAGAATTGGGAGGAATTTTATGGCT
GTCTTTCCCTCAGCTCTTTTTTCTTTTGT
CTTCTTTGAAGAATGACTTTAGACATTTT
ATTTACATATTTAACCATGGATGAAAGAC
GGAAAAGAAAGCTTTCATATTCAAGAGCA
AAGTAACTGAATTTGAAACTTTTATTAAT
AATGTAAAAGGCTTGCGTGACACGCAGAA
GCTGGAAAAATATGGGGAAATCAGAGGAG
ACTTTGCTTTATCAAAGAGCAGCCAAATA
AAGGTTGGGCTTGCTTCTGCGGTGGGAGG
AGGGGAGAAACGCCTCCAGGGAGGAGGTC
AATGTCTTTTTCTCCACTTGAGTGCTAGG
ACTTTGGGACTGAGGACCACCAAT
Promoter Vs Negative Control3
>O
AGCCGGGGTCCCCCGCTGCTCAGCCCTGG
CTGGCAACCGACCCCCCTCTGGCAAATGT
TATGGAGAATTGGGAGGAATTTTATGGCT
GTCTTTCCCTCAGCTCTTTTTTCTTTTGT
CTTCTTTGAAGAATGACTTTAGACATTTT
ATTTACATATTTAACCATGGATGAAAGAC
GGAAAAGAAAGCTTATCAGGCATTTAATA
CATAAGATCTCCTTCCATCCCCACAAAAA
TATTGTTATTCCAGTTTTCCAGGAAGGAG
AAATGAGGGTTAAAGAGAAAGTAGGGAAA
AGAAAGGATGCTTGCATAGCCAAGGCCAC
CAATCAGGAGCAGAACAGTTATCAATCTT
CAGGTTGATTTTTCTTTAAATAATTCatt
gaggtgaaattcacacaacataaagtta
E F
153
(cont…) (E) Red represents primer 17. (F) Dark grey represents primer 18.
Figure 5.17. Amplification of PCR products from synthetic positive
controls for loops with promoter of FZD10. A set of PCR reactions were
performed using the synthetic positive control as template at 60°C. The
reactions were performed with and without Phusion polymerase to corroborate
that there was no contamination in any of the components of the reaction, the
expected size of amplification to be correct, and that such polymerase would
function as expected.
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(continues from page 149) Aiming to test both the primers and the 
synthetic controls as template, an initial PCR was set up with and without the 
polymerase at 60°C, controlling for external contamination. This temperature 
was used since the design of the primers set the Tm to 60°C. Subsequently, 
the PCR products were loaded in an agarose gel, and an electrophoresis was 
run, resulting in clear bands of the intended size in lanes containing primers, 
template and polymerase. No amplification was observed in the lanes with 
primers and template, but without polymerase; indicative of no contamination 
(Figure 5.17). 
A gradient of temperatures were used in PCR using the template from 
LCL#3 cells and the primers for loops A and B. The products were loaded in an 
agarose gel, and after an electrophoresis was run, it was observed 
that lower temperatures resulted in non-specific amplification, and higher 
temperatures reversed this (Figure 5.18). Synthetic positive controls were 
amplified at the closest temperature to 60°C, found in the gradient. 
Aiming to test if evidence for looping events was observed, the 
PCR amplifications were performed at 64°C; and the products run in an 
agarose gel electrophoresis. No evidence of loops forming between 
fragments with Zta interactions and promoter region of FZD10 can be 
observed. (Figure 5.19). The positive controls were run in the same PCR 
reaction at the same temperature, time and day as the tested samples.
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Figure 5.18. Temperature gradients used to optimise melting temperatures
for loops to FZD10. Using template from LCL#3 cells, four gradients were
tested searching for amplification of loops. Black triangle on top represents the
increasing temperature in the gradient. (A) Performed at a 15.4°C gradient with
60°C as a midpoint testing for loop J. (B) Performed at a 11.5°C gradient with
54°C as midpoint testing for loop J. (C) Performed at a 11.5°C gradient with
54°C as a midpoint testing for loop K. (figure legend continues…)
155
48
.2
48
.6
49
.7
59
.7
51
.0
52
.1
53
.4
54
.6
56
.0
57
.2
58
.5
59
.3
48
.2
48
.6
49
.7
59
.7
51
.0
52
.1
53
.4
54
.6
56
.0
57
.2
58
.5
59
.3
52
.2
52
.8
54
.3
56
.0
57
.5
59
.2
60
.8
62
.7
64
.2
65
.9
67
.0
67
.6
45
.2
45
.6
46
.7
56
.7
48
.0
49
.1
50
.4
51
.6
53
.0
54
.2
55
.5
56
.3
+C
trl
 L
E
La
dd
er
La
dd
er
54°C
↓
(cont…) (D) Performed at a 11.5°C gradient with 51°C as midpoint testing for
loop K.(E) Performed at a 11.5°C gradient with 54°C as midpoint testing for
loop L. Each control was amplified at whichever temperature was closest to
60°C in the gradient.
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Figure 5.19. Chromosome conformation capture analysis of the FZD10
promotor region. Image captures of 1.2% Agarose gels after electrophoresis of
PCR amplification products. The PCR amplification was performed at 64°C.
Each panel (B) is composed of sections (lanes) coming from the same gel. (A)
There is no band of similar size to the synthetic positive control for loop J in
lanes with the LCL#3 and GM2188 templates. (B) The image shows no product
amplification of comparable size to the synthetic positive control for loop K in
lanes with LCL#3 and GM2188 templates. (C) There is no band of similar size to
the synthetic positive control for loop L in lanes with the LCL#3 and GM2188
templates. (D) The image shows no product amplification of comparable size to
the negative control for loop M in lanes with LCL#3 and GM2188 templates.
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5.2.5 Zta and promoter sequence of cluster VWF and CD9 
Since two different gene promoters were found with Zta interactions in its vicinity, 
two sets of loops were considered for cluster VWF and CD9 (Fig 5.20). For the 
promoter region of VWF loops CA and CB correspond to loops between the 
anchor fragment and fragments with Zta peaks. Given the specific properties 
found in the sequence of the anchor fragment of the promoter region of VWF, two 
primers instead of one had to be designed. The sequence close to the restriction 
site finds repetitive sequence surrounding a small “island” of unique sequence, 
this raises problems when trying to design primes that amplify regions 80 to a 
150 bp away from the restriction site following the recommendations by Naumova 
et al (2012). Being aware that it could cause problems, rather than designing a 
primer in a repetitive sequence that might bind somewhere else, two primers were 
designed in the unique sequence, one being relatively close to the restriction site, 
and another one relatively far (Fig 5.21 A and B sequence highlighted in light grey 
and dark grey). This in turn duplicates the primer pairs used to amplify a single 
loop, in other words; CAs and CBs, reflect the same looping event as CA and CB 
respectively. Loops CE and CG were considered negative looping controls since 
they are formed from fragments without Zta peaks (Fig 5.20 A).  
For the promoter region of gene CD9 two loops, CC and CD, were hypothesised 
based on the presence of Zta peaks in vicinity. Loops CF and CH were 
considered negative looping controls since they don't contain Zta peaks (Figure 
5.20 B). 
The virtually assembled sequences hypothesised to be forming through looping, 
were formed using the sequences from the fragments, so that they could be 
synthetically generated to be used as template for positive controls. This resulted 
in 8 positive controls, one corresponding to each loop (Figure 5.21) 
Aiming to test both the primers and the synthetic controls template, an initial PCR 
was set up with and without the polymerase at 60°C, controlling for external 
contamination. This temperature was chosen since the design of the primers set 
the Tm to 60°C. Subsequently, the PCR products were loaded in an agarose gel, 
and an electrophoresis was run, resulting in clear bands of the intended size 
in lanes containing primers, template and polymerase. (continues in page 164)  
Figure 5.20. Maps of potential looping regions at cluster VWF-CD9. The Zta
peaks in proximity to a cluster of genes increase the level of complexity. However
this can be broken down into the potential loops to each gene. (A) Blue arrows
represent the potential loops forming across regions to the VWF promoter
fragment (anchor). The track labelled as “Zta – acyclovir QC” shows the stacked
reads of Zta alignments to the hg19 release of the human genome. This data was
previously generated in the lab, from ChIP-sequencing in Akata cells. The track
labelled “Zta common NPC BL” corresponds to the peaks called by MACS from
previous ChIP-Seq experiments performed in both HONE1 NPC cells and Akata
BL cells. The genes displayed come from the UCSC Genes database. The
following track shows circled in red, the alignments and names of the primers
designed to amplify possible loops. The track labelled as “Restr Enzymes” shows
the sites where EcoRI aligns to. The track labelled as “Layered H3K27Ac” shows
the regions with heavy acetylation on cell lines GM12878, H1-hESC, HSMM,
HUVEC, K562, NHEK, NHLF, signalling for active enhancing regions. Circled in
red, are the alignments and names of the primers designed to amplify possible
loops. (Figure legend continues…)
CA, CAs
CB, CBs
CE CG
A
CC
CH
CD
CF
B
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Fragment containing promoter
of CD9 (anchor)
D
Fragment containing peak
for loop CB and loop CD
E
Fragment containing peak
for loop CA and loop CC
F
Fragment containing promoter
of VWF (anchor)
C
160
Fragment of interest for
loop CG and loop CH
G
Fragment of interest for loop CE and loop CF
H
(cont..) (B) Red arrows represent the potential loops forming across regions to
the CD9 promoter fragment (anchor). (C) Local map of the region containing the
promoter region of gene VWF. Due to the specific properties of the sequence in
this fragment, two primers had to be designed even though they have the same
target of amplification. (D) Local map of the region containing the promoter
region of gene CD9. (E, F) Local maps of regions containing a Zta peak that
could be looping to the anchors of VWF or CD9. (G, H) Local maps of regions
with a low Zta signal, used to design negative controls.
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Figure 5.21. Sequences used as template for synthetic controls for cluster
VWF and CD9. These were generated by uniting at the restriction site; the
reverse-complemented sequence of the anchor amplification target, and the
sequence from the proposed loops amplification targets. Sequence highlighted
in green represents EcoRI. Please note that there is a big a zone of repetitive
sequence in the fragment of the VWF anchor, therefore 2 primers had to be
devised. (A to H) Sequence highlighted (figure legend continues…)
Promoter1 Vs Potential Enhancer1
>CA
AACATTCCTTGGAAGTACATGAGCTATGA
AAAATGCACAGGATAATTATCAAACCCTA
CTTCAGGACGTCCATGCTGCCTCCTTCAT
CCGTCTCTTCTCCACTTCATTCCAGCTGC
TCTGCTTCAAGTCCCTGGaattcatcgtc
aagagagctttatttgCATGAGTGCAAAG
GATGAAAATTCTAgactgggcgtggtggc
tcacgcctgtaatcccagcactttgggag
accgaggtgggcagatcacgaggtcagga
gtttgagaccagcctggctaacatagtgg
aaccccatctctactaaaaatacaaaaaa
ttagctgggtgtagtggtgtgtgcatgta
atcccagctacttgggaggctgaggcagg
agaattgcttgaagccgggaggcagaggt
tgcagtgagccatgattgcatcactgcac
tccagcccagcggacagtgcgagactcca
tctcaaaaaaaaaaaaagaaagaaaagaa
TATTCTAAAAAAAGACTTAATTCC
A Promoter1 Vs Potential Enhancer2
>CB
AAACTTACAAGAATCCACGCAGTGGGGAG
TGGGAGGCAGAGGGGCTGCTGCCCACACT
CACCGTGAGGATTCCTGGATCGCTCTCAT
CTGCTGGGCAGGATGACTTTCCTGTGTCC
CATCCTCCCACTCCTCCCATTCTGAATTG
TACCAAGTTAGACATTAAAATGGCGGAGa
attcatcgtcaagagagctttatttgCAT
GAGTGCAAAGGATGAAAATTCTAgactgg
gcgtggtggctcacgcctgtaatcccagc
actttgggagaccgaggtgggcagatcac
gaggtcaggagtttgagaccagcctggct
aacatagtggaaccccatctctactaaaa
atacaaaaaattagctgggtgtagtggtg
tgtgcatgtaatcccagctacttgggagg
ctgaggcaggagaattgcttgaagccggg
aggcagaggttgcagtgagccatgattgc
atcactgcactccagcccagcggacagtg
cgagactccatctcaaaaaaaaaaaaaga
aagaaaagaaTATTCTAAAAAAAGACTTA
ATTCC
B
Promoter2 Vs Potential Enhancer1
>CC
AACATTCCTTGGAAGTACATGAGCTATGA
AAAATGCACAGGATAATTATCAAACCCTA
CTTCAGGACGTCCATGCTGCCTCCTTCAT
CCGTCTCTTCTCCACTTCATTCCAGCTGC
TCTGCTTCAAGTCCCTGGaattcccagtg
taggtctctgtgtttcgcACCAGCCTCCC
CTAGGTCTAGGGGATATGGTTTCTTGGGA
AAGAGACCTCCCAGCCCCACACTGCTGTT
TCCATCAGTGAGCGAGGCATGAGAGACAG
TAAGCAAAGGGGCTGAGGGAGGTGGGGAG
GGGATTGGGCTCTGTCAGTATAGCCAAAC
CTTTCCCTCTTTTGCCCTAAGGAGTTCCT
CCCCTTCTCTGACCAGAAAGAGGGCAGAC
ATGCATGTGTCAGACTGGACTGGCCCTAA
CCCTGGTTCCCCATTTC
C
Promoter2 Vs Potential Enhancer2
>CD
AAACTTACAAGAATCCACGCAGTGGGGAG
TGGGAGGCAGAGGGGCTGCTGCCCACACT
CACCGTGAGGATTCCTGGATCGCTCTCAT
CTGCTGGGCAGGATGACTTTCCTGTGTCC
CATCCTCCCACTCCTCCCATTCTGAATTG
TACCAAGTTAGACATTAAAATGGCGGAGa
attcccagtgtaggtctctgtgtttcgcA
CCAGCCTCCCCTAGGTCTAGGGGATATGG
TTTCTTGGGAAAGAGACCTCCCAGCCCCA
CACTGCTGTTTCCATCAGTGAGCGAGGCA
TGAGAGACAGTAAGCAAAGGGGCTGAGGG
AGGTGGGGAGGGGATTGGGCTCTGTCAGT
ATAGCCAAACCTTTCCCTCTTTTGCCCTA
AGGAGTTCCTCCCCTTCTCTGACCAGAAA
GAGGGCAGACATGCATGTGTCAGACTGGA
CTGGCCCTAACCCTGGTTCCCCATTTC
D
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Promoter2 Vs Negative Control2
>CH
GACTGCTGATGGAAGTGAGTGGGTGCTCA
GGAGGGGACCCTGGCACAGCCCGACCTCT
GAGCCTGGGGATGAGGGTGGGCCCTCCAG
CCATCCCTGTCTGaattcccagtgtaggt
ctctgtgtttcgcACCAGCCTCCCCTAGG
TCTAGGGGATATGGTTTCTTGGGAAAGAG
ACCTCCCAGCCCCACACTGCTGTTTCCAT
CAGTGAGCGAGGCATGAGAGACAGTAAGC
AAAGGGGCTGAGGGAGGTGGGGAGGGGAT
TGGGCTCTGTCAGTATAGCCAAACCTTTC
CCTCTTTTGCCCTAAGGAGTTCCTCCCCT
TCTCTGACCAGAAAGAGGGCAGACATGCA
TGTGTCAGACTGGACTGGCCCTAACCCTG
GTTCCCCATTTC
Promoter1 Vs Negative Control2
>CG
GACTGCTGATGGAAGTGAGTGGGTGCTCA
GGAGGGGACCCTGGCACAGCCCGACCTCT
GAGCCTGGGGATGAGGGTGGGCCCTCCAG
CCATCCCTGTCTGaattcatcgtcaagag
agctttatttgCATGAGTGCAAAGGATGA
AAATTCTAgactgggcgtggtggctcacg
cctgtaatcccagcactttgggagaccga
ggtgggcagatcacgaggtcaggagtttg
agaccagcctggctaacatagtggaaccc
catctctactaaaaatacaaaaaattagc
tgggtgtagtggtgtgtgcatgtaatccc
agctacttgggaggctgaggcaggagaat
tgcttgaagccgggaggcagaggttgcag
tgagccatgattgcatcactgcactccag
cccagcggacagtgcgagactccatctca
aaaaaaaaaaaagaaagaaaagaaTATTC
TAAAAAAAGACTTAATTCC
Promoter2 Vs Negative Control1
>CF
GGAAGGATGATGGACGGAAGATTCACCCT
ATAGTAAGTACTTGTTAAAACTTCCTAAT
CTGGTGGTTACAAACGTCTAAAAAAACAC
ACACAATAAACTGaattcccagtgtaggt
ctctgtgtttcgcACCAGCCTCCCCTAGG
TCTAGGGGATATGGTTTCTTGGGAAAGAG
ACCTCCCAGCCCCACACTGCTGTTTCCAT
CAGTGAGCGAGGCATGAGAGACAGTAAGC
AAAGGGGCTGAGGGAGGTGGGGAGGGGAT
TGGGCTCTGTCAGTATAGCCAAACCTTTC
CCTCTTTTGCCCTAAGGAGTTCCTCCCCT
TCTCTGACCAGAAAGAGGGCAGACATGCA
TGTGTCAGACTGGACTGGCCCTAACCCTG
GTTCCCCATTTC
Promoter1 Vs Negative Control1
>CE
GGAAGGATGATGGACGGAAGATTCACCCT
ATAGTAAGTACTTGTTAAAACTTCCTAAT
CTGGTGGTTACAAACGTCTAAAAAAACAC
ACACAATAAACTGaattcatcgtcaagag
agctttatttgCATGAGTGCAAAGGATGA
AAATTCTAgactgggcgtggtggctcacg
cctgtaatcccagcactttgggagaccga
ggtgggcagatcacgaggtcaggagtttg
agaccagcctggctaacatagtggaaccc
catctctactaaaaatacaaaaaattagc
tgggtgtagtggtgtgtgcatgtaatccc
agctacttgggaggctgaggcaggagaat
tgcttgaagccgggaggcagaggttgcag
tgagccatgattgcatcactgcactccag
cccagcggacagtgcgagactccatctca
aaaaaaaaaaaagaaagaaaagaaTATTC
TAAAAAAAGACTTAATTCC
E F
G H
(cont…) in light gray represents the alignment region of the promoter primer
C5. Sequence highlighted in dark gray represents the alignment region of the
promoter primer C7. Sequence in yellow represents promoter primer C6. Dark
green represents primer C1. purple represents primer C2, dark red represents
primer C3, sequence underlined represents primer C4.
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(continues from page 158) No amplification was observed in the lanes with 
primers and template, but without polymerase; indicative of no contamination 
(Figure 5.22). 
To test if evidence for looping events was observed, the PCR amplifications were 
performed at 64°C since this temperature minimized the non-specific 
amplification in previous experiments. Then, the products were run in an agarose 
gel electrophoresis. No evidence of loops forming between fragments with Zta 
interactions and promoter regions of VWF or CD9 can be observed. (Figure 5.23). 
The positive controls were run in the same PCR reaction at the same temperature, 
time and day as the tested samples. 
5.2.6 Template controls 
Since no product of comparable size to the positive control was found in the 
agarose electrophoresis in the previous experiments across the several different 
cell templates; a subsequent experiment was performed to corroborate that 
indeed the different templates contained DNA. Primers aiming to amplify a 
fragment of DNA were used in PCR reactions with the same concentration of 
template and amplifying temperature. This resulted in clear bands of expected 
size in 6 out of 8 templates tested, reflecting that those templates used in previous 
experiments were capable of producing bands, and that if an absence of bands 
is noted, is not due to an inadequate template production (Figure 5.24). The 
template for Akata-Zta shows faint bands, however, in Fig 5.3 it is clear that there 
is Chromatin present in those samples. 
Finally, to validate the quality of the 3C process, primers for the MYC loop proved 
to be present in ER-EB cells (Wood et al. 2016) were used in a PCR (Figure 5.25 
B). A synthetic template was used as control; in the lane with template from ER-
EB cells, as expected, a band of similar size to the control can be observed. In 
the lanes with template from LCL#3 cells and GM2188 cells, a band of similar 
size can be found (Figure 5.25 A). Although the band can be seen fainter than in 
template coming from ER-EB cells, it cannot be expected to be of the same 
intensity, since different cells lines provide a different context. The presence of 
the band reflects a looping event being detected; this in turn means that the 3C 
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method employed to generate the template of LCL#3 cells and GM2188 cells is 
valid and that looping events can be detected using these templates (Figure 5.25). 
Figure 5.23. Chromosome conformation capture analysis of cluster VWF-
CD9. Image captures of 1.2% Agarose gels after electrophoresis of PCR
amplification products. The PCR reactions were performed at 64 °C. Each panel
(A-F) is composed of sections (lanes) coming from the same gel. (A) There is
no band of similar size to the synthetic positive control for loop CA in lanes with
the Akata and Akata-Zta templates. (B) No product amplification of comparable
size to the synthetic positive control for loop CAs in lanes with the Akata and
Akata-Zta templates. (C) There is no band of similar size to the synthetic
positive control for loop CB in lanes with the Akata and Akata-Zta templates. (D)
No product amplification of comparable size to the synthetic positive control for
loop CBs in lanes with the Akata and Akata-Zta templates. (figure legend
continues…)
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(cont…) (E) There is no band of similar size to the synthetic positive control for
loop CC in lanes with the Akata and Akata-Zta templates. (F) No product
amplification of comparable size to the synthetic positive control for loop CD in
lanes with the Akata and Akata-Zta templates.
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Figure 5.24. Amplification of DNA in 3C templates. Primers were designed
for the amplification of a contiguous region of 304 bp, this to show that indeed
there was DNA in the template used in the previous experiments. PCR reaction
was performed at 64°C. (A) LCL#3 and GM2188 templates (B) Akata and
Akata-Zta templates. (C) Primers designed to amplify a 304bp product,
independently from digestion, in chr8:128,206,689-128,208,688.
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Figure 5.25. Template amplification of control loop MYC. To show the validity
of the 3C process, DNA digested with HindIII was used to amplify the control loop
MYC, known to loop in ER-EB cells. (A) Template coming from ER-EB cells
show the amplification desired. Template from LCL#3 and GM2188 show a faint
band of the expected size. On the far right, a synthetic positive control show the
233 bp band. PCR amplification was performed at 64°C (B) Map of the MYC loop
to the EBNA2 ChIP peaks detected by Wood et al, performed using a HindIII
digestion. Fragments containing the peaks (C) and MYC promotor (D) and the
respective primers circled in red.
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5.3 Discussion 
The design of the 3C experiments was completed for each target and executed 
in cells that displayed lytic activity or, for comparison, cells which stayed in latency. 
The cross-linked chromatin from the cells was digested with specific restriction 
enzymes and then reverse cross-linked. Synthetic controls were designed and 
the designed primers were used, this resulted in the amplification of a product of 
the expected size. Initially the amplification of the controls was performed at 60°C, 
the Tm used when designing the primers. However, the temperature was then 
increased to 64°C in all subsequent experiments, since this increase of 
temperature reduced the background caused by non-specific amplification 
present in the temperature gradients, but maintained the signal for positive 
controls. 
It was disappointing that we found no evidence of looping between the proposed 
Zta interactions and the promoter regions of SLC6A7, LHX1, FZD10 and cluster 
VWF and CD9 in our results. It is important to keep in mind that given the complex 
process of undertaking 3C experiments, it is inherently difficult to interpret 
correctly and reliably negative results obtained by any 3C assay; however, since 
we tested the capability of the templates to detect loops with the MYC loop, the 
observed results from the experiments seem to hold validity. The reason why the 
MYC loop could not be analysed in Akata and Akata-Zta cells was that EcoRI and 
BamHI were used in the digestion, and the primers used by Wood et al to detect 
the MYC loop were designed on a digestion by HindIII. Even if new primers were 
to be designed based on an EcoRI and BamHI digestion for a MYC loop, we 
couldn’t be certain that we would capture the MYC loop. 
Not finding evidence of looping between the proposed Zta interactions and the 
studied promoter regions is not enough evidence to claim that the loops are not 
forming. Since the execution of 3C experiments is so detailed and specific, it is 
necessary to consider alternative explanations for our results. It is possible that 
the fixation time might have affected the efficiency of the crosslinking by capturing 
protein complexes that occupy and block restriction sites, therefore affecting the 
subsequent restriction digestion, and in turn producing partial digestion and large 
DNA fragments (Naumova et al. 2012). Parallel to this, some of the templates in 
section 5.2.1.2 show a smear, signifying degradation of the 3C template, this was 
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tolerated since according to the guidelines of Naumova et al, the quality is 
passable; however, the quality reflected for LCL#3 and GM2188 was low. 
Being aware of the limitations of the executed experiments, it would be valuable 
to point out where future design could improve the assay if more time and 
resources were available. Besides altering the fixation time, the primer design 
could be more specific and with a higher Tm. By obtaining primers longer than 20 
bp, any non-specific amplification like we found with “sequenceX” when testing 
for loop E would be minimized.  
As the 3C assay technologies evolve, new improvements come over the quantity 
of interactions found and information gathered on these interactions. One of these 
evolved 3C assays is called 4C, where a second digestion is followed by a second 
ligation, allowing small DNA circles to be formed (reviewed by (Denker and de 
Laat 2016). Then, after using inverse PCR with primers designed to bind in the 
region of interest (a prominent Zta peak in our case) this region gets sequenced 
and mapped. As suggestions for future research, this approach could be taken; 
since interactions have already been proposed, the use of 4C would allow to find 
in a single run several looping interactions between the selected Zta binding sites 
and many other possible regions, this could be subsequently corroborated by 3C. 
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Chapter 6. Discussion 
In this project, a possible enhancer influence by central EBV factor Zta, over gene 
regulation was explored in different cellular contexts. Two different methods of 
analysis were used to probe different aspects of the interactions between Zta and 
the human genome. 
Research previously performed in the Sinclair Lab studied the change of mRNA 
levels in the transcriptome of lytic B cells, as well as a genome wide analysis of 
Zta interactions found in the human genome; this identified genes that are 
regulated and have Zta binding sites associated with them, which allowed us to 
prioritize which Zta interactions to investigate (Ramasubramanyan et al. 2015).  
Sequences corresponding to the upstream region of 30 highly regulated genes 
were analysed and, through computational analysis, conserved sequences were 
found. Interestingly, the identified sequences did not resemble the well 
characterized 7 base motif of AP1 (TGAGTCA) to which Zta is known to bind, or 
its variants in ZREs. 
Two elements (1OEM, 4OEM) consisting of the most representative sequence of 
the conserved regions were designed, under the supposition that those 
sequences could present enhancer activity since they were found in highly 
regulated genes with Zta peaks close to its promoters.  
Parallel to this, two other elements (AHNAK, FOSB) were designed based on the 
presence of Zta peaks near the promoter region of highly regulated genes 
AHNAK and FOSB observed in the ChIP-seq performed previously in the Sinclair 
Lab.  
The designed elements were synthesized and then cloned into 3 different vectors 
each containing a different promotor reactive to Zta of known behaviour in 
different cell environments. After this, the vectors containing the elements were 
transformed into bacterial cells, and cultured overnight for a subsequent DNA 
extraction. The obtained DNA samples were verified through a 3rd party 
sequencing service. 
After this, the DNA was transfected into EBV negative BL cells (DG75) and EBV 
negative epithelial cells (293T) together with an expression vector for His-tagged 
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Zta or an empty vector as a control. The transfected cells were cultured and 
harvested. Then, the presence of Zta was confirmed in the samples through 
Western blot assays, and the Luciferase assays were executed.  
The results obtained showed interesting but modest and diverse enhancer effects 
over the expression of luciferase in a cell dependent context. Still, although the 
controls reflected the behaviour expected of the vectors relative to the cell line, 
agreeing with previous literature; the enhancer effect of the elements was not 
substantial overall.  
The constrained enhancer effect found in the experiments was also limited by the 
problematic reproducibility encountered in subsequent experiments. However, 
future analysis could benefit from this initial undertaking, perhaps with some 
changes and tweaks in the virtual sequence analysis.  
In a different approach to study Zta and its regulation over gene expression, a 
chromosome conformation capture assay was designed. This was based on the 
observation that a large proportion of Zta interactions were found several kb away 
from the promotor region of any genes in vicinity.  
As a first step, a selection criteria had to be designed to discriminate amongst 
many Zta peaks and the promoter region of many genes. One such criteria 
involved analysing the presence of any Zta peaks in distal vicinity of the promoter 
region of 30 genes previously identified as highly regulated.  
Regions that allowed an appropriate digestion in the context of 3C experimental 
design allowed to postulate 3 candidates for looping re-arrangement to the 
promoter region of genes FZD10, SLC6A7 and LHX1. 
In a parallel analysis, a computational selection criteria was devised that cross 
related genes known to be highly regulated that could be clustered together, and 
the presence of Zta interactions in vicinity of the cluster. This analysis helped 
identify 8 gene clusters from which one cluster of 2 genes (VWF and CD9) was 
postulated as candidate of looping regulation. 
This first step of finding which interactions to research was followed up by 
designing a digestion regimen that would cut the DNA into fragments that would 
contain the potential looping regions. After this, primers for the amplification of 
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looping events were designed and synthesized. Positive controls that would 
result from such amplification were also designed and synthesized. 
The primers were tested as well as the positive controls, showing that an 
amplification of products of expected size based on the design of the assay was 
possible using the appropriate primer pairs and the temperature selected when 
designing the primers (60°C).  
Chromatin coming from EBV-positive inducible BL cells, as well as chromatin 
from latent and lytic LCL cells, was used and the protein-DNA interactions were 
fixed with the use of formaldehyde. After this, the chromatin was digested and 
then re-ligated, followed by a reversal of the crosslink; lastly DNA was purified. A 
temperature gradient PCR was used to explore the presence of products of 
similar size to the control synthetic DNA; a band of similar size to the control in 
loop E to the promoter region of LHX1 was appreciated at 55°C in chromatin from 
latent and lytic LCLs. This band was excised from the electrophoresis gel and the 
DNA was purified for a subsequent 3rd party sequencing verification. 
The retrieved sequence from the band did not match the sequence employed for 
the generation of the looping control DNA, however they shared a similar length.  
A virtual alignment allowed to see that this DNA band of similar size corresponded 
to a different place in the genome, and flanked by regions of similar  sequence to 
the primers employed, showing that the band was a product of non-specific 
amplification. Based on this, and following the literature guidelines for 
troubleshooting 3C assays, a higher temperature was used in subsequent PCR 
reactions (64°C). 
No evidence of loops forming in the studied regions was found in the chromatin 
employed. The capability of capturing any loops, in chromatin coming from the 
inducible BL cells employed, was tested by using primers employed by Wood in 
testing the presence of MYC loop; a band of similar size to the synthetic control 
was found in our template, confirming the potential of the chromatin to capture 
loops (Wood et al. 2016). 
Despite the lack of evidence for looping events in the work presented here, no 
final claim that the looping events are not occurring can be postulated. One of the 
factors that limited the capacity to draw a final strong conclusion arose in the 
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quality of the digested chromatin used in the experiments. Still, in the undertaking 
of this research, a novel method of grouping gene clusters and relating them to 
Zta peaks was developed, and future analysis could benefit from this method. 
The research presented here shows an initial attempt to analyse any enhancing 
effect found in sequences where Zta is binding to in the human genome, as well 
as an attempt to study any regulation of expression by Zta, performed through 
chromatin rearranging by looping. Although no breakthrough kind of finding was 
observed, during the presented research interesting computational methods of 
analysis were generated. 
As a suggestion to consider for future research; a very interesting genome wide 
analysis of long-range interactions between transcription start sites and distal 
enhancer elements in several human cells lines, found a bias favouring the 
looping interactions with enhancers that were located ~120kb upstream of the 
TSS. Additionally, they observed that only 7% of looping events were occurring 
to the nearest gene, indicating that genomic proximity is not a simple predictor 
for long-range interactions (Sanyal et al. 2012). If taken into consideration, this 
could easily be implemented in the computational analysis presented in chapter 
4 of this thesis by excluding any peak found closer than 100 kb away or farther 
than 140 kb from the found clusters. 
The integration of next generation sequencing to the 3C technologies, has greatly 
broadened the information that can be gathered from chromatin conformation 
capture experiments. The use of 4C, 5C or Hi-C (amongst many others) present 
very viable options to study chromatin rearrangement and gene regulation by Zta 
over “classical” 3C.  
The 4C assay follows a similar method as used in 3C assays, except that after 
the reversal of the crosslink a secondary digestion is performed, followed by a 
new ligation. This produces small DNA fragments that form circles, and through 
the use of inverse PCR, primers designed to bind to the postulated enhancer 
region, enrich the presence of products. These amplified products are analysed 
through sequencing and generate a map of interactions of a few kilobases of 
resolution. This represents an immediate advantage over 3C; using inverse PCR 
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an experiment can be designed without a priori hypotheses of both candidate 
regions forming long range interactions.  
The use of 4C for the exploration of the interactions of Zta could bring some 
insights on particular looping regions. If an interaction of Zta was selected based 
on the value from the ChIP-seq peak, to design the primers for the inverse PCR; 
a profile of all the interactions to that single particular Zta interaction would be 
obtained, however, data from previous studies gave a large amount of 
interactions to study, therefore 4C might not be the best choice.  
The 5C assay differs from the “classic” 3C in that after the reversal of the crosslink, 
primers with a particular 5’ “adaptor” tail are designed to bind to the fragments of 
interest, if the postulated interaction exists and the fragments are ligated, then 
the primers would amplify a product which can be subsequently amplified with 
universal primers complementary to the “adaptor” tail of the first round of 
amplification. After this, next generation sequencing would create an interaction 
frequency matrix. 
The use of 5C for the exploration of Zta interactions could take advantage of data 
previously generated. The list of highly regulated genes presented in previous 
chapters could be used to generate primers for the promoter regions of the 10 
most highly regulated genes; and if the value of the Zta peaks from the ChIP-seq 
was to be used to narrow the top 10 Zta interactions, then primers could be 
designed for those targets. This, however, would limit the study to only 10 genes 
out of hundreds that are known to be highly regulated in lytic cycle, and 10 Zta 
peaks out of hundreds in vicinity. 
In the Hi-C assay, after a regular chromatin cross-link, a restriction digest that 
leaves an overhang in the 5’ end of the fragments takes place. Then, using biotin-
labelled nucleotides the 5’ overhang gets complemented; this is followed by a 
blunt end ligation, which unites the biotin labelled ends. Then the reversal of the 
crosslink allows for a DNA purification, followed by a sonication and a streptavidin 
pulldown of the ligation junctions. Finally, using paired-end sequencing, a matrix 
of pair-wise interaction frequencies would be obtained. This wouldn’t require the 
use of previous data to find interactions in cells undergoing lytic cycle, however, 
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when mapped and compared to the mapped generated with ChIP-seq, a very 
interesting overlap could be seen in regions shown to be binding, and Zta peaks. 
Finally, the emerging Capture-C technologies allow for a further target 
enrichment in the preparation of 3C libraries; this is achieved by using a digestion 
enzyme in the first digestion, followed by a second fragmentation by sonication. 
Then designed biotinylated RNA baits bind to the fragments of interest and a 
streptavidin bead pull down increase the presence of only the interactions of 
interest. This technique is still evolving (NG Capture-C), but if was to be employed 
in the study of Zta interactions with the genome, it would help obtain more 
detailed results than the initial first wave of 3C technologies (Dekker et al 2016).  
As a final summation, the advent of new technologies for enrichment of products 
and interest; and the decline in the price of sequencing techniques will create an 
enormously good opportunity to vastly expand the knowledge of Zta regulation of 
gene expression. This, with much better ease than when using 3C as an initial 
exploration. 
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